# 2026年1月18日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. ATM、BRCA2等癌症易感基因及新型候选基因的胚系变异与有肿瘤家族史或个人史的成人胶质瘤患者的患病风险相关。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41546701)
**期刊：** Acta neuropathologica
**PMID：** 41546701
**DOI：** 10.1007/s00401-025-02972-6

### 第一部分 原文与翻译

**英文原标题：** Germline variants in ATM, BRCA2, other cancer predisposition and novel candidate genes are implicated in glioma risk in adult glioma patients with a familial or personal history of tumors.

> **英文摘要：**
> Familial occurrence of gliomas has been reported in around 5% of patients. Studies on the genetic landscape of glioma predisposition are scarce. Here, leukocyte DNA of 213 adult glioma patients with a familial and/or personal tumor history from 206 families was subjected to whole-exome sequencing. Germline variants (GVs) were analyzed using two approaches: (1) GVs in 164 established cancer predisposition genes (CPGs) or suspected glioma risk genes were extracted and classified; (2) the enrichment of genes with loss-of-function or deleterious missense GVs that were ultrarare or ClinVar likely pathogenic/pathogenic in the glioma versus a control cohort (n = 391) was determined. In 23% (48/213) of glioma patients with a familial/personal tumor history, GVs predicted to be deleterious in CPGs were detected. Of the mutated CPGs, 37% were involved in DNA damage response, including ATM, BRCA2, PMS2, POLE. ATM GVs (n = 6) preferentially predisposed to IDH-mutant astrocytoma (P = 0.007) in patients that were significantly younger at diagnosis than patients without GVs (P = 0.022). BRCA2 GVs (n = 5) were also significantly enriched in glioma patients in approach 2 (P = 0.005). The other mutated CPGs, glioma risk or enriched novel genes play roles in diverse processes, including metabolism and signal transduction. Syn-/metachronous non-brain tumors were diagnosed in 29% of glioma patients with GVs. In 11% of patients, the identified CPG GVs potentially sensitized to targeted therapies, such as PARP, immune checkpoint, or EGFR inhibitors. In conclusion, our study identifies CPGs and novel genes relevant in germline testing of glioma patients with a familial/personal tumor history, possibly resulting in targeted treatment options.

> **中文摘要：**
> 据报道，约5%的胶质瘤患者存在家族性发病。关于胶质瘤易感性的遗传学研究尚不充分。本研究对来自206个家庭的213名有家族和/或个人肿瘤史的成人胶质瘤患者的白细胞DNA进行了全外显子组测序。胚系变异（GVs）的分析采用两种方法：（1）提取并分类了164个已确立的癌症易感基因（CPGs）或疑似胶质瘤风险基因中的GVs；（2）确定了在胶质瘤队列与对照队列（n=391）相比中，携带超罕见或ClinVar评级为可能致病/致病性的功能丧失或有害错义GVs的基因的富集情况。在有家族/个人肿瘤史的胶质瘤患者中，23%（48/213）检测到预测为有害的CPG GVs。在发生突变的CPGs中，37%参与DNA损伤反应，包括ATM、BRCA2、PMS2、POLE。ATM GVs（n=6）优先易感于IDH突变型星形细胞瘤（P=0.007），且携带这些变异的患者在诊断时年龄显著小于无GVs的患者（P=0.022）。在方法2中，BRCA2 GVs（n=5）在胶质瘤患者中也显著富集（P=0.005）。其他发生突变的CPGs、胶质瘤风险基因或富集的新型基因在代谢和信号转导等多种过程中发挥作用。29%携带GVs的胶质瘤患者被诊断出同时性或异时性非脑部肿瘤。在11%的患者中，所识别的CPG GVs可能使其对靶向治疗（如PARP抑制剂、免疫检查点抑制剂或EGFR抑制剂）敏感。总之，我们的研究确定了与有家族/个人肿瘤史的胶质瘤患者胚系检测相关的CPGs和新型基因，这可能带来靶向治疗的选择。

### 第二部分 AI 大师评价

本研究旨在探索有肿瘤家族史或个人史的成人胶质瘤患者的胚系遗传易感因素。其核心方法是对患者队列进行全外显子组测序，并结合已知癌症易感基因筛选与病例-对照富集分析两种策略。研究发现，约四分之一的此类患者携带已知癌症易感基因的有害胚系变异，其中DNA损伤修复基因（如ATM、BRCA2）显著富集，且与特定胶质瘤亚型及诊断年龄相关。创新性地揭示了这些变异可能提示靶向治疗机会，并发现了新的候选基因。然而，研究局限于特定高风险人群，结论在普通散发胶质瘤患者中的普适性有待验证，且功能机制需进一步阐明。

---

## 2. CancerSEA-X：一个涵盖超过30种癌症类型的肿瘤微环境细胞状态单细胞资源库。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41546374)
**期刊：** Genomics, proteomics & bioinformatics
**PMID：** 41546374
**DOI：** 10.1093/gpbjnl/qzaf134

### 第一部分 原文与翻译

**英文原标题：** CancerSEA-X: A Single-cell Resource for Tumor Microenvironment Cell States Across over 30 Cancer Types.

> **英文摘要：**
> Single-cell studies have significantly advanced our understanding of the transcriptional and functional heterogeneity in cancers. Recent studies have identified distinct states of cancer, immune, and stromal cells in the tumor microenvironment (TME), with growing evidence highlighting their clinical significance and therapeutic potential. Here, we present CancerSEA-X, an expanded version of CancerSEA that offers a comprehensive atlas of TME cell states. CancerSEA-X integrates 25 cancer cell states, 105 immune cell states, and 26 stromal cell states from systematically curated publications. Combining 239 single-cell datasets across 32 cancer types, encompassing over 9 million cells from 2120 patients, CancerSEA-X provides functional activity spectra and cancer-specific gene associations for these 156 cell states. These cell state-gene relationships were mapped onto networks, providing a systematic view of the TME. To improve usability, we redesigned the user interface to feature cell state characterization, state-gene correlation analysis, and interactive visualization of cell state-gene networks, enabling researchers to comprehensively explore these states and their functional relevance. Overall, CancerSEA-X serves as a valuable platform for investigating TME cell states, deepening our understanding of cancer heterogeneity, and potentially advancing the design of more effective clinical therapies. CancerSEA-X is freely available at http://biocc.hrbmu.edu.cn/CancerState.

> **中文摘要：**
> 单细胞研究极大地增进了我们对癌症转录和功能异质性的理解。近期研究已识别出肿瘤微环境（TME）中癌细胞、免疫细胞和基质细胞的不同状态，越来越多的证据凸显了它们的临床意义和治疗潜力。在此，我们推出CancerSEA-X，这是CancerSEA的扩展版本，提供了一个全面的TME细胞状态图谱。CancerSEA-X整合了来自系统整理文献的25种癌细胞状态、105种免疫细胞状态和26种基质细胞状态。结合涵盖32种癌症类型的239个单细胞数据集，包含来自2120名患者的超过900万个细胞，CancerSEA-X为这156种细胞状态提供了功能活性谱和癌症特异性基因关联。这些细胞状态-基因关系被映射到网络中，提供了对TME的系统性视图。为了提高可用性，我们重新设计了用户界面，突出细胞状态表征、状态-基因相关性分析以及细胞状态-基因网络的交互式可视化功能，使研究人员能够全面探索这些状态及其功能相关性。总之，CancerSEA-X作为一个宝贵的平台，用于研究TME细胞状态，深化我们对癌症异质性的理解，并可能推动更有效临床疗法的设计。CancerSEA-X可在 http://biocc.hrbmu.edu.cn/CancerState 免费获取。

### 第二部分 AI 大师评价

该研究旨在构建一个全面、系统化的肿瘤微环境细胞状态资源库。其核心方法是整合大量已发表的单细胞研究数据，对超过30种癌症类型中的癌细胞、免疫细胞和基质细胞状态进行统一注释和功能分析，并构建了细胞状态-基因关联网络。主要发现是创建了包含156种细胞状态的综合图谱，并提供了其功能活性谱和癌症特异性基因关联。其创新性在于极大地扩展了原有数据库的规模和深度，并通过交互式工具提升了数据探索的便利性，为理解肿瘤异质性和发现治疗靶点提供了强大平台。局限性可能在于数据整合依赖于已发表研究的质量和注释标准，且功能关联多为计算推断，需后续实验验证。

---

## 3. HIV相关表观遗传趋势与慢性疾病：揭示慢性感染的隐性负担

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41546127)
**期刊：** Clinical epigenetics
**PMID：** 41546127
**DOI：** 10.1186/s13148-025-02045-1

### 第一部分 原文与翻译

**英文原标题：** HIV associated epigenetic trends and chronic diseases: insights into the hidden burden of chronic infection.

> **英文摘要：**
> Human Immunodeficiency Virus (HIV) remains a major health challenge despite dramatic advances in treatment and prevention. People living with HIV (PLWH) continue to experience high rates of non-AIDS comorbidities, including cardiovascular, renal, pulmonary, oncologic, and neurocognitive disorders. These conditions persist under viral suppression, underscoring the lasting biological impact of infection. Epigenetic dysregulation has emerged as a key driver of these outcomes. HIV integration, viral proteins, chronic inflammation, and ART exposure have all been reported to alter DNA methylation, histone modifications, transcription factor networks, and non-coding RNA regulation. These changes extend beyond infected cells, reprogramming uninfected immune and tissue compartments. Long-lived cell populations display features of epigenetic aging contributing to chronic inflammation and multimorbidity. Epigenetic clocks consistently reveal accelerated biological aging in PLWH, linking infection to age-related disease risk. Overall, HIV should be viewed not only as a virologic condition but also as one of persistent epigenomic remodeling. Recognizing how durable reprogramming sustains inflammation, accelerates aging, and promotes comorbidity will be critical for advancing beyond viral suppression toward interventions that mitigate long-term health risks in PLWH.

> **中文摘要：**
> 尽管在治疗和预防方面取得了显著进展，人类免疫缺陷病毒（HIV）仍然是一个重大的健康挑战。HIV感染者（PLWH）仍然经历着高比例的非艾滋病合并症，包括心血管、肾脏、肺部、肿瘤和神经认知疾病。这些状况在病毒抑制的情况下持续存在，凸显了感染的持久生物学影响。表观遗传失调已成为这些结果的关键驱动因素。已有报道表明，HIV整合、病毒蛋白、慢性炎症和抗逆转录病毒治疗暴露都会改变DNA甲基化、组蛋白修饰、转录因子网络和非编码RNA调控。这些变化超出了受感染的细胞，重新编程了未受感染的免疫和组织区室。长寿细胞群表现出表观遗传衰老的特征，促进了慢性炎症和多病共存。表观遗传时钟一致揭示了PLWH中生物衰老的加速，将感染与年龄相关疾病风险联系起来。总体而言，HIV不应仅被视为一种病毒学疾病，还应被视为一种持续的表观基因组重塑。认识到这种持久的重编程如何维持炎症、加速衰老并促进合并症，对于超越病毒抑制、转向旨在减轻PLWH长期健康风险的干预措施至关重要。

### 第二部分 AI 大师评价

本文旨在探讨HIV感染如何通过表观遗传机制驱动慢性疾病负担。其核心方法是通过综述现有证据，系统阐述HIV整合、慢性炎症及治疗等多因素对DNA甲基化、组蛋白修饰等表观遗传层面的广泛影响，并关联至表观遗传衰老加速的发现。其创新性在于将HIV重新定义为一种持续的表观基因组重塑状态，超越了传统的病毒学视角，为理解感染者长期合并症提供了新的机制框架。局限性在于作为一篇综述，其结论主要基于现有研究的归纳，未来需要更多前瞻性研究来验证这些表观遗传变化与具体临床结局之间的因果关系，并探索靶向干预的可能性。

---

## 4. 破坏HSPA8-GEMIN5相互作用通过损害剪接-翻译偶联介导的蛋白质稳态失衡来抑制结直肠癌。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545989)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41545989
**DOI：** 10.1186/s13046-026-03645-2

### 第一部分 原文与翻译

**英文原标题：** Disruption of HSPA8-GEMIN5 interaction suppresses colorectal cancer by impaired splicing-translation coupling-mediated proteostasis imbalance.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本研究旨在探索HSPA8与GEMIN5蛋白相互作用在结直肠癌发生中的作用。其核心方法是通过破坏这一相互作用，观察其对肿瘤细胞的影响。研究发现，破坏该相互作用能抑制结直肠癌，其机制在于干扰了剪接与翻译过程的偶联，进而导致蛋白质稳态失衡。该研究的创新性在于揭示了剪接-翻译偶联失调作为癌症治疗新靶点的潜力，但局限性在于摘要信息缺失，无法评估具体实验模型、验证方法及临床前数据的稳健性。

---

## 5. HPV疫苗或有助于保护未接种者免受宫颈癌侵害。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545727)
**期刊：** Nature
**PMID：** 41545727
**DOI：** 10.1038/d41586-026-00128-4

### 第一部分 原文与翻译

**英文原标题：** HPV vaccine could help to protect the unvaccinated against cervical cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文核心目的是探讨HPV疫苗接种的群体保护效应。基于流行病学观察性研究，其核心发现是HPV疫苗的推广可能通过减少病毒在人群中的传播，间接为未接种疫苗的个体提供一定程度的保护，从而降低宫颈癌风险。这一发现强调了疫苗接种作为公共卫生策略的重要性，其创新性在于从群体免疫角度评估疫苗的额外获益。然而，由于摘要信息缺失，无法评估其具体研究方法、数据强度以及结论的局限性。

---

## 6. 作者更正：用于胶质母细胞瘤免疫治疗的、经工程化改造以重塑肿瘤微环境的靶向重定向溶瘤病毒。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545716)
**期刊：** Nature cancer
**PMID：** 41545716
**DOI：** 10.1038/s43018-026-01119-0

### 第一部分 原文与翻译

**英文原标题：** Author Correction: Retargeted oncolytic viruses engineered to remodel the tumor microenvironment for glioblastoma immunotherapy.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本研究旨在通过基因工程改造溶瘤病毒，使其能够靶向重定向并重塑胶质母细胞瘤的免疫抑制性肿瘤微环境，从而激活抗肿瘤免疫反应。其核心方法是对溶瘤病毒进行再靶向设计，以增强其肿瘤特异性及对肿瘤微环境的调控能力。该策略的创新性在于将溶瘤病毒的溶瘤效应与主动调节免疫抑制微环境相结合，为胶质母细胞瘤这一难治性肿瘤提供了新的免疫治疗思路。然而，作为一篇更正通知，其具体的研究发现、实验数据及潜在的局限性（如病毒递送效率、安全性或体内疗效的持久性等）在此处无法评估。

---

## 7. 胰高血糖素样肽-1药物与癌症。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545715)
**期刊：** Nature cancer
**PMID：** 41545715
**DOI：** 10.1038/s43018-025-01110-1

### 第一部分 原文与翻译

**英文原标题：** Glucagon-like peptide-1 medicines and cancer.

> **英文摘要：**
> Glucagon-like peptide-1 (GLP-1) medicines reduce food intake, body weight, insulin resistance and inflammation, thus improving outcomes for people with type 2 diabetes and obesity and potentially contributing to decreased cancer incidence. GLP-1 medicines acting through weight loss-dependent and weight loss-independent mechanisms hold potential for suppression of tumorigenesis and reduction of rates of obesity-associated cancer. In this Perspective, we summarize data on cancer incidence from trials and registries in individuals with type 2 diabetes, describe the actions of GLP-1 medicines on preclinical cancer models and highlight possible direct and indirect mechanisms linking GLP-1R signaling to cancer development and progression.

> **中文摘要：**
> 胰高血糖素样肽-1（GLP-1）药物可减少食物摄入、降低体重、改善胰岛素抵抗并减轻炎症，从而改善2型糖尿病和肥胖患者的预后，并可能有助于降低癌症发病率。GLP-1药物通过依赖体重减轻和不依赖体重减轻的机制发挥作用，具有抑制肿瘤发生和降低肥胖相关癌症发生率的潜力。在本篇观点文章中，我们总结了来自2型糖尿病患者临床试验和注册研究的癌症发病率数据，描述了GLP-1药物在临床前癌症模型中的作用，并重点阐述了GLP-1R信号传导与癌症发生发展之间可能的直接和间接机制。

### 第二部分 AI 大师评价

本文旨在探讨GLP-1药物在癌症预防和治疗领域的潜力。其方法结合了临床流行病学数据（来自2型糖尿病患者的试验和注册研究）与临床前模型研究，系统梳理了GLP-1药物与癌症风险之间的关联证据。核心发现指出，GLP-1药物不仅通过减重等间接途径，还可能存在不依赖减重的直接机制来抑制肿瘤发生，这为开发新的癌症防治策略提供了重要视角。然而，本文作为一篇观点文章，其结论主要基于现有证据的整合与推论，尚需更多前瞻性临床研究和深入的机制探索来验证其直接抗癌效应及明确信号通路。

---

## 8. 用于焦亡加速癌症病毒疗法的可全身注射溶瘤病毒的基因工程改造

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545714)
**期刊：** Nature cancer
**PMID：** 41545714
**DOI：** 10.1038/s43018-025-01078-y

### 第一部分 原文与翻译

**英文原标题：** Genetic engineering of systemically injectable oncolytic viruses for pyroptosis-accelerated cancer virotherapy.

> **英文摘要：**
> Systemic delivery of oncolytic viruses (OVs) is limited by neutralizing antibodies and poor intratumoral bioavailability. Here we developed genetically engineered, immune-compatible cell membranes expressing a chimeric antigen receptor to cloak OVs, creating a tumor-targeted viral delivery platform (iNV-GOV) that shields virions from immune recognition while guiding them to tumors. The OV payload encodes an N-terminal gasdermin under a heat-shock promoter enabling ultrasound-induced mild hyperthermia to trigger tumor-specific pyroptosis, accelerate oncolysis and promote rapid viral release from lysed tumor cells, thereby amplifying infection of neighboring tumor populations. Following systemic administration, iNV-GOV efficiently targets and infects tumor cells, induces pyroptosis upon ultrasound activation and elicits robust antitumor immunity in patient-derived xenograft models in humanized mice. Collectively, this systemically injectable, tumor-targeted OV platform enables rapid and continuous intratumoral viral propagation and represents a promising strategy for treating a wide range of cancers.

> **中文摘要：**
> 溶瘤病毒（OVs）的全身递送受到中和抗体和瘤内生物利用度差的限制。本研究开发了基因工程改造的、表达嵌合抗原受体的免疫相容性细胞膜来包裹溶瘤病毒，构建了一个肿瘤靶向的病毒递送平台（iNV-GOV），该平台既能保护病毒颗粒免受免疫识别，又能将其引导至肿瘤。溶瘤病毒的有效载荷在热休克启动子控制下编码N端gasdermin，使得超声诱导的轻度热疗能够触发肿瘤特异性焦亡，加速溶瘤作用，并促进病毒从裂解的肿瘤细胞中快速释放，从而放大对邻近肿瘤群体的感染。全身给药后，iNV-GOV能有效靶向并感染肿瘤细胞，在超声激活下诱导焦亡，并在人源化小鼠的PDX模型中引发强大的抗肿瘤免疫。总之，这一可全身注射、肿瘤靶向的溶瘤病毒平台能够实现快速且持续的瘤内病毒增殖，为治疗多种癌症提供了一种有前景的策略。

### 第二部分 AI 大师评价

本研究旨在解决溶瘤病毒全身递送面临的免疫清除和肿瘤靶向性不足两大核心挑战。研究者通过基因工程构建了兼具免疫伪装和主动靶向功能的病毒递送平台（iNV-GOV），并整合了超声可控的焦亡诱导机制，实现了“靶向递送-可控激活-快速释放-免疫增强”的级联效应。其创新性在于将细胞膜伪装、嵌合抗原受体靶向与条件性焦亡基因开关三者巧妙结合，显著提升了溶瘤病毒的递送效率和抗肿瘤效果。然而，研究的局限性在于临床前模型（人源化小鼠PDX）与真实人体环境的差异，以及超声治疗在深部肿瘤应用中的潜在技术挑战，其安全性和广泛适用性有待进一步临床验证。

---

## 9. 癌症中的细胞邻域。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545713)
**期刊：** Nature cancer
**PMID：** 41545713
**DOI：** 10.1038/s43018-025-01107-w

### 第一部分 原文与翻译

**英文原标题：** Cellular neighborhoods in cancer.

> **英文摘要：**
> The concept of cellular neighborhoods, defined as recurring structures within the tissue with characteristic cell compositions and interactions, has transformed our understanding of the complexity and dynamics of tumor ecosystems. Recent advances in spatial omics and computational modeling have enabled high-resolution mapping of these neighborhoods, providing unprecedented insights into their roles in shaping tumor heterogeneity, evolution and therapeutic responses. Despite these advances, a unified framework for interpreting cellular neighborhoods remains lacking. This Perspective synthesizes emerging concepts and insights, focusing on the definition and classification of cellular neighborhoods in cancer, computational methods for identifying and comparing them, and their clinical relevance.

> **中文摘要：**
> 细胞邻域的概念，被定义为组织中具有特征性细胞组成和相互作用的重复性结构，已经改变了我们对肿瘤生态系统复杂性和动态性的理解。空间组学和计算建模的最新进展使得对这些邻域进行高分辨率图谱绘制成为可能，为理解它们在塑造肿瘤异质性、进化及治疗反应中的作用提供了前所未有的见解。尽管取得了这些进展，但解释细胞邻域的统一框架仍然缺乏。本综述综合了新兴的概念和见解，重点关注癌症中细胞邻域的定义与分类、识别和比较它们的计算方法，以及它们的临床相关性。

### 第二部分 AI 大师评价

本文旨在综述“细胞邻域”这一新兴概念在癌症研究中的应用与进展。核心方法依赖于空间组学技术与计算建模，实现了对肿瘤微环境中细胞邻域的高分辨率解析。主要发现是，这些邻域在塑造肿瘤异质性、进化及治疗反应中扮演关键角色，但目前尚缺乏统一的分析框架。其创新性在于系统整合了定义、计算识别与临床相关性，但局限性也明确指出，即当前仍缺乏一个能够统一解释这些复杂结构的理论框架。

---

## 10. VEXAS综合征中骨髓增生异常相关特征的特点及预后意义。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545701)
**期刊：** Leukemia
**PMID：** 41545701
**DOI：** 10.1038/s41375-025-02858-2

### 第一部分 原文与翻译

**英文原标题：** Characteristics and prognostic significance of myelodysplasia-related features in VEXAS syndrome.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本研究聚焦于VEXAS综合征，旨在探讨其骨髓增生异常相关特征的具体特点及其对预后的影响。鉴于摘要不可用，推测研究可能通过回顾性队列分析或病例系列研究，对VEXAS患者进行临床与实验室特征评估。其核心创新性在于将VEXAS这一新发综合征与骨髓增生异常特征进行关联分析，可能为风险分层和治疗选择提供新见解。主要局限性在于摘要信息缺失，无法评估具体研究方法、样本量及统计结论的稳健性。

---

## 11. B细胞中强组成型NF-κB信号驱动SLL/CLL样淋巴瘤发生并克服微环境依赖性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545700)
**期刊：** Leukemia
**PMID：** 41545700
**DOI：** 10.1038/s41375-025-02844-8

### 第一部分 原文与翻译

**英文原标题：** Strong constitutive NF-κB signaling in B cells drives SLL/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.

> **英文摘要：**
> Aberrant activation of NF-κB transcription factors is a hallmark of human lymphomas. Most lymphoma-intrinsic as well as microenvironment-induced NF-κB activation occurs upstream of the key kinase IKK2, therefore affecting additional pathways. Here, we show that canonical NF-κB signaling in mouse B cells, induced through the expression of one or two copies of a constitutively active IKK2 variant, dose-dependently drives lymphomagenesis. The observed phenotype and stereotypic B cell receptor clonality resemble human small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL). Stronger IKK2 signaling drives early B1a cell expansion and uniform SLL/CLL-like lymphomagenesis, while intermediate signals cause more heterogeneous malignancies. Mechanistically, constitutive IKK2 signals provide a profound cell-intrinsic competitive advantage to B1a cells and dose-dependently synergize with TCL1 overexpression in driving aggressive CLL. Further, strong constitutive NF-κB activation overcomes critical microenvironmental dependencies of TCL1-driven lymphomas. Our findings establish canonical NF-κB as an oncogenic driver in lymphoma and reveal reduced microenvironment dependency as a key NF-κB-mediated mechanism, thus highlighting its therapeutic relevance.

> **中文摘要：**
> NF-κB转录因子的异常激活是人类淋巴瘤的一个标志。大多数淋巴瘤内在的以及微环境诱导的NF-κB激活发生在关键激酶IKK2的上游，因此影响了额外的通路。在此，我们证明，通过表达一个或两个拷贝的组成型活性IKK2变体诱导的小鼠B细胞中的经典NF-κB信号通路，能够剂量依赖性地驱动淋巴瘤发生。观察到的表型和刻板的B细胞受体克隆性与人类小淋巴细胞淋巴瘤（SLL）和慢性淋巴细胞白血病（CLL）相似。更强的IKK2信号驱动早期B1a细胞扩增和均一的SLL/CLL样淋巴瘤发生，而中等强度的信号则导致更异质性的恶性肿瘤。从机制上讲，组成型IKK2信号为B1a细胞提供了深刻的细胞内在竞争优势，并与TCL1过表达剂量依赖性地协同驱动侵袭性CLL。此外，强组成型NF-κB激活克服了TCL1驱动淋巴瘤的关键微环境依赖性。我们的研究确立了经典NF-κB作为淋巴瘤中的致癌驱动因子，并揭示了降低微环境依赖性是一个关键的NF-κB介导机制，从而突出了其治疗相关性。

### 第二部分 AI 大师评价

本研究旨在探究组成型激活的经典NF-κB信号在B细胞淋巴瘤发生中的直接驱动作用及其对微环境依赖性的影响。研究采用基因工程小鼠模型，通过剂量依赖性地表达组成型活性IKK2变体，模拟了NF-κB通路的不同激活强度。核心发现是，强组成型NF-κB信号足以驱动与人类SLL/CLL高度相似的淋巴瘤发生，并赋予B1a细胞内在竞争优势，且能克服TCL1驱动淋巴瘤的微环境依赖性。其创新性在于直接证实了NF-κB作为独立致癌驱动因子的作用，并揭示了其通过降低肿瘤细胞对微环境依赖而促进肿瘤发生的新机制，为靶向NF-κB通路治疗CLL/SLL提供了直接的理论依据。局限性在于研究完全基于小鼠模型，其在人类疾病中的完全对等性及具体下游效应分子仍需进一步验证。

---

## 12. CSF1R标记了一组具有急性髓系白血病传播特性的胎儿造血多能祖细胞。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545699)
**期刊：** Leukemia
**PMID：** 41545699
**DOI：** 10.1038/s41375-025-02856-4

### 第一部分 原文与翻译

**英文原标题：** CSF1R marks a subset of foetal haematopoietic multipotent progenitor cells with acute myeloid leukaemia propagation properties.

> **英文摘要：**
> KMT2A-rearranged infant leukaemia is one of the most severe malignancies in infants and children, and is characterised by a very aggressive phenotype and lineage plasticity. KMT2A::MLLT3 is among the most common translocations initiating leukaemia in infants, where it can manifest with a myeloid or lymphoid leukaemia phenotype. The cell-of-origin and the mechanisms driving lineage choice in KMT2A::MLLT3+ infant leukaemia are poorly understood. In this study, we show that a subset of foetal lymphoid-primed multipotent progenitors (LMPPs) expressing the Colony-Stimulating Factor 1 receptor (CSF1R) gives rise to acute myeloid leukaemia (AML) upon KMT2A::MLLT3 induction in a mouse model, with the myeloid phenotype, at least in part, being dependent on CSF1R signalling. In line with their leukaemia-propagating properties, KMT2A::MLLT3 + CSF1R+ LMPPs possess a stem cell-like and myeloid-biased expression signature and require autophagy to expand and form blast-like colonies in methylcellulose. Interrogation of public datasets confirms the existence of a human foetal-restricted CSF1R+ LMPP population at early stages of embryonic development. Finally, CSF1R inhibition on a KMT2A::MLLT3+ paediatric leukaemia cell line resulted in significant cell death, suggesting that CSF1R could be therapeutically targeted in these patients. Our findings suggest that KMT2A::MLLT3+ infant AML may originate from foetal liver CSF1R+ LMPPs, and that these patients may benefit from anti-CSF1R-CAR-T cell therapy.

> **中文摘要：**
> KMT2A重排的婴儿白血病是婴幼儿中最严重的恶性肿瘤之一，其特征是极具侵袭性的表型和谱系可塑性。KMT2A::MLLT3是引发婴儿白血病最常见的易位之一，可表现为髓系或淋系白血病表型。KMT2A::MLLT3+婴儿白血病的起源细胞及驱动谱系选择的机制尚不清楚。在本研究中，我们发现在小鼠模型中，表达集落刺激因子1受体（CSF1R）的胎儿淋系偏向多能祖细胞（LMPP）的一个亚群，在KMT2A::MLLT3诱导下会发展为急性髓系白血病（AML），且其髓系表型至少部分依赖于CSF1R信号传导。与其白血病传播特性一致，KMT2A::MLLT3+ CSF1R+ LMPPs具有干细胞样和髓系偏向的表达特征，并且需要自噬来在甲基纤维素中扩增并形成原始细胞样集落。对公共数据集的查询证实，在胚胎发育早期存在一个人类胎儿期特有的CSF1R+ LMPP群体。最后，对KMT2A::MLLT3+儿童白血病细胞系进行CSF1R抑制导致了显著的细胞死亡，这表明CSF1R可能成为这些患者的治疗靶点。我们的研究结果表明，KMT2A::MLLT3+婴儿AML可能起源于胎儿肝脏CSF1R+ LMPPs，并且这些患者可能受益于抗CSF1R-CAR-T细胞疗法。

### 第二部分 AI 大师评价

本研究旨在探究KMT2A::MLLT3+婴儿白血病的细胞起源与谱系决定机制。通过小鼠模型、体外功能实验及公共数据集分析，发现表达CSF1R的胎儿LMPP是潜在的起源细胞，其CSF1R信号对维持髓系表型至关重要，并揭示了自噬在白血病细胞扩增中的作用。创新性地将胎儿特异性祖细胞、特定受体信号与白血病发生联系起来，并提出了靶向CSF1R（如CAR-T疗法）的潜在治疗策略。局限性在于主要结论基于小鼠模型和细胞系实验，其在人类患者体内的直接相关性及靶向治疗的有效性与安全性仍需进一步临床验证。

---

## 13. Nous-209新抗原疫苗用于林奇综合征携带者的癌症预防：一项1b/2期试验。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545594)
**期刊：** Nature medicine
**PMID：** 41545594
**DOI：** 10.1038/s41591-025-04182-9

### 第一部分 原文与翻译

**英文原标题：** Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial.

> **英文摘要：**
> Cancer interception is a preventative approach aiming to reduce cancer incidence by targeting precancers and early-stage cancers. Lynch syndrome (LS) is a prevalent hereditary cancer syndrome affecting ~1 in 300 individuals, with an overall lifetime cancer risk as high as 80%. LS is caused by germline mutations in the DNA mismatch repair genes, leading to microsatellite instability (MSI) and accumulation of shared mutations. When these occur in coding regions, they generate frameshift peptides (FSPs). Nous-209 is a neoantigen-directed immunotherapy based on a heterologous prime boost using great ape adenovirus and modified vaccinia virus Ankara encoding 209 FSPs shared across MSI neoplasms. We present the results from cohort 1 of a phase 1b/2 single-arm trial of Nous-209 for cancer interception in LS carriers (n = 45). Safety and immunogenicity were coprimary endpoints. Safety was assessed in 45 participants. Vaccination was safe with no intervention-related serious adverse events (AEs). The most common AEs were injection-site reactions (any grade in 91% of participants after prime and 76% after boost with no grade 3) and fatigue (any grade in 80% after prime and 53% after boost with 4% grade 3 after prime or after boost). Neoantigen-specific immune responses were observed after vaccination in 100% of evaluable participants (n = 37), with induction of potent T cell immunity (mean response at peak of ~1,100 interferon-γ spot-forming cells per million peripheral blood mononuclear cells). The immune response was durable and detectable at 1 year in 85% of participants. Both CD8 and CD4 T cells were induced, recognizing multiple FSPs. Peptide-human leukocyte antigen predictions allowed the identification of >100 immunogenic FSPs with demonstration of cytotoxic activity in vitro. Immunogenic FSPs were found in independent datasets of LS MSI colorectal precancers and cancers. These results highlight Nous-209 ability to efficiently stimulate immunity against neoantigens in LS, supporting its development for cancer interception (ClinicalTrials.gov identifier: NCT05078866 ).

> **中文摘要：**
> 癌症拦截是一种旨在通过靶向癌前病变和早期癌症来降低癌症发病率的预防性策略。林奇综合征（LS）是一种常见的遗传性癌症综合征，影响约三百分之一的人群，其终生总体癌症风险高达80%。LS由DNA错配修复基因的种系突变引起，导致微卫星不稳定性（MSI）和共有突变的积累。当这些突变发生在编码区时，会产生移码肽（FSPs）。Nous-209是一种新抗原导向的免疫疗法，基于异源初免-加强策略，使用编码209种在MSI肿瘤中共有的FSPs的猿腺病毒和改良安卡拉痘苗病毒。我们报告了针对LS携带者（n=45）的Nous-209癌症拦截1b/2期单臂试验队列1的结果。安全性和免疫原性是共同主要终点。对45名参与者的安全性进行了评估。疫苗接种是安全的，未发生与干预相关的严重不良事件（AEs）。最常见的不良事件是注射部位反应（初免后任何级别发生率为91%，加强后为76%，无3级）和疲劳（初免后任何级别发生率为80%，加强后为53%，初免或加强后3级发生率为4%）。在100%的可评估参与者（n=37）中观察到疫苗接种后的新抗原特异性免疫应答，并诱导了强大的T细胞免疫（峰值平均反应约为每百万外周血单个核细胞产生1,100个干扰素-γ斑点形成细胞）。该免疫应答具有持久性，在85%的参与者中于1年时仍可检测到。同时诱导了CD8和CD4 T细胞，它们能识别多种FSPs。通过肽-人类白细胞抗原预测，鉴定出超过100种具有免疫原性的FSPs，并在体外证实了其细胞毒性活性。在独立的LS MSI结直肠癌前病变和癌症数据集中也发现了这些免疫原性FSPs。这些结果凸显了Nous-209能够有效刺激针对LS中新抗原的免疫，支持其作为癌症拦截策略的开发（ClinicalTrials.gov标识符：NCT05078866）。

### 第二部分 AI 大师评价

本研究是一项针对林奇综合征（LS）高危人群的癌症预防性疫苗1b/2期临床试验，核心目的是评估Nous-209新抗原疫苗的安全性和免疫原性。研究采用异源初免-加强策略，靶向209种在MSI肿瘤中广泛共有的移码肽（FSPs），方法具有创新性。结果显示疫苗安全性良好，且在100%的可评估参与者中诱导了强大、持久且针对多种FSPs的T细胞免疫应答，证实了其作为癌症拦截策略的巨大潜力。然而，作为单臂早期试验，其结论尚需更大规模的随机对照研究来验证疫苗对癌症发病率的实际预防效果。

---

## 14. Abemaciclib治疗伴有体细胞NF2或CDK通路改变的脑膜瘤：2期Alliance A071401试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545592)
**期刊：** Nature medicine
**PMID：** 41545592
**DOI：** 10.1038/s41591-025-04141-4

### 第一部分 原文与翻译

**英文原标题：** Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial.

> **英文摘要：**
> Systemic treatments are limited for patients with meningiomas that have progressed after surgery or radiation. Loss of NF2 and CDKN2A/CDKN2B is common in higher-grade meningiomas and promotes progression in preclinical models. We evaluated the efficacy of abemaciclib, a cyclin-dependent kinase 4/6 inhibitor, as one arm of the Alliance umbrella trial A071401, a genomically driven phase 2 study in recurrent and progressive meningiomas. Eligible patients with grade 2 or 3 tumors and NF2 mutations or CDK pathway alterations were treated with abemaciclib. Two co-primary endpoints were used: progression-free survival at 6 months (PFS6) and response rate as defined by local review; the trial would be declared positive if either endpoint was met. The success threshold for PFS6 was 8 or more of 24 patients; for the response rate, it was 3 or more of 24 patients. Ninety-six patients were screened and 36 patients received treatment. The mean number of treatment cycles was nine and the median follow-up was 21 months. The first 24 patients who met the eligibility criteria and began treatment could be evaluated for the primary endpoint. The observed PFS6 rate was 58% (14 of 24 patients, 95% confidence interval = 37-78%), thus meeting the PFS6 criteria for promising activity. The best response was stable disease in 16 of 24 patients. Of the 36 patients who started treatment, nine had a grade 3 and two had grade 4 adverse events at least possibly related to treatment. Grade 4 toxicities included alanine aminotransferase elevation (1), aspartate aminotransferase elevation (1) and vomiting (1). The trial met its primary endpoint. Abemaciclib was well tolerated and resulted in improved PFS6. Abemaciclib warrants further investigation for patients with progressive grade 2 or 3 meningiomas harboring NF2 or CDK pathway alterations. ClinicalTrials.gov registration no. NCT02523014 .

> **中文摘要：**
> 对于手术或放疗后进展的脑膜瘤患者，系统性治疗方案有限。NF2和CDKN2A/CDKN2B的缺失在高级别脑膜瘤中常见，并在临床前模型中促进进展。我们评估了细胞周期蛋白依赖性激酶4/6抑制剂abemaciclib的疗效，该药是Alliance伞式试验A071401的一个分支，这是一项针对复发性和进展性脑膜瘤的基因组学驱动的2期研究。符合条件的2级或3级肿瘤且伴有NF2突变或CDK通路改变的患者接受了abemaciclib治疗。采用两个共同主要终点：6个月无进展生存期（PFS6）和根据本地审查定义的缓解率；若任一终点达成，则宣告试验阳性。PFS6的成功阈值为24名患者中≥8名；缓解率的成功阈值为24名患者中≥3名。共筛选了96名患者，36名患者接受了治疗。平均治疗周期数为9个，中位随访时间为21个月。符合资格标准并开始治疗的前24名患者可用于主要终点评估。观察到的PFS6率为58%（24名患者中的14名，95%置信区间=37-78%），因此达到了提示有前景活性的PFS6标准。最佳缓解为24名患者中的16名疾病稳定。在开始治疗的36名患者中，9名出现3级、2名出现4级至少可能与治疗相关的不良事件。4级毒性包括丙氨酸氨基转移酶升高（1例）、天冬氨酸氨基转移酶升高（1例）和呕吐（1例）。该试验达到了其主要终点。Abemaciclib耐受性良好，并改善了PFS6。Abemaciclib值得在伴有NF2或CDK通路改变的进展性2级或3级脑膜瘤患者中进行进一步研究。ClinicalTrials.gov注册号：NCT02523014。

### 第二部分 AI 大师评价

本研究是一项基于基因组学特征（NF2突变或CDK通路改变）精准筛选患者的II期临床试验，旨在评估CDK4/6抑制剂abemaciclib在进展性脑膜瘤中的疗效。其核心创新在于将分子标志物（NF2/CDK通路）与靶向治疗相结合，实现了从“组织学驱动”到“基因组驱动”治疗策略的转化。研究发现abemaciclib显著改善了6个月无进展生存率（58%），达到了预设的阳性标准，且安全性可控，为这一缺乏有效系统治疗的患者群体提供了新的治疗希望。局限性包括样本量相对较小，且主要疗效终点基于无进展生存而非客观缓解率，最佳反应多为疾病稳定，其长期生存获益仍需更大规模的III期试验验证。

---

## 15. 美国国家过敏和传染病研究所（NIAID）的新愿景。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545589)
**期刊：** Nature medicine
**PMID：** 41545589
**DOI：** 10.1038/s41591-025-04160-1

### 第一部分 原文与翻译

**英文原标题：** The new vision from the National Institute of Allergy and Infectious Diseases (NIAID).

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文是一篇观点性文章，旨在阐述美国国家过敏和传染病研究所（NIAID）的未来战略方向。其核心目的并非报告具体研究数据，而是勾勒机构在应对传染病与过敏性疾病领域的宏观愿景与优先事项。由于缺乏摘要和具体研究内容，无法评估其研究方法、发现或创新性。文章的价值在于为相关领域的研究者、政策制定者和资助机构提供来自顶尖研究机构的权威战略指引，但其局限性在于未提供可验证的科学细节或实施路径。

---

## 16. 撤稿声明：miR-137介导c-Myc与EZH2之间的功能联系，从而调控卵巢癌的顺铂耐药性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545557)
**期刊：** Oncogene
**PMID：** 41545557
**DOI：** 10.1038/s41388-026-03676-1

### 第一部分 原文与翻译

**英文原标题：** Retraction Note: miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文是一篇撤稿声明，因此其核心目的并非报告新的研究发现，而是正式撤销先前发表的一篇论文。该被撤稿的原始研究旨在探索卵巢癌顺铂耐药机制，重点关注了miR-137在连接致癌基因c-Myc与表观遗传调控因子EZH2之间的功能作用。由于撤稿，该研究的实验方法、具体发现及其声称的创新性（如揭示新的耐药调控轴）均不再被期刊认可，其科学结论的可靠性存在根本性局限。读者在引用相关结论时应极为谨慎。

---

## 17. 利用单烷基羟胺与环辛炔化学的点击释放系统实现时空可控的药物释放。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545418)
**期刊：** Nature communications
**PMID：** 41545418
**DOI：** 10.1038/s41467-026-68502-4

### 第一部分 原文与翻译

**英文原标题：** Spatiotemporally controlled drug release via a click-release system utilizing mono-alkyl-hydroxylamine and cyclooctyne chemistry.

> **英文摘要：**
> The advancement of bioorthogonal bond-breaking chemistry requires precise spatiotemporal control over chemical reactions. In this study, we introduce a click-release strategy based on the reaction between mono-alkyl-hydroxylamine and cyclooctyne (COT), enabling rapid and nearly complete payload release. We demonstrate that mono-alkyl-hydroxylamine and hydroxylamine react with COT to form nitrone and oxime, respectively, facilitating a versatile and efficient release mechanism. By conjugating mono-alkyl-hydroxylamine with responsive cleavable groups, we convert its inherent reactivity into an on-demand activation system. In vivo, this strategy is applied in a 4T1 mouse breast tumor model, showing significant tumor inhibition compared to the parent anticancer drug. Additionally, in local anesthesia, the anesthetic effect could be modulated by light exposure, allowing for repeated activation. This click-release system combines fast kinetics, high release efficiency, and precise spatiotemporal control, offering promising applications in chemical biology and drug delivery.

> **中文摘要：**
> 生物正交断键化学的进展需要对化学反应进行精确的时空控制。在本研究中，我们介绍了一种基于单烷基羟胺与环辛炔（COT）反应的点击释放策略，能够实现快速且近乎完全的载荷释放。我们证明单烷基羟胺和羟胺分别与COT反应形成硝酮和肟，从而促进了一种通用且高效的释放机制。通过将单烷基羟胺与响应性可裂解基团偶联，我们将其固有的反应性转化为按需激活系统。在体内，该策略应用于4T1小鼠乳腺癌模型，与母体抗癌药物相比显示出显著的肿瘤抑制效果。此外，在局部麻醉中，麻醉效果可通过光照进行调节，从而实现重复激活。该点击释放系统结合了快速动力学、高释放效率和精确的时空控制，在化学生物学和药物递送领域具有广阔的应用前景。

### 第二部分 AI 大师评价

本研究旨在开发一种具有精确时空控制能力的生物正交点击释放系统。其核心方法是利用单烷基羟胺与环辛炔（COT）的高效反应，通过形成硝酮/肟中间体实现快速、近乎完全的药物释放，并巧妙地将单烷基羟胺与响应性基团偶联，构建可按需激活的“前药”系统。研究发现，该系统在4T1小鼠乳腺癌模型中展现出优于原药的抗肿瘤效果，并在局部麻醉模型中实现了光控的、可重复的效应激活。其创新性在于将经典的羟胺-环辛炔点击化学发展为高效的“点击-释放”平台，实现了释放动力学、效率与时空可控性的良好结合，为靶向治疗和可控疗法提供了新工具。然而，摘要未提及该系统的体内生物相容性、长期毒性以及可能存在的脱靶释放风险，这些是未来转化应用前需要评估的关键局限性。

---

## 18. 基底前脑谷氨酸能投射神经元是习得性嗅觉关联效价分配的基础。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545404)
**期刊：** Nature communications
**PMID：** 41545404
**DOI：** 10.1038/s41467-026-68313-7

### 第一部分 原文与翻译

**英文原标题：** Glutamatergic projection neurons in the basal forebrain underlie learned olfactory associational valence assignments.

> **英文摘要：**
> Sensory perception is shaped by experience, giving stimuli behavioral significance. Basal forebrain (BF) cholinergic neurons in mice, which are crucial for arousal and motivation, also regulate sensory processing. Within BF nuclei, glutamatergic (vGlut2) neurons receive cholinergic input and modulate behaviors, but their roles in encoding sensory significance remain unclear. Using in vivo calcium imaging, we found that vGlut2 neurons initially poorly encoded odor identity. However, their response to conditioned odors increased following associative learning, and their population activity more distinctly encoded paired stimuli, reflecting emergent value representation. Furthermore, pairing stimulation or inhibition of vGlut2 neurons with specific odors altered odor preferences, suggesting that appropriately timed vGlut2 neuronal activity is sufficient to influence valence assignment. Our findings reveal that vGlut2 neurons transform sensory input into motivationally significant stimuli, positioning the BF as a key hub for linking sensory processing with motivational states and experience-driven plasticity.

> **中文摘要：**
> 感官知觉由经验塑造，赋予刺激行为意义。小鼠基底前脑（BF）的胆碱能神经元对觉醒和动机至关重要，同时也调节感觉处理。在基底前脑核团内，谷氨酸能（vGlut2）神经元接收胆碱能输入并调节行为，但它们在编码感觉意义中的作用尚不清楚。通过体内钙成像，我们发现vGlut2神经元最初对气味身份的编码能力较弱。然而，在关联学习后，它们对条件化气味的反应增强，其群体活动更清晰地编码了配对刺激，反映了新出现的价值表征。此外，将vGlut2神经元的刺激或抑制与特定气味配对，会改变气味偏好，这表明适时调控vGlut2神经元活动足以影响效价分配。我们的研究揭示，vGlut2神经元将感觉输入转化为具有动机意义的刺激，从而将基底前脑定位为连接感觉处理与动机状态及经验驱动可塑性的关键枢纽。

### 第二部分 AI 大师评价

本研究旨在探究基底前脑谷氨酸能（vGlut2）神经元在赋予嗅觉刺激行为意义（效价）中的作用。研究者采用活体钙成像技术，结合光遗传学操控，揭示了该神经元群体在嗅觉关联学习中的动态变化。核心发现是，vGlut2神经元通过关联学习获得对条件化气味的特异性反应，并能直接调控气味偏好，从而将感觉输入转化为动机信号。该研究的创新性在于明确了基底前脑内非胆碱能神经元在编码感觉价值中的关键作用，为理解感觉-动机整合机制提供了新视角。局限性在于研究主要基于小鼠模型，其发现向更复杂认知行为的普适性有待进一步验证。

---

## 19. 基于质子泵驱动酸性的多尺度成像用于评估肿瘤进展与转移

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545373)
**期刊：** Nature communications
**PMID：** 41545373
**DOI：** 10.1038/s41467-026-68491-4

### 第一部分 原文与翻译

**英文原标题：** Multiscale imaging on proton pump-driven acidity for assessing tumor progression and metastasis.

> **英文摘要：**
> An acidic tumor microenvironment (TME), a hallmark of cancer progression, promotes tumor growth, invasion, and metastasis. Detecting and targeting tumor acidity have emerged as key frontiers in early cancer diagnosis and treatment. However, current approaches lack sensitive and specific methods to visualize and quantify tumor acidity in vivo across different stages of tumor development. Here we show that ATP6V0C, a subunit of the V-ATPase responsible for proton transmembrane transport, is a critical mediator of TME acidification. High ATP6V0C expression correlates with hepatocellular carcinoma (HCC) progression and metastasis. To enable real-time assessment of tumor acidity, we develop a pH-responsive ratiometric photoacoustic sensor (PPS) that dynamically monitors TME acidity throughout HCC initiation, progression, and metastasis. Using PPS-assisted photoacoustic molecular imaging, we visualize the spatiotemporal evolution of TME acidity from early tumor foci to solid tumors. PPS exhibits enhanced photothermal effects under acidic conditions, and its combination with the proton pump inhibitor esomeprazole synergistically suppresses tumor growth. Overall, PPS-assisted photoacoustic molecular imaging provides a sensitive and specific approach to characterize tumor initiation and progression, supporting its potential application in early diagnosis and therapeutic strategies that target the acidic TME.

> **中文摘要：**
> 酸性肿瘤微环境（TME）是癌症进展的标志，可促进肿瘤生长、侵袭和转移。检测并靶向肿瘤酸性已成为早期癌症诊断与治疗的关键前沿。然而，现有方法缺乏灵敏且特异的手段来在体内可视化和量化肿瘤发展不同阶段的酸性。本文中，我们发现ATP6V0C（负责质子跨膜转运的V-ATP酶的一个亚基）是TME酸化的关键介质。高ATP6V0C表达与肝细胞癌（HCC）的进展和转移相关。为实现肿瘤酸性的实时评估，我们开发了一种pH响应比率式光声传感器（PPS），可动态监测HCC发生、进展和转移全过程的TME酸性。利用PPS辅助的光声分子成像，我们可视化了从早期微小病灶到实体瘤的TME酸性的时空演变。PPS在酸性条件下表现出增强的光热效应，其与质子泵抑制剂埃索美拉唑联用可协同抑制肿瘤生长。总之，PPS辅助的光声分子成像提供了一种灵敏且特异的方法来表征肿瘤的发生与进展，支持其在靶向酸性TME的早期诊断和治疗策略中的潜在应用。

### 第二部分 AI 大师评价

本研究旨在解决肿瘤微环境（TME）酸性在体可视化与量化不足的难题，核心目的是开发一种新型成像工具以评估肿瘤进展。研究者首先明确了V-ATP酶亚基ATP6V0C在驱动TME酸化及与肝癌进展相关中的关键作用，并以此为基础，创新性地开发了pH响应比率式光声传感器（PPS）。该方法学的主要创新在于实现了从肿瘤发生到转移全过程的、动态的、高特异性的酸性TME多尺度成像，并将诊断成像与基于质子泵抑制剂的协同治疗潜力相结合。然而，摘要未提及该传感器在更广泛肿瘤类型中的验证数据，也未讨论其潜在的体内生物相容性或长期毒性，这些是未来临床转化前需进一步评估的局限性。

---

## 20. DNA末端构型决定非同源末端连接介导的末端桥接过程中的突触复合物形成。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545368)
**期刊：** Nature communications
**PMID：** 41545368
**DOI：** 10.1038/s41467-026-68417-0

### 第一部分 原文与翻译

**英文原标题：** DNA end configurations dictate synaptic complex formation during NHEJ-mediated end bridging.

> **英文摘要：**
> Synapsis, the physical bridging of two broken DNA ends, is a critical step in non-homologous DNA end joining (NHEJ), the primary pathway for repairing DNA double-strand breaks (DSBs) in vertebrates. While NHEJ synapsis has been well characterized using blunt-ended DNA, how diverse DNA end configurations influence synaptic complex formation remains much less clear. Here, using single-molecule FRET, we show that end configurations play a decisive role in synapsis pathway choice, with end pairing compensating for XLF in facilitating synaptic complex transitions. Notably, 3-nucleotide (nt) microhomology at DNA ends significantly enhances close synaptic (CS) complex formation mediated by Ku70-Ku80 (Ku) and XRCC4-Ligase IV (X4L4), even in the absence of XLF. Although XLF is nonessential for synapsis with 3-nt microhomology, it further promotes CS formation when present. The FRET analysis reveals that the single-stranded and double-stranded junctions of the DNA ends are in close contact within the primary CS complex, while the overhangs flip out of the duplex, potentially stabilizing the complex. These findings underscore the pivotal role of DNA end configurations in regulating synapsis and their broader implications for NHEJ repair efficiency and fidelity.

> **中文摘要：**
> 突触，即两个断裂DNA末端的物理桥接，是脊椎动物修复DNA双链断裂的主要途径——非同源末端连接中的关键步骤。虽然利用平末端DNA已对NHEJ突触进行了很好的表征，但不同的DNA末端构型如何影响突触复合物的形成仍远不清楚。在此，我们利用单分子FRET技术表明，末端构型在突触途径选择中起决定性作用，末端配对可补偿XLF以促进突触复合物的转变。值得注意的是，DNA末端的3个核苷酸微同源性显著增强了由Ku70-Ku80和XRCC4-Ligase IV介导的紧密突触复合物的形成，即使在缺乏XLF的情况下也是如此。虽然XLF对于具有3-nt微同源性的突触并非必需，但当其存在时，会进一步促进CS复合物的形成。FRET分析揭示，在初级CS复合物中，DNA末端的单链和双链连接处紧密接触，而突出端则从双链体中翻转出来，这可能稳定了复合物。这些发现强调了DNA末端构型在调控突触中的关键作用及其对NHEJ修复效率和保真度的更广泛意义。

### 第二部分 AI 大师评价

本研究旨在阐明DNA末端构型对NHEJ修复中关键步骤——突触复合物形成的调控机制。研究团队创新性地运用单分子FRET技术，系统分析了不同末端构型（特别是具有微同源性的末端）对突触途径选择及复合物稳定性的影响。核心发现是，3-nt微同源性可显著促进由Ku和X4L4介导的紧密突触复合物形成，并揭示了末端配对可部分替代XLF功能，以及复合物内独特的结构特征。该研究深化了对NHEJ机制多样性的理解，但主要基于体外单分子观察，其生理相关性及在复杂染色质环境中的适用性仍需进一步验证。

---

## 21. NALIRIFOX对比吉西他滨联合白蛋白结合型紫杉醇治疗中国晚期胰腺导管腺癌患者：一项随机、开放标签的II期试验。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545349)
**期刊：** Nature communications
**PMID：** 41545349
**DOI：** 10.1038/s41467-026-68409-0

### 第一部分 原文与翻译

**英文原标题：** NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial.

> **英文摘要：**
> In this phase 2 study (NCT05047991), patients with unresectable metastatic pancreatic adenocarcinoma were randomized to receive NALIRIFOX (liposomal irinotecan, 5-FU, leucovorin, and oxaliplatin) or gemcitabine plus nab-paclitaxel. The primary endpoint was progression free survival (PFS). Secondary endpoints included other efficacy outcomes (overall survival, objective response rate, disease control rate, and duration of response), as well as safety, pharmacokinetic parameters, and evaluation of the relationship between UGT1A1*6 and UGT1A1*28 polymorphisms and safety. A total of 117 patients were enrolled and randomly assigned to NALIRIFOX (n = 78) or gemcitabine plus nab-paclitaxel (n = 39). At a median follow-up of 18.7 months (interquartile range [IQR], 7.5-22.1) for NALIRIFOX and 12.1 months (IQR: 6.4-14.8) for the gemcitabine plus nab-paclitaxel, median PFS was 7.6 months (95% CI 5.52-9.23) with NALIRIFOX versus 3.7 months (95% CI 3.38-5.32) with gemcitabine plus nab-paclitaxel (hazard ratio, 0.56; 95% CI, 0.35-0.88; P = 0.0115). ≥ Grade 3 treatment-emergent adverse events (TEAEs) occurred in 73.1% of patients receiving NALIRIFOX and 84.6% of patients receiving gemcitabine plus nab-paclitaxel, respectively. Despite the premature termination (predetermined sample size of n = 153 not reached) of the study, NALIRIFOX demonstrated improvement in PFS compared with gemcitabine plus nab-paclitaxel, with a manageable safety profile in Chinese patients with advanced pancreatic adenocarcinoma.

> **中文摘要：**
> 在这项II期研究（NCT05047991）中，不可切除的转移性胰腺导管腺癌患者被随机分配接受NALIRIFOX（伊立替康脂质体、5-FU、亚叶酸和奥沙利铂）或吉西他滨联合白蛋白结合型紫杉醇治疗。主要终点是无进展生存期（PFS）。次要终点包括其他疗效结果（总生存期、客观缓解率、疾病控制率和缓解持续时间），以及安全性、药代动力学参数，并评估UGT1A1*6和UGT1A1*28多态性与安全性的关系。共入组117例患者，随机分配至NALIRIFOX组（n=78）或吉西他滨联合白蛋白结合型紫杉醇组（n=39）。NALIRIFOX组的中位随访时间为18.7个月（四分位距[IQR]，7.5-22.1），吉西他滨联合白蛋白结合型紫杉醇组为12.1个月（IQR：6.4-14.8）。NALIRIFOX组的中位PFS为7.6个月（95% CI 5.52-9.23），而吉西他滨联合白蛋白结合型紫杉醇组为3.7个月（95% CI 3.38-5.32）（风险比，0.56；95% CI，0.35-0.88；P=0.0115）。接受NALIRIFOX治疗的患者中有73.1%发生了≥3级的治疗中出现的不良事件（TEAEs），而接受吉西他滨联合白蛋白结合型紫杉醇治疗的患者中这一比例为84.6%。尽管研究提前终止（未达到预设的153例样本量），但在中国晚期胰腺导管腺癌患者中，与吉西他滨联合白蛋白结合型紫杉醇相比，NALIRIFOX显示出PFS的改善，且安全性可控。

### 第二部分 AI 大师评价

本研究是一项针对中国晚期胰腺癌患者的II期随机对照试验，核心目的是比较NALIRIFOX方案与标准方案（吉西他滨+白蛋白紫杉醇）的疗效与安全性。研究采用随机、开放标签设计，主要终点为PFS，并探索了UGT1A1基因多态性与安全性的关系。研究发现，NALIRIFOX组的中位PFS显著优于对照组（7.6个月 vs. 3.7个月），且≥3级不良事件发生率更低，提示该方案在中国人群中具有潜在优势。其创新性在于提供了该联合方案在中国人群中的首个关键性疗效与安全性数据，并关注了药物基因组学。主要局限性在于研究因故提前终止，样本量未达预设目标，可能影响结果的统计效力与普适性。

---

## 22. CREB1通过调控应激耐受性维持多发性骨髓瘤细胞存活

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545347)
**期刊：** Cell death & disease
**PMID：** 41545347
**DOI：** 10.1038/s41419-025-08246-z

### 第一部分 原文与翻译

**英文原标题：** Regulation of stress tolerance by CREB1 sustains multiple myeloma cell survival.

> **英文摘要：**
> Multiple myeloma (MM) cells originate from antibody-producing plasma cells and endure chronic oxidative and proteotoxic stress due to the excessive production of immunoglobulins and free light chains. We previously demonstrated that CD56 (also known as neuronal cell adhesion molecule 1) promotes cAMP-responsive element binding (CREB1) activation in MM cells to drive survival, without fully elucidating its mechanism of action. In this study, we describe the global role of CREB1 in regulating tolerance to cellular stresses in MM. Here, we present data to demonstrate that CREB1 directly or indirectly influences key proteins involved in the clearance of oxidants, the unfolded protein response (UPR), and autophagy. In silico data from real patients with MM showed that patients with high CREB1 expression have greater activation of gene sets associated with endurance of stress. We confirmed by genomic and pharmacological modulation that CREB1 activates the mTOR pathway, halting autophagy, and directly binds to the promoter of NRF2 and PERK, modulating genes involved in oxidation and protein stress adaptation. Of particular importance was the identification of TXNIP among the regulated genes. Notably, the TXNIP gene belongs to the 1q21 cytoband, which is amplified in 30 percent of patients with MM, leading to poor outcomes. We showed for the first time that TXNIP inhibition is also toxic against MM cells, interfering with UPR and autophagy. Thus, our data highlights the essential roles of CREB1 and TXNIP in MM cell survival under chronic stress, providing new insights into MM pathophysiology and novel therapeutic strategies for patients with high-risk disease.

> **中文摘要：**
> 多发性骨髓瘤（MM）细胞起源于抗体分泌性浆细胞，并因免疫球蛋白和游离轻链的过量生产而承受着慢性的氧化应激和蛋白毒性应激。我们先前已证明CD56（也称为神经细胞粘附分子1）能促进MM细胞中cAMP反应元件结合蛋白（CREB1）的活化以驱动细胞存活，但未完全阐明其作用机制。在本研究中，我们描述了CREB1在调控MM细胞应激耐受性中的全局性作用。我们在此提供数据证明，CREB1直接或间接地影响参与氧化剂清除、未折叠蛋白反应（UPR）和自噬的关键蛋白。来自真实MM患者的生物信息学数据显示，CREB1高表达的患者与应激耐受相关的基因集具有更强的活化。我们通过基因组学和药理学调控证实，CREB1激活mTOR通路，从而抑制自噬，并直接结合NRF2和PERK的启动子，调控参与氧化和蛋白质应激适应的基因。尤为重要的是，在被调控的基因中鉴定出了TXNIP。值得注意的是，TXNIP基因位于1q21细胞带，该区域在30%的MM患者中发生扩增，导致不良预后。我们首次证明，抑制TXNIP同样对MM细胞具有毒性作用，干扰UPR和自噬。因此，我们的数据强调了CREB1和TXNIP在慢性应激下MM细胞存活中的关键作用，为MM的病理生理学提供了新见解，并为高危疾病患者提供了新的治疗策略。

### 第二部分 AI 大师评价

本研究旨在系统阐明转录因子CREB1在多发性骨髓瘤（MM）细胞应对慢性应激中的核心调控作用。研究综合运用了生物信息学分析、基因组学与药理学干预等方法，揭示了CREB1通过激活mTOR通路抑制自噬、直接调控NRF2和PERK等关键节点，从而整合氧化应激、UPR和自噬等多条应激响应通路的分子机制。其核心创新点在于首次将CREB1定位为MM细胞应激耐受的全局调控枢纽，并发现了位于高危扩增区域1q21的TXNIP是CREB1的关键下游效应分子，其抑制同样具有抗MM活性，为高危MM提供了新的潜在治疗靶点。然而，研究主要在细胞层面展开，CREB1/TXNIP轴在体内MM微环境中的具体作用及其作为治疗靶点的转化潜力，仍需后续实验验证。

---

## 23. TRIM3/TLR3轴通过克服IFN-β反馈抑制来抑制非小细胞肺癌进展。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545343)
**期刊：** Cell death & disease
**PMID：** 41545343
**DOI：** 10.1038/s41419-025-08265-w

### 第一部分 原文与翻译

**英文原标题：** The TRIM3/TLR3 axis overrides IFN-β feedback inhibition to suppress NSCLC progression.

> **英文摘要：**
> Interferon-beta (IFN-β) has potent antitumor activity, but its clinical therapeutic potential is undermined by intrinsic negative feedback loops that suppress IFN-β production. However, the feedback mechanisms regulating IFN-β homeostasis in non-small cell lung cancer (NSCLC) remain unclear. We found that tripartite motif containing 3 (TRIM3) promotes the transcription and mRNA expression of IFNB1. Conversely, excessive IFN-β inhibits expression of TRIM3, creating their reciprocal feedback loop. Mass spectrometry revealed that toll-like receptor 3 (TLR3), a key sensor that triggers IFN-β production, is the interacting partner of TRIM3. Following the elucidation of the interactive mode between TRIM3 and TLR3, we found that activation of the TRIM3/TLR3 axis induced IFN-β secretion and overrode the feedback inhibition. Sustained IFN-β secretion subsequently inhibits NSCLC cell proliferation and reprograms the tumor microenvironment by increasing the infiltration levels of CD4 T cells, M1 macrophages and NK cells. Our findings revealed a reciprocal negative feedback loop in the regulation of IFN-β signaling, highlighting the role of the TRIM3/TLR3 axis in the suppression of NSCLC progression and offering a promising strategy to suppress tumor growth and enhance immunotherapy efficacy in NSCLC.

> **中文摘要：**
> 干扰素-β（IFN-β）具有强大的抗肿瘤活性，但其临床治疗潜力受到抑制IFN-β产生的内在负反馈环路的影响。然而，在非小细胞肺癌（NSCLC）中调节IFN-β稳态的反馈机制尚不清楚。我们发现，包含三方基序的蛋白3（TRIM3）能促进IFNB1的转录和mRNA表达。相反，过量的IFN-β会抑制TRIM3的表达，从而形成它们之间的相互反馈环路。质谱分析揭示，Toll样受体3（TLR3）——一个触发IFN-β产生的关键传感器——是TRIM3的相互作用伙伴。在阐明TRIM3与TLR3之间的相互作用模式后，我们发现激活TRIM3/TLR3轴可诱导IFN-β分泌并克服反馈抑制。持续的IFN-β分泌随后抑制NSCLC细胞增殖，并通过增加CD4 T细胞、M1巨噬细胞和NK细胞的浸润水平来重编程肿瘤微环境。我们的研究结果揭示了IFN-β信号调控中存在一个相互负反馈环路，凸显了TRIM3/TLR3轴在抑制NSCLC进展中的作用，并为抑制肿瘤生长和增强NSCLC免疫治疗效果提供了一种有前景的策略。

### 第二部分 AI 大师评价

本研究旨在阐明NSCLC中IFN-β稳态调控的反馈机制。通过结合分子生物学和质谱分析，发现TRIM3与TLR3相互作用，并揭示了TRIM3/TLR3轴能够克服IFN-β与TRIM3之间的相互负反馈，从而持续激活IFN-β信号。其创新性在于发现了一个新的调控轴，不仅抑制肿瘤细胞增殖，还能重塑免疫微环境，为NSCLC治疗提供了潜在靶点。然而，研究主要基于机制探索，其临床转化潜力及在复杂人体肿瘤微环境中的具体作用仍需后续实验验证。

---

## 24. 环氧-氧脂素在人类炎症消退过程中指导单核细胞命运。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545341)
**期刊：** Nature communications
**PMID：** 41545341
**DOI：** 10.1038/s41467-025-67961-5

### 第一部分 原文与翻译

**英文原标题：** Epoxy-oxylipins direct monocyte fate in inflammatory resolution in humans.

> **英文摘要：**
> The role of cytochrome P450-derived epoxy-oxylipins and their metabolites in human inflammation and resolution is unknown. We report that epoxy-oxylipins are present in blood of healthy, male volunteers at baseline and following intradermal injection of UV-killed Escherichia coli, an experimental model of acute resolving inflammation. At the site of inflammation, cytochrome P450s and epoxide hydrolase (EH) isoforms, which catabolise oxylipins to corresponding diols, are differentially upregulated throughout the inflammatory response, as is the biosynthesis of epoxy-oxylipins. GSK2256294, a selective sEH inhibitor specifically elevates 12,13-EpOME and 14,15-EET. While inhibition of sEH hastens pain resolution, it has no effect on tissue heat, redness and swelling. GSK2256294, however, significantly reduces numbers of circulating intermediate monocytes that expand during inflammation. We find that 12,13-EpOME blocks the transition of classical to intermediate monocytes in a p38 MAPK-dependent manner, results that are recapitulated when blocking p38 MAPK in vitro and when administering the p38 MAPK inhibitor losmapimod in vivo to healthy volunteers. Furthermore, fewer intermediate monocytes are observed at the site of inflammation, accompanied by reduced tissue CD4 T cells. Hence, we have mapped the expression, activity and function of epoxy-oxylipins in human inflammation revealing new mechanisms of monocyte differentiation and resolution biology.

> **中文摘要：**
> 细胞色素P450来源的环氧-氧脂素及其代谢物在人类炎症和消退中的作用尚不清楚。我们报告，在基线状态及皮内注射紫外线灭活的大肠杆菌（一种急性消退性炎症的实验模型）后，健康男性志愿者的血液中存在环氧-氧脂素。在炎症部位，将氧脂素分解为相应二醇的细胞色素P450s和环氧化物水解酶（EH）亚型，以及环氧-氧脂素的生物合成，在整个炎症反应过程中均被差异性上调。选择性sEH抑制剂GSK2256294特异性升高了12,13-EpOME和14,15-EET。虽然抑制sEH加速了疼痛消退，但对组织发热、发红和肿胀没有影响。然而，GSK2256294显著减少了炎症期间扩增的循环中间型单核细胞数量。我们发现，12,13-EpOME以p38 MAPK依赖的方式阻断经典单核细胞向中间型单核细胞的转变，这一结果在体外阻断p38 MAPK以及向健康志愿者体内给予p38 MAPK抑制剂losmapimod时得到了重现。此外，在炎症部位观察到更少的中间型单核细胞，并伴有组织CD4 T细胞的减少。因此，我们绘制了环氧-氧脂素在人类炎症中的表达、活性和功能图谱，揭示了单核细胞分化和消退生物学的新机制。

### 第二部分 AI 大师评价

本研究旨在探究环氧-氧脂素在人类炎症消退中的作用机制。研究采用急性消退性炎症模型，结合选择性sEH抑制剂干预，发现环氧-氧脂素通过p38 MAPK信号通路调控单核细胞亚型转换，从而影响炎症消退，揭示了脂质介质调控免疫细胞命运的新机制。创新性在于首次在人体中系统描绘了环氧-氧脂素的动态变化及其对单核细胞分化的直接调控作用，为靶向炎症消退提供了新思路。局限性在于研究对象为健康男性志愿者，模型为急性细菌成分诱导的炎症，其结论在慢性炎症或女性群体中的普适性有待验证。

---

## 25. 代谢功能障碍相关脂肪性肝病通过巨噬细胞迁移抑制因子-CD44轴加速胰腺癌进展和转移。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545340)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41545340
**DOI：** 10.1038/s41392-025-02562-8

### 第一部分 原文与翻译

**英文原标题：** Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via the macrophage migration inhibitory factor-CD44 axis.

> **英文摘要：**
> Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a poor prognosis, particularly in the presence of liver metastases. The mechanisms by which metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), influences PDAC progression and metastasis remain poorly understood. This study investigates the role of MASLD in fostering an immunosuppressive microenvironment conducive to PDAC liver metastases and identifies the macrophage migration inhibitory factor (MIF)-CD44 axis as a key mediator of this process. Utilizing data from the UK Biobank (450,754 participants, median follow-up 14.5 years), we observed an overall increased risk of PDAC in the MASLD population (HR: 3.48; 95% CI: 2.69-4.50; P < 0.0001). Clinical cohorts confirmed the strong association between MASLD and hepatic metastases (OR: 7.06; 95% CI: 4.62-10.78; P < 0.0001). Experimental mouse models demonstrated that MASLD enhances tumor cell stem性、免疫逃逸和转移性肝组织中的粘着斑形成。从机制上讲，MASLD诱导的MIF分泌促进了CD44阳性PDAC细胞的迁移、干细胞特性和粘附。通过基因或药理学手段（使用MIF互变异构酶抑制剂IPG1576）靶向MIF，在临床前模型中显著减轻了肝转移。患者样本验证显示，在MASLD相关的PDAC肝转移灶中，肝脏MIF和CD44表达升高。本研究强调了MIF-CD44轴是一个有前景的治疗靶点，并强调了为合并MASLD的PDAC患者制定针对性治疗的重要性。

> **中文摘要：**
> 胰腺导管腺癌（PDAC）是一种高度侵袭性、预后不良的恶性肿瘤，尤其是在存在肝转移的情况下。代谢功能障碍相关脂肪性肝病（MASLD，原名非酒精性脂肪性肝病，NAFLD）影响PDAC进展和转移的机制尚不清楚。本研究探讨了MASLD在促进有利于PDAC肝转移的免疫抑制微环境中的作用，并确定了巨噬细胞迁移抑制因子（MIF）-CD44轴是这一过程的关键介质。利用英国生物银行的数据（450,754名参与者，中位随访14.5年），我们观察到MASLD人群的PDAC总体风险增加（HR：3.48；95% CI：2.69-4.50；P < 0.0001）。临床队列证实了MASLD与肝转移之间的强相关性（OR：7.06；95% CI：4.62-10.78；P < 0.0001）。实验小鼠模型证明，MASLD增强了转移性肝组织中肿瘤细胞的干细胞特性、免疫逃逸和粘着斑形成。从机制上讲，MASLD诱导的MIF分泌促进了CD44阳性PDAC细胞的迁移、干细胞特性和粘附。通过基因或药理学手段（使用MIF互变异构酶抑制剂IPG1576）靶向MIF，在临床前模型中显著减轻了肝转移。患者样本验证显示，在MASLD相关的PDAC肝转移灶中，肝脏MIF和CD44表达升高。本研究强调了MIF-CD44轴是一个有前景的治疗靶点，并强调了为合并MASLD的PDAC患者制定针对性治疗的重要性。

### 第二部分 AI 大师评价

本研究旨在阐明代谢功能障碍相关脂肪性肝病（MASLD）促进胰腺导管腺癌（PDAC）肝转移的机制。研究综合运用了大规模人群队列（UK Biobank）、临床队列、小鼠模型及患者样本，方法学严谨。核心发现是MASLD通过诱导巨噬细胞迁移抑制因子（MIF）分泌，激活CD44通路，从而增强PDAC细胞的干细胞特性、迁移和粘附，最终驱动肝转移。其创新性在于首次系统揭示了MIF-CD44轴在MASLD相关PDAC进展中的关键作用，并提供了靶向该轴的临床前治疗证据。局限性可能在于，尽管机制研究深入，但将MIF抑制剂转化为临床应用的疗效和安全性仍需进一步验证，且MASLD的异质性对PDAC的影响可能未被完全解析。

---

## 26. 胰腺癌中RAS通路的垂直抑制驱动可被治疗性利用的线粒体改变。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545339)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41545339
**DOI：** 10.1038/s41392-025-02563-7

### 第一部分 原文与翻译

**英文原标题：** Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations.

> **英文摘要：**
> Oncogenic KRAS mutations drive metabolic reprogramming in pancreatic ductal adenocarcinoma (PDAC). Src-homology 2 domain-containing phosphatase 2 (SHP2) is essential for full KRAS activity, and promising dual SHP2/mitogen-activated protein kinase (MAPK) inhibition is currently being tested in clinical trials. Exploitable metabolic adaptations may contribute to invariably evolving resistance. To understand the metabolic changes induced by dual inhibition, we comprehensively tested human and murine PDAC cell lines, endogenous tumor models, and patient-derived organoids, which are representative of the full spectrum of PDAC molecular subtypes. We found that dual SHP2/mitogen-activated protein kinase kinase (MEK1/2) inhibition induces major alterations in mitochondrial mass and function, impacts reactive oxygen species (ROS) homeostasis and triggers lipid peroxidase dependency. Anabolic pathways, autophagy and glycolysis were also profoundly altered. However, most strikingly, mitochondrial remodeling was evident, persisting into a therapy-resistant state. The resulting vulnerability to the induction of ferroptotic cell death via the combination of vertical SHP2/MEK1/2 with glutathione peroxidase (GPX4) inhibition was largely independent of the PDAC molecular subtype and was confirmed with direct targeting of RAS. The triple combination of SHP2/MEK1/2 inhibition and the ferroptosis-inducing natural compound withaferin A suppressed tumor progression in an endogenous PDAC tumor model in vivo. Our study offers a metabolic leverage point to reinforce RAS pathway interference for targeted PDAC treatment.

> **中文摘要：**
> 致癌性KRAS突变驱动胰腺导管腺癌（PDAC）的代谢重编程。含Src同源2结构域的磷酸酶2（SHP2）对于KRAS的完全活性至关重要，目前有前景的SHP2/丝裂原活化蛋白激酶（MAPK）双重抑制疗法正在临床试验中进行测试。可被利用的代谢适应可能导致了不可避免的耐药性演化。为了理解双重抑制诱导的代谢变化，我们全面测试了人源和鼠源PDAC细胞系、内源性肿瘤模型以及患者来源的类器官，这些模型代表了PDAC全谱系的分子亚型。我们发现，SHP2/丝裂原活化蛋白激酶激酶（MEK1/2）双重抑制会诱导线粒体质量和功能的重大改变，影响活性氧（ROS）稳态并触发对脂质过氧化物酶的依赖性。合成代谢途径、自噬和糖酵解也发生了深刻改变。然而，最引人注目的是，线粒体重塑非常明显，并持续存在于治疗抵抗状态中。由此产生的、通过垂直SHP2/MEK1/2抑制与谷胱甘肽过氧化物酶4（GPX4）抑制相结合来诱导铁死亡细胞死亡的脆弱性，在很大程度上与PDAC的分子亚型无关，并且通过直接靶向RAS得到了证实。SHP2/MEK1/2抑制与铁死亡诱导天然化合物醉茄素A的三联组合，在体内内源性PDAC肿瘤模型中抑制了肿瘤进展。我们的研究为加强RAS通路干预以进行靶向PDAC治疗提供了一个代谢杠杆点。

### 第二部分 AI 大师评价

本研究旨在探索胰腺癌中RAS通路垂直抑制（SHP2/MEK1/2双重抑制）引发的代谢变化及其治疗意义。研究团队采用了涵盖PDAC全谱系分子亚型的多层次模型（细胞系、内源性肿瘤模型、患者类器官），方法学较为全面。核心发现是，该抑制策略会驱动显著的、持续至耐药状态的线粒体重塑，并导致肿瘤细胞对铁死亡的脆弱性增加，这种脆弱性具有广谱性。其创新性在于揭示了线粒体代谢改变作为克服耐药性的新靶点，并提出了SHP2/MEK1/2抑制剂联合铁死亡诱导剂（如醉茄素A）的三联疗法新策略，为临床转化提供了新思路。局限性在于，研究主要基于临床前模型，其体内疗效和安全性仍需进一步临床试验验证。

---

## 27. 胰腺癌中细胞外囊泡来源的miRNA-182-5p诱导巨噬细胞向免疫抑制表型转化。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545338)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41545338
**DOI：** 10.1038/s41392-025-02559-3

### 第一部分 原文与翻译

**英文原标题：** Extracellular vesicle-derived miRNA-182-5p educates macrophages towards an immunosuppressive phenotype in pancreatic cancer.

> **英文摘要：**
> Reprogramming the immunosuppressive milieu in pancreatic cancer (PaCa) remains an important yet unmet therapeutic goal. Although tumor-associated macrophages (TAMs) are known to promote tumor growth and metastasis, little is known about the underlying mechanisms driving macrophage plasticity in PaCa. Herein, we show that extracellular vesicles (EVs) released by PaCa cells as well as circulating EVs in patient plasma, facilitate cellular crosstalk thereby promoting preferential skewing of recipient macrophages towards an M2-like TAM phenotype. PaCa-EV educated macrophages predominantly secrete anti-inflammatory cytokines, adapt an M2-like metabolic phenotype, have a higher expression of PD-L1, and suppress the proliferation of CD8 T cells. An increased payload of miR-182-5p in PaCa-EV cargo causes a decrease in TLR4 expression in recipient macrophages and a concomitant upregulation of JAK/STAT3 pathway and elevated secretion of IL-10 and TGF-β, leading to increased PD-L1 expression. Most notably, targeted therapeutic delivery of antagomiR-182-5p in pancreatic tumor-bearing mice with varying immunogenic potential results in a significant decrease in tumor体积, increased survival, restoration of M1/M2 ratio, and an overall increase in CD8 T cell activation in the TME. Taken together, we demonstrate a direct role of EVs in subverting the immune microenvironment and altering macrophage plasticity in a manner conducive to both tumor growth and proliferation. As such, a targeted delivery of microRNA inhibitors as drugs for altering macrophage plasticity may likely achieve better therapeutic response in pancreatic tumors.

> **中文摘要：**
> 重编程胰腺癌（PaCa）中的免疫抑制微环境仍然是一个重要但尚未实现的治疗目标。尽管已知肿瘤相关巨噬细胞（TAMs）能促进肿瘤生长和转移，但对于驱动胰腺癌中巨噬细胞可塑性的潜在机制知之甚少。在此，我们证明胰腺癌细胞释放的细胞外囊泡（EVs）以及患者血浆中的循环EVs，促进了细胞间通讯，从而优先诱导受体巨噬细胞向M2样TAM表型偏移。经胰腺癌EV“教育”的巨噬细胞主要分泌抗炎细胞因子，适应M2样代谢表型，PD-L1表达更高，并能抑制CD8 T细胞的增殖。胰腺癌EV货物中miR-182-5p载量的增加导致受体巨噬细胞中TLR4表达下降，并伴随JAK/STAT3通路上调以及IL-10和TGF-β分泌增加，从而导致PD-L1表达升高。最值得注意的是，在不同免疫原性潜能的胰腺癌荷瘤小鼠中，靶向递送antagomiR-182-5p进行治疗，可导致肿瘤体积显著减小、生存期延长、M1/M2比例恢复，以及肿瘤微环境中CD8 T细胞活化的整体增加。综上所述，我们证明了EVs在颠覆免疫微环境和改变巨噬细胞可塑性方面发挥直接作用，其方式有利于肿瘤生长和增殖。因此，靶向递送microRNA抑制剂作为改变巨噬细胞可塑性的药物，可能在胰腺肿瘤中取得更好的治疗反应。

### 第二部分 AI 大师评价

本研究旨在阐明胰腺癌免疫抑制微环境中巨噬细胞表型转化的新机制。作者通过实验证明，胰腺癌细胞来源的细胞外囊泡（EVs）通过递送miR-182-5p，下调巨噬细胞TLR4并激活JAK/STAT3通路，从而诱导其向免疫抑制性M2表型极化，并促进肿瘤生长。研究的创新性在于揭示了EV-miR-182-5p-TLR4轴是调控巨噬细胞可塑性的关键通路，并通过靶向抑制该miRNA在动物模型中验证了其治疗潜力，为胰腺癌免疫治疗提供了新靶点。局限性在于，研究主要基于临床前模型，其转化至临床应用的有效性及潜在副作用仍需进一步探索。

---

## 28. 可切除非小细胞肺癌患者围手术期基于派安普利单抗的联合治疗（ALTER-L043）：一项开放标签、多中心、随机、II期试验。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545337)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41545337
**DOI：** 10.1038/s41392-025-02544-w

### 第一部分 原文与翻译

**英文原标题：** Perioperative penpulimab-based combination therapy in patients with resectable non-small cell lung cancer (ALTER-L043): an open-label, multicenter, randomized, phase II trial.

> **英文摘要：**
> Although perioperative immunotherapy combined with neoadjuvant chemotherapy has improved the clinical outcomes of patients with resectable non-small cell lung cancer (NSCLC), the optimal combination strategy remains unknown. This multicenter, open-label, randomized, phase II trial (ALTER-L043; NCT04846634) evaluated the efficacy and safety of perioperative penpulimab plus anlotinib with or without neoadjuvant chemotherapy in patients with resectable NSCLC. Eligible patients were randomly assigned (1:1:1) to receive 3-4 cycles of neoadjuvant penpulimab (200 mg on day 1) plus anlotinib (12 mg on days 1-14) and chemotherapy, penpulimab plus chemotherapy, or penpulimab plus anlotinib, followed by surgery and matching adjuvant therapy. The primary endpoint was the investigator-assessed major pathologic response (MPR) rate. Between December 3, 2021, and January 23, 2024, 90 patients were randomly assigned to the penpulimab plus anlotinib and chemotherapy (n = 30), penpulimab plus chemotherapy (n = 30), or penpulimab plus anlotinib (n = 30) groups. Definitive surgery was performed in 92.6%, 89.7%, and 70.0% of patients, respectively. Among those who underwent surgery, the MPR and pathological complete response rates were 76.0% (95% CI 54.9-90.6) and 52.0% (95% CI 31.3-72.2), respectively, in the penpulimab plus anlotinib and chemotherapy group; 57.7% (95% CI 36.9-76.7) and 50.0% (95% CI 29.9-70.1), respectively, in the penpulimab plus chemotherapy group; and 52.4% (95% CI 29.8-74.3) and 38.1% (95% CI 18.1-61.6), respectively, in the penpulimab plus anlotinib group. Across all treatment phases, the incidences of grade ≥3 treatment-related adverse events were 26.7%, 20.0%, and 30.0%, respectively. Penpulimab plus anlotinib with or without neoadjuvant chemotherapy demonstrated promising efficacy and a manageable safety profile in patients with resectable NSCLC, suggesting its potential as a viable perioperative treatment option.

> **中文摘要：**
> 尽管围手术期免疫治疗联合新辅助化疗改善了可切除非小细胞肺癌（NSCLC）患者的临床结局，但最佳联合策略仍不明确。这项多中心、开放标签、随机、II期试验（ALTER-L043；NCT04846634）评估了围手术期派安普利单抗联合安罗替尼，联合或不联合新辅助化疗，在可切除NSCLC患者中的疗效和安全性。符合条件的患者被随机分配（1:1:1）接受3-4个周期的新辅助派安普利单抗（第1天200 mg）联合安罗替尼（第1-14天12 mg）和化疗、派安普利单抗联合化疗、或派安普利单抗联合安罗替尼治疗，随后进行手术和匹配的辅助治疗。主要终点是研究者评估的主要病理缓解（MPR）率。在2021年12月3日至2024年1月23日期间，90名患者被随机分配到派安普利单抗联合安罗替尼和化疗组（n=30）、派安普利单抗联合化疗组（n=30）或派安普利单抗联合安罗替尼组（n=30）。各组分别有92.6%、89.7%和70.0%的患者接受了根治性手术。在接受手术的患者中，派安普利单抗联合安罗替尼和化疗组的MPR率和病理完全缓解率分别为76.0%（95% CI 54.9-90.6）和52.0%（95% CI 31.3-72.2）；派安普利单抗联合化疗组分别为57.7%（95% CI 36.9-76.7）和50.0%（95% CI 29.9-70.1）；派安普利单抗联合安罗替尼组分别为52.4%（95% CI 29.8-74.3）和38.1%（95% CI 18.1-61.6）。在所有治疗阶段，≥3级治疗相关不良事件的发生率分别为26.7%、20.0%和30.0%。派安普利单抗联合安罗替尼，联合或不联合新辅助化疗，在可切除NSCLC患者中显示出有前景的疗效和可控的安全性，表明其可能成为一种可行的围手术期治疗选择。

### 第二部分 AI 大师评价

本研究旨在探索可切除NSCLC围手术期免疫联合治疗的最佳策略，创新性地评估了PD-1抑制剂（派安普利单抗）联合抗血管生成药物（安罗替尼）这一“去化疗”方案，并与传统免疫联合化疗方案进行对比。结果显示，三联方案（免疫+抗血管+化疗）获得了最高的主要病理缓解率（76.0%），而“去化疗”的双联方案（免疫+抗血管）也显示出相当的疗效潜力（MPR率52.4%），且安全性可控。该研究为围手术期治疗提供了新的、可能更精准的联合模式选择。然而，作为II期试验，其样本量有限，且随访时间可能不足以评估长期生存结局，结论需更大规模的III期试验验证。

---

## 29. 细胞核内的Gasdermin E独立于细胞焦亡驱动内皮素-1诱导的转移进展。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545335)
**期刊：** Cell death & disease
**PMID：** 41545335
**DOI：** 10.1038/s41419-025-08202-x

### 第一部分 原文与翻译

**英文原标题：** Nuclear gasdermin E drives endothelin-1-induced metastatic progression independently of the pyroptosis.

> **英文摘要：**
> Elucidation of the molecular mechanism underlying metastatic dissemination in patients with high-grade serous ovarian carcinoma (HG-SOC) has the potential to affect patient outcome. This study explores the role of gasdermins (GSDMs) in HG-SOC, focusing on novel pyroptosis-independent nuclear functions of GSDME, which are integrated with the endothelin-1 (ET-1)/ET-1 receptor A (ETR) signaling to sustain metastatic progression. In this tumor, GSDME upregulation is correlated to epithelial-mesenchymal transition (EMT) and ETR expression. ET-1 signaling fuels GSDME expression by inducing its transcription via the core EMT factors, ZEB1 and ZEB2. GSDME, in turn, translocates to the nucleus to engage ZEB1 and transcriptionally regulate genes coupled with EMT and inflammatory signals, such as E-cadherin, vimentin and interleukin (IL)-6. GSDME depletion, similarly to ZEB1 and ETR blockade, restrains ET-1-induced EMT phenotypic plasticity and inflammatory cytokine release. Clinically relevant, ET-1 receptor (ET-1R) antagonist, by depleting the nuclear reservoir of the GSDME/ZEB1 transcriptional complex, hinders the metastatic traits of HG-SOC. The intertwined ETR/GSDME/ZEB1 circuitry characterizes mesenchymal HG-SOC patients and associates with a high-risk of poor survival. Together, these findings unveil GSDME as a key transcriptional regulator of aggressive behaviors and worse prognosis in HG-SOC patients, in an ET-1-driven alliance with ZEB1, which could be targeted by ET-1R antagonist to reduce the metastatic burden of this tumor.

> **中文摘要：**
> 阐明高级别浆液性卵巢癌（HG-SOC）患者转移扩散的分子机制，有可能影响患者的预后。本研究探讨了gasdermin蛋白（GSDMs）在HG-SOC中的作用，重点关注GSDME独立于细胞焦亡的新型核功能，该功能与内皮素-1（ET-1）/ET-1受体A（ETR）信号通路整合，共同维持转移进展。在该肿瘤中，GSDME的上调与上皮-间质转化（EMT）和ETR表达相关。ET-1信号通过核心EMT因子ZEB1和ZEB2诱导GSDME的转录，从而促进其表达。GSDME随后转位至细胞核，与ZEB1结合，并转录调控与EMT和炎症信号相关的基因，如E-钙黏蛋白、波形蛋白和白细胞介素（IL）-6。与ZEB1和ETR阻断类似，GSDME的耗竭可抑制ET-1诱导的EMT表型可塑性和炎性细胞因子的释放。具有临床相关性的是，ET-1受体（ET-1R）拮抗剂通过耗竭GSDME/ZEB1转录复合物的核储备，阻碍了HG-SOC的转移特性。相互交织的ETR/GSDME/ZEB1信号回路是间质型HG-SOC患者的特征，并与不良生存的高风险相关。总之，这些发现揭示了GSDME是HG-SOC患者侵袭行为和不良预后的关键转录调节因子，它与ZEB1在ET-1驱动下形成联盟，而ET-1R拮抗剂可以靶向该联盟，以减轻该肿瘤的转移负荷。

### 第二部分 AI 大师评价

本研究旨在阐明HG-SOC转移的新机制，聚焦于GSDME独立于焦亡的核内转录调控功能。研究采用分子生物学方法，揭示了ET-1信号通过ZEB1/2上调GSDME，后者入核与ZEB1形成复合物调控EMT及炎症相关基因表达的级联通路。其核心创新在于发现了GSDME在细胞核内作为转录共调节因子的新功能，并构建了ETR/GSDME/ZEB1这一驱动转移的信号轴，为使用ET-1R拮抗剂治疗提供了直接的理论依据。局限性在于研究主要基于机制探索，其临床转化潜力（如拮抗剂疗效）仍需后续的体内外实验和临床研究进一步验证。

---

## 30. 阿替利珠单抗联合或不联合贝伐珠单抗治疗后的原发性和继发性假性稳定与进展。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545308)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41545308
**DOI：** 10.1136/jitc-2025-013727

### 第一部分 原文与翻译

**英文原标题：** Primary and secondary pseudo-stability and progression after atezolizumab with and without bevacizumab.

> **英文摘要：**
> BACKGROUND: Atypical tumor response patterns associated with immunotherapies pose significant challenges for assessing treatment response and clinical decision-making. We characterized the epidemiology, clinical impact, and molecular determinants of pseudo-stability/progression after atezolizumab with and without bevacizumab across several histologies. METHODS: Post hoc individual-level analysis of 2980 patients across eight randomized trials of atezolizumab in non-small cell lung cancer, urothelial carcinoma, renal cell carcinoma (RCC), and hepatocellular carcinoma. RESULTS: Analyses of the temporal characteristics of atypical responses revealed two distinct patterns including primary and secondary pseudo-stability/progression. Primary pseudo-stability/progression is characterized by initial disease progression and subsequent regression, which occurs in 7.7%-12.5% of patients according to cancer type. In contrast, secondary progression is characterized by initial disease control with subsequent radiographic progression followed by tumor regression, and this occurs in 4.4%-10.8% of patients according to cancer type. Compared with patients matched by the same initial radiographic response, primary and secondary pseudo-stability/progression could be associated with similar or inferior overall survival outcomes depending on the cancer type and classification of the initial tumor response. Exploratory analyses indicate that clinical factors are not predictive of atypical responses, but pseudo-stability/progression could be associated with distinct genomic alterations including  in RCC. CONCLUSIONS: Primary and secondary pseudo-stability/progression occur in a non-trivial proportion of patients across cancer types. Outcomes after pseudo-stability/progression are dependent on cancer type and initial response. Uncovering the clinical and molecular features of pseudo-stability/progression subtypes may guide treatment decisions and identify patients who may benefit from continued immunotherapy despite radiographic progression.

> **中文摘要：**
> 背景：与免疫疗法相关的非典型肿瘤反应模式对评估治疗反应和临床决策提出了重大挑战。我们旨在描述阿替利珠单抗联合或不联合贝伐珠单抗治疗后，在不同组织学类型中假性稳定/进展的流行病学特征、临床影响及分子决定因素。方法：对八项阿替利珠单抗随机试验中的2980名患者（涵盖非小细胞肺癌、尿路上皮癌、肾细胞癌（RCC）和肝细胞癌）进行个体水平的回顾性分析。结果：对非典型反应时间特征的分析揭示了两种不同的模式，包括原发性和继发性假性稳定/进展。原发性假性稳定/进展的特征是初始疾病进展后出现后续消退，根据癌症类型，其发生率为7.7%-12.5%。相反，继发性进展的特征是初始疾病控制后出现影像学进展，随后肿瘤消退，根据癌症类型，其发生率为4.4%-10.8%。与具有相同初始影像学反应的患者相比，原发性和继发性假性稳定/进展可能与相似或更差的总生存结局相关，具体取决于癌症类型和初始肿瘤反应的分类。探索性分析表明，临床因素不能预测非典型反应，但假性稳定/进展可能与特定的基因组改变相关，包括RCC中的。结论：原发性和继发性假性稳定/进展在各类癌症患者中均占有不可忽视的比例。假性稳定/进展后的结局取决于癌症类型和初始反应。揭示假性稳定/进展亚型的临床和分子特征，可能有助于指导治疗决策，并识别那些尽管出现影像学进展但仍可能从持续免疫治疗中获益的患者。

### 第二部分 AI 大师评价

本研究旨在系统阐明阿替利珠单抗±贝伐珠单抗治疗中出现的非典型反应模式——原发性和继发性假性稳定/进展。其核心创新在于，通过对多项随机试验的个体水平数据进行回顾性分析，首次在多种实体瘤中量化了这两种模式的发生率，并揭示了其不同的时间动力学特征和潜在的分子关联。研究发现，这些非典型反应并非罕见，且其预后意义因癌症类型和初始反应而异，这挑战了单纯依赖早期影像学进展决定是否停止免疫治疗的常规做法。然而，研究为回顾性分析，且未明确阐述具体的分子决定因素（如RCC中的具体基因改变），其结论需在前瞻性研究中验证，以转化为可靠的临床预测工具。

---

## 31. 阻断CD300ld可克服晚期肿瘤中由PMN-MDSC介导的疫苗抵抗。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545307)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41545307
**DOI：** 10.1136/jitc-2025-013336

### 第一部分 原文与翻译

**英文原标题：** CD300ld blockade overcomes PMN-MDSC-mediated vaccine resistance in advanced tumors.

> **英文摘要：**
> BACKGROUND: While cancer vaccines have demonstrated promising clinical potential, their therapeutic efficacy against advanced tumors remains suboptimal, highlighting the critical need to elucidate resistance mechanisms and develop targeted solutions. We previously developed a stimulator of interferon genes (STING)-activating PC7A nanovaccine that elicits strong antitumor efficacy in multiple tumor models. In this study, we systematically investigated the mechanisms mediating nanovaccine resistance and provided targeting approaches to overcome this therapeutic barrier.
> 
> METHODS: Vaccine efficacy at early stage and advanced-stage tumors was investigated in the B16-OVA melanoma model and TC-1 human papillomavirus-induced cancer model, with tumor microenvironment being comprehensively analyzed by flow cytometry. In a vaccine-resistant tumor, elevated immunosuppressive activity of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) was assessed through multi-analysis including surface marker staining, reverse transcription-quantitative PCR, and functional T cell-suppression assay. To investigate the CD300ld blockade strategy, we employed CD300ld-knockout (KO) mice for genetic ablation, or recombinant protein capable of competitive inhibition for pharmacological intervention. For clinical relevance assessment, we tested different cancer vaccine formulations at late-stage tumors in humanized-CD3000ld mice.
> 
> RESULTS: In contrast to early stage vaccination, PC7A nanovaccine administration at the late tumor stage exhibited minimal therapeutic effects on tumor progression, while concurrently increasing PMN-MDSC infiltration and enhancing their immunosuppressive activity. KO of CD300ld, a critical immune suppressor on PMN-MDSCs, abolished both PMN-MDSC recruitment and their T-cell suppressive function, restoring the antitumor efficacy of PC7A vaccine in multiple advanced tumor models. Furthermore, in wild-type and CD300ld humanized mouse models, competitive blockade of CD300ld using recombinant extracellular domain proteins overcame resistance of advanced tumors to different cancer vaccine formulations.
> 
> CONCLUSION: Our results reveal that vaccination at the late tumor stage significantly augments the recruitment and immunosuppressive capacity of PMN-MDSCs, driving resistance of advanced tumors to cancer vaccines. The findings demonstrate PMN-MDSCs as critical mediators of vaccine resistance in advanced tumors and highlight modulation of PMN-MDSCs by CD300ld blockade as a promising strategy to enhance the therapeutic efficacy of cancer vaccines, particularly for patients with late-stage malignancies.

> **中文摘要：**
> 背景：尽管癌症疫苗已显示出良好的临床潜力，但其针对晚期肿瘤的治疗效果仍不理想，这凸显了阐明耐药机制和开发针对性解决方案的迫切需求。我们先前开发了一种激活干扰素基因刺激因子（STING）的PC7A纳米疫苗，该疫苗在多种肿瘤模型中均能引发强烈的抗肿瘤效果。在本研究中，我们系统性地研究了介导纳米疫苗耐药的机制，并提供了克服这一治疗障碍的靶向方法。
> 
> 方法：在B16-OVA黑色素瘤模型和TC-1人乳头瘤病毒诱导的癌症模型中，研究了疫苗在早期和晚期肿瘤中的疗效，并通过流式细胞术全面分析了肿瘤微环境。在疫苗耐药的肿瘤中，通过表面标志物染色、逆转录定量PCR和功能性T细胞抑制实验等多种分析，评估了多形核髓源性抑制细胞（PMN-MDSCs）增强的免疫抑制活性。为了研究CD300ld阻断策略，我们使用了CD300ld敲除（KO）小鼠进行基因消融，或使用能够进行竞争性抑制的重组蛋白进行药理学干预。为了评估临床相关性，我们在人源化CD300ld小鼠的晚期肿瘤中测试了不同的癌症疫苗制剂。
> 
> 结果：与早期疫苗接种相比，在肿瘤晚期给予PC7A纳米疫苗对肿瘤进展的治疗效果甚微，同时却增加了PMN-MDSC的浸润并增强了其免疫抑制活性。敲除PMN-MDSCs上的关键免疫抑制因子CD300ld，既能消除PMN-MDSC的募集，也能消除其T细胞抑制功能，从而在多种晚期肿瘤模型中恢复了PC7A疫苗的抗肿瘤疗效。此外，在野生型和CD300ld人源化小鼠模型中，使用重组胞外域蛋白竞争性阻断CD300ld，克服了晚期肿瘤对不同癌症疫苗制剂的耐药性。
> 
> 结论：我们的研究结果表明，在肿瘤晚期进行疫苗接种会显著增强PMN-MDSC的募集和免疫抑制能力，从而驱动晚期肿瘤对癌症疫苗产生耐药性。这些发现证明了PMN-MDSCs是晚期肿瘤疫苗耐药的关键介质，并强调了通过阻断CD300ld来调节PMN-MDSCs是一种有前景的策略，可增强癌症疫苗的疗效，尤其适用于晚期恶性肿瘤患者。

### 第二部分 AI 大师评价

本研究旨在揭示晚期肿瘤对癌症疫苗产生耐药的机制，并探索克服策略。核心方法是利用PC7A纳米疫苗模型，结合基因敲除和药理学阻断，系统评估了PMN-MDSCs及其表面分子CD300ld在介导耐药中的作用。研究发现，晚期疫苗接种会反常地增强PMN-MDSC的免疫抑制功能，而靶向CD300ld能有效逆转此过程，恢复疫苗疗效。其创新性在于明确了CD300ld是PMN-MDSCs介导疫苗耐药的关键节点，并提供了基因和药物两种干预的实证；局限性在于临床前模型的转化潜力仍需在人体试验中进一步验证，且未深入探讨CD300ld信号通路的下游具体机制。

---

## 32. Cergutuzumab amunaleukin在晚期实体瘤患者中的I期研究：活性生物标志物分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545306)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41545306
**DOI：** 10.1136/jitc-2025-012885

### 第一部分 原文与翻译

**英文原标题：** Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumors.

> **英文摘要：**
> BACKGROUND: Cergutuzumab amunaleukin (CA) is an immunocytokine comprising an anticarcinoembryonic antigen (CEA) linked to an interleukin-2 (IL-2) variant. CA does not bind to CD25 (IL-2 receptor α) and was designed to maintain the T and natural killer (NK) cell stimulatory effect, while avoiding stimulating effects on regulatory T cells (Tregs). In mouse models, CA previously demonstrated superior tumor targeting to CEA surface expression-positive (CEA+) tumors and increased CD8+ T cells and NK cell numbers in peripheral blood and tumor tissue when compared with wild-type IL-2. We present biomarker data from the first-in-human, open-label, multicenter, phase I, dose-escalation study investigating CA in patients with metastatic/unresectable CEA+ solid tumors (NCT02004106). METHODS: Patients received ascending doses of CA intravenously weekly (qw: 6/10/20 mg) or every 2 weeks (q2w: 10/20/30/40 mg). Flow cytometry determined absolute numbers/mL of CD4+ and CD8+ T cells, NK cells, macrophages/monocytes, Tregs, and B cells and their expression of activation and proliferation markers in circulation. Sequential pretreatment and on-treatment paired tumor biopsies were studied by flow cytometry, multicolor immunohistochemistry, and bulk RNA sequencing. Antitumor activity was used for correlative studies. RESULTS: Biomarker data were collected from 55 patients. After treatment, peripheral blood samples showed increased proliferating NK cells, CD8+ T cells, and CD4+ T cells, without an apparent dose effect. Levels of circulating soluble CD25 increased in patients with intermediate/high CA doses on-treatment; levels of cytokines, such as tumor necrosis factor, also increased with high CA dose levels. On-treatment tumor samples showed increases in total and proliferating CD8+ T cells as well as CD3+ perforin+ T cells but, importantly, not in Tregs. Notably, increases in the ratio of CD8+/CD4+ T cells were more pronounced for qw than for q2w dosing, while programmed death ligand-1-positive CD14+ cells increased, particularly for the q2w schedule. Higher on-treatment circulating levels of cytokines correlated with longer progression-free survival (PFS). Apart from the positive correlation with NK cell density, no other correlations between PFS and infiltrating immune cell populations in the tumor were observed. CONCLUSIONS: CA-induced immune pharmacodynamic effects in peripheral blood and in the tumor microenvironment without preferential Treg cell activation in patients with metastatic/unresectable CEA+ solid tumors. TRIAL REGISTRATION NUMBER: NCT02004106; BP28920.

> **中文摘要：**
> 背景：Cergutuzumab amunaleukin (CA) 是一种免疫细胞因子，由抗癌胚抗原 (CEA) 与一种白细胞介素-2 (IL-2) 变体连接而成。CA 不结合 CD25 (IL-2 受体 α)，其设计旨在维持对 T 细胞和自然杀伤 (NK) 细胞的刺激作用，同时避免对调节性 T 细胞 (Tregs) 的刺激作用。在小鼠模型中，与野生型 IL-2 相比，CA 先前已证明对 CEA 表面表达阳性 (CEA+) 的肿瘤具有更优的靶向性，并能增加外周血和肿瘤组织中的 CD8+ T 细胞和 NK 细胞数量。我们报告了首次人体、开放标签、多中心、I 期剂量递增研究 (NCT02004106) 中，CA 在转移性/不可切除 CEA+ 实体瘤患者中的生物标志物数据。方法：患者每周 (qw: 6/10/20 mg) 或每两周 (q2w: 10/20/30/40 mg) 静脉接受递增剂量的 CA。通过流式细胞术测定循环中 CD4+ 和 CD8+ T 细胞、NK 细胞、巨噬细胞/单核细胞、Tregs 和 B 细胞的绝对数量/mL 及其活化和增殖标志物的表达。通过流式细胞术、多色免疫组织化学和批量 RNA 测序对治疗前和治疗中序贯配对的肿瘤活检样本进行研究。抗肿瘤活性被用于相关性分析。结果：从 55 名患者收集了生物标志物数据。治疗后，外周血样本显示增殖的 NK 细胞、CD8+ T 细胞和 CD4+ T 细胞增加，无明显剂量效应。在接受中/高剂量 CA 治疗的患者中，循环可溶性 CD25 水平升高；细胞因子（如肿瘤坏死因子）水平在高 CA 剂量水平下也升高。治疗中的肿瘤样本显示，总 CD8+ T 细胞、增殖的 CD8+ T 细胞以及 CD3+ 穿孔素+ T 细胞增加，但重要的是，Tregs 没有增加。值得注意的是，CD8+/CD4+ T 细胞比率的增加在 qw 给药方案中比在 q2w 方案中更显著，而程序性死亡配体-1 阳性的 CD14+ 细胞增加，尤其是在 q2w 方案中。治疗中较高的循环细胞因子水平与较长的无进展生存期 (PFS) 相关。除了与 NK 细胞密度呈正相关外，未观察到 PFS 与肿瘤内浸润免疫细胞群之间的其他相关性。结论：在转移性/不可切除 CEA+ 实体瘤患者中，CA 诱导了外周血和肿瘤微环境中的免疫药效学效应，且未优先激活 Treg 细胞。试验注册号：NCT02004106; BP28920。

### 第二部分 AI 大师评价

本研究旨在评估新型免疫细胞因子CA在晚期实体瘤患者中的免疫药效学生物标志物。研究通过多维度流式细胞术、组织病理学和RNA测序，系统地分析了外周血和肿瘤微环境中免疫细胞亚群的变化。核心发现是CA能选择性激活CD8+ T细胞和NK细胞，而不刺激Tregs，并揭示了不同给药频率对免疫细胞比例的影响差异，以及循环细胞因子水平与PFS的相关性。其创新性在于验证了CA设计的靶向性激活机制，但作为I期研究，样本量有限且主要关注生物标志物，其临床疗效和最佳生物标志物组合仍需后续研究确认。

---

## 33. 硬脂酰辅酶A去饱和酶-1调控Th9淋巴细胞的分化及其抗肿瘤功能。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545305)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41545305
**DOI：** 10.1136/jitc-2025-013102

### 第一部分 原文与翻译

**英文原标题：** Stearoyl-CoA desaturase-1 controls the differentiation and antitumoral function of Th9 lymphocytes.

> **英文摘要：**
> BACKGROUND: Stearoyl-CoA desaturase 1 (SCD1) is a key enzyme in fatty acid (FA) metabolism that catalyzes the addition of a cis double bond to palmitic and stearic saturated FAs, producing palmitoleic and oleic monounsaturated FAs, respectively. Interleukin (IL)9-secreting CD4 T-helper lymphocytes (Th9) exert antitumoral activity in preclinical cancer models. In the present study, we evaluated the role of SCD1 in Th9 differentiation and their antitumoral properties. RESULTS: A specific monounsaturated FA profile is found in Th9 lymphocytes compared with Th1, Th2, Th17 and regulatory T cell (Treg) lymphocyte subsets and is correlated to the induction of SCD1 expression in mouse and human Th9 differentiated in vitro with TGFβ1 and IL4. The expression of SCD1 is also detected in tumor-draining lymph nodes and tumor-infiltrating Th9 lymphocytes of mice. The canonical Smad3 and non-canonical Pi3K members of the TGFβ signaling drive SCD1 expression in combination with IL4 during Th9 polarization. The invalidation of  gene expression or inhibition of its activity blocks Th9 differentiation by disrupting Smad2/3 activation. Furthermore, the lipidomic analysis between Th9 and Th9 invalidated for SCD1 gene or activity reveals a change in the FA profile, specifically a decrease in palmitoleic and oleic acids. Nevertheless, only oleic acid restores Th9 differentiation in CD4 T lymphocytes invalidated for SCD1 gene or activity under TGFβ1 and IL4 polarizing conditions. Finally, invalidation of the  gene or its activity leads to the loss of Th9 antitumoral functions and promotes tumor growth through the production of TGFβ1. CONCLUSION: We demonstrate that SCD1 contributes to Th9 differentiation and their antitumoral activity via the regulation of Smad2/3 signaling.

> **中文摘要：**
> 背景：硬脂酰辅酶A去饱和酶1（SCD1）是脂肪酸（FA）代谢中的关键酶，它催化棕榈酸和硬脂酸这两种饱和脂肪酸形成顺式双键，分别产生棕榈油酸和油酸这两种单不饱和脂肪酸。分泌白细胞介素（IL）9的CD4 T辅助淋巴细胞（Th9）在临床前癌症模型中发挥抗肿瘤活性。在本研究中，我们评估了SCD1在Th9分化及其抗肿瘤特性中的作用。结果：与Th1、Th2、Th17和调节性T细胞（Treg）淋巴细胞亚群相比，Th9淋巴细胞具有独特的单不饱和脂肪酸谱，并且这与用TGFβ1和IL4体外分化的小鼠和人Th9细胞中SCD1表达的诱导相关。在小鼠的肿瘤引流淋巴结和肿瘤浸润的Th9淋巴细胞中也检测到了SCD1的表达。在Th9极化过程中，TGFβ信号通路的经典成员Smad3和非经典成员Pi3K与IL4共同驱动SCD1的表达。基因表达的失活或其活性的抑制会破坏Smad2/3的激活，从而阻断Th9分化。此外，对Th9细胞与SCD1基因或活性失活的Th9细胞进行的脂质组学分析显示，其脂肪酸谱发生了变化，特别是棕榈油酸和油酸含量降低。然而，在TGFβ1和IL4极化条件下，只有油酸能够恢复SCD1基因或活性失活的CD4 T淋巴细胞中的Th9分化。最后，SCD1基因或其活性的失活会导致Th9抗肿瘤功能的丧失，并通过产生TGFβ1促进肿瘤生长。结论：我们证明SCD1通过调控Smad2/3信号通路，促进Th9分化及其抗肿瘤活性。

### 第二部分 AI 大师评价

本研究旨在探究脂肪酸代谢关键酶SCD1在Th9细胞分化及抗肿瘤功能中的作用。研究采用体外分化、基因敲除/抑制、脂质组学分析及小鼠肿瘤模型等方法。核心发现是SCD1通过TGFβ/Smad2/3信号通路调控Th9分化，其产物油酸是关键介质，且SCD1缺失会损害Th9的抗肿瘤能力并促进肿瘤生长。创新性在于首次将SCD1介导的脂代谢与Th9细胞功能直接关联，揭示了代谢重编程调控免疫细胞命运的新机制，为肿瘤免疫治疗提供了潜在靶点。局限性在于结论主要基于小鼠模型和体外实验，其在人体肿瘤微环境中的确切作用及靶向SCD1的治疗潜力有待临床验证。

---

## 34. CAR T细胞：改善儿童癌症疗效所需的关键拼图？

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545304)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41545304
**DOI：** 10.1136/jitc-2025-013325

### 第一部分 原文与翻译

**英文原标题：** CAR T cells: the missing piece needed to improve outcomes for children with cancer?

> **英文摘要：**
> B cell acute lymphoblastic leukemia (B-ALL) is the most common cancer of childhood. Outcomes for B-ALL have steadily improved over the last five decades, most recently due to impressive activity of chimeric antigen receptor modified T (CAR-T) cells and bispecific antibodies targeting CD19. In contrast, progress against other pediatric cancers has largely stalled. Significant academic effort is underway to expand the reach of CAR T cell therapy in pediatric cancer beyond B-ALL to other hematologic malignancies, solid cancers and brain tumors. Promising clinical activity using CAR-modified T cells has already been demonstrated in neuroblastoma and diffuse midline glioma by targeting the GD2 ganglioside, in pediatric sarcomas by targeting Her2, in Hodgkin's disease by targeting CD30, in T cell lymphoblastic leukemia by targeting CD5 or CD7, and in CAR19 refractory B-ALL by targeting CD22. Comprehensive surfaceome profiling of pediatric tumors is revealing additional novel candidate CAR targets expressed on pediatric cancers, including oncofetal cell surface antigens such as GPC2 and GPC3, which are expressed broadly on pediatric solid and brain tumors, and major histocompatibility complex bound peptides from oncofetal intracellular proteins such as  Next-generation CAR T cell therapeutics that incorporate suicide domains, regulatory circuits, logic gating and potency enhancements as well as combination immunotherapies are expected to further augment efficacy while maintaining safety. Current trials are administering CAR T cells in patients with refractory disease, but future studies are warranted to determine whether adjuvant use of CAR T cells could deliver cures with lower intensity standard therapy regimens and thereby reduce long-term toxicities in pediatric cancer survivors. Despite this scientific and clinical progress, the high cost of developing CAR T cells through the traditional biopharma pathway is limiting late-stage clinical development, necessitating the creation of new business models to commercialize CAR T cells for these small markets. CAR T cells hold great promise for improving outcomes for pediatric patients with cancer, but substantial additional research and clinical development is needed if this promise is to be realized for children afflicted with cancer.

> **中文摘要：**
> B细胞急性淋巴细胞白血病（B-ALL）是儿童期最常见的癌症。过去五十年来，B-ALL的治疗效果稳步提高，最近主要归功于靶向CD19的嵌合抗原受体修饰T（CAR-T）细胞和双特异性抗体的显著活性。相比之下，针对其他儿童癌症的进展则基本停滞。目前正投入大量学术努力，以将CAR T细胞疗法在儿童癌症中的应用范围从B-ALL扩展到其他血液系统恶性肿瘤、实体瘤和脑肿瘤。通过靶向GD2神经节苷脂在神经母细胞瘤和弥漫性中线胶质瘤中，靶向Her2在儿童肉瘤中，靶向CD30在霍奇金病中，靶向CD5或CD7在T细胞淋巴细胞白血病中，以及靶向CD22在CAR19难治性B-ALL中，均已显示出使用CAR修饰T细胞的有前景的临床活性。对儿童肿瘤进行的全面表面组分析，正在揭示更多在儿童癌症上表达的新型候选CAR靶点，包括癌胚细胞表面抗原，如GPC2和GPC3，它们在儿童实体瘤和脑肿瘤中广泛表达，以及来自癌胚细胞内蛋白（如）的主要组织相容性复合体结合肽。整合了自杀结构域、调控回路、逻辑门控和效力增强功能以及联合免疫疗法的下一代CAR T细胞疗法，有望在保持安全性的同时进一步增强疗效。目前的试验主要在难治性疾病患者中应用CAR T细胞，但未来的研究有必要确定CAR T细胞的辅助使用是否能在较低强度的标准治疗方案下实现治愈，从而减少儿童癌症幸存者的长期毒性。尽管取得了这些科学和临床进展，但通过传统生物制药途径开发CAR T细胞的高昂成本限制了其后期临床开发，因此需要创建新的商业模式来为这些小型市场实现CAR T细胞的商业化。CAR T细胞在改善儿童癌症患者预后方面前景广阔，但要为罹患癌症的儿童实现这一前景，还需要进行大量额外的研究和临床开发。

### 第二部分 AI 大师评价

本文旨在探讨CAR T细胞疗法作为改善儿童癌症（尤其是B-ALL以外类型）疗效的关键潜在手段。其方法学回顾了CAR T在多种儿童肿瘤（如神经母细胞瘤、肉瘤、脑瘤等）中针对新靶点（如GD2、Her2、CD30等）的临床进展，并展望了整合自杀开关、逻辑门控等技术的下一代疗法及辅助治疗模式。核心发现是CAR T疗法已展现出超越B-ALL的潜力，但针对儿童实体瘤和脑瘤的广泛应用仍面临靶点发现、安全性优化及成本控制等挑战。创新性在于系统梳理了儿童肿瘤特异性靶点（如GPC2/GPC3）和下一代技术方向，并前瞻性地指出了从难治性疾病向辅助治疗拓展的临床路径及商业化模式创新的必要性。局限性在于所述多数进展仍处于早期临床或临床前阶段，其最终疗效与安全性尚需大规模试验验证，且高昂成本是制约其可及性的关键现实瓶颈。

---

## 35. 管理免疫相关不良事件的类固醇减量策略。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545303)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41545303
**DOI：** 10.1136/jitc-2025-013776

### 第一部分 原文与翻译

**英文原标题：** Steroid-sparing strategies for managing immune-related adverse events.

> **英文摘要：**
> Although immune checkpoint inhibitors (ICI) have greatly improved outcomes in several cancer types, their use is also associated with immune-related adverse events (irAEs) that can impact any organ system and lead to significant morbidity and even mortality. Current approaches to treatment of irAEs largely rely on the use of systemic corticosteroids, which can compromise antitumor immune responses and oncologic outcomes. Prolonged use of systemic corticosteroids is also associated with its own set of toxicities. Thus, there is a critical need for steroid-sparing treatment approaches for irAEs.In this article, we review the literature for alternative therapeutic approaches for irAEs, which include targeted delivery (alternate routes of administration) of steroids (eg, budesonide) as well as systemic non-steroidal strategies using other mechanisms of action, such as integrin/cytokine blockade, antibody depletion, disease-modifying antirheumatic drugs and fecal microbiota transplant, among others. Many of these approaches have shown significant promise in their ability to induce a clinical response and improve symptoms, even in the setting of steroid-refractory or steroid-dependent irAEs. These approaches are being increasingly used as primary and secondary prophylaxis in patients at high risk of irAEs. Importantly, these strategies may mitigate steroid-associated toxicities, preserve antitumor immune responses and allow continuation of ICI after development of irAEs, hence enabling the full potential of ICI against cancer.

> **中文摘要：**
> 尽管免疫检查点抑制剂（ICI）极大地改善了几种癌症类型的治疗结局，但其使用也与免疫相关不良事件（irAEs）相关，这些事件可影响任何器官系统，并导致显著的发病率甚至死亡率。目前治疗irAEs的方法主要依赖于全身性皮质类固醇的使用，这可能损害抗肿瘤免疫应答和肿瘤学结局。长期使用全身性皮质类固醇也与其自身的一系列毒性相关。因此，迫切需要针对irAEs的类固醇减量治疗方法。在本文中，我们综述了关于irAEs替代治疗方法的文献，这些方法包括类固醇的靶向递送（替代给药途径，例如布地奈德）以及利用其他作用机制的系统性非类固醇策略，如整合素/细胞因子阻断、抗体耗竭、改善病情的抗风湿药和粪便微生物群移植等。其中许多方法在诱导临床应答和改善症状方面显示出显著前景，即使在类固醇难治性或类固醇依赖性irAEs的情况下也是如此。这些方法正越来越多地被用作irAEs高风险患者的一级和二级预防。重要的是，这些策略可能减轻类固醇相关的毒性，保留抗肿瘤免疫应答，并允许在发生irAEs后继续使用ICI，从而充分发挥ICI对抗癌症的潜力。

### 第二部分 AI 大师评价

本文旨在系统综述免疫相关不良事件（irAEs）的类固醇减量治疗策略，以应对当前过度依赖全身性皮质类固醇所带来的抗肿瘤免疫抑制及长期毒性问题。文章方法上，通过文献回顾，归纳了靶向递送类固醇及多种系统性非类固醇替代疗法（如整合素/细胞因子阻断、抗体耗竭、DMARDs及粪菌移植等）的作用机制与应用。核心发现是，这些替代策略在类固醇难治或依赖的irAEs中显示出良好临床前景，并正被用于高危患者的预防。其创新性在于提出了一个旨在平衡irAEs管理与维持ICI疗效的综合治疗框架，但局限性在于，作为一篇综述，其结论主要基于现有文献的归纳，仍需更多前瞻性临床研究来验证各策略的有效性与安全性。

---

## 36. 整合cfDNA甲基化与EV-miRNA多组学分析鉴定非小细胞肺癌免疫治疗结局的分子亚型。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545302)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41545302
**DOI：** 10.1136/jitc-2025-013592

### 第一部分 原文与翻译

**英文原标题：** Integrative multiomic profiling of cfDNA methylation and EV-miRNAs identifies immunotherapy-outcome molecular subtypes in NSCLC.

> **英文摘要：**
> BACKGROUND: Patients with non-small cell lung cancer (NSCLC) exhibit heterogeneous responses to immunotherapy (IT) with high resistance rates, highlighting the need for precise biomarkers of treatment outcomes. METHODS: In a prospective队列研究中，我们在四个不同时间点（T1治疗前、T2第二周期后、T3 6个月、T4 1年）纵向评估了接受免疫治疗的NSCLC患者的液体活检样本。我们对79例接受免疫检查点抑制剂（ICIs）治疗的转移性NSCLC患者的血浆来源的游离DNA甲基化和细胞外囊泡相关microRNA进行了分析。使用多组学因子分析（MOFA2）整合高维组学数据，以揭示潜在的分子亚型，我们称之为MOFA衍生簇（MDCs），这些亚型分别在基线（MDC-T1）和第二周期后（MDC-T2）独立建立。采用差异表达和甲基化分析、通路富集以及通过流式细胞术进行的免疫表型分析来表征每个MDC的分子和免疫学特征。使用独立的NSCLC队列对miRNA（Genova， 2024， n=54）和甲基化（SMC Cohort， GSE119144， n=57）进行了外部验证。RESULTS: MDCs捕获了不同的生存结局，并反映了生物学上一致的过程，包括血管生成、细胞骨架重塑和免疫信号传导。将MDCs投射到后续时间点（T3， T4）支持了早期分子特征的时间相关性。MDCs还通过循环免疫细胞亚群显示出免疫学相关性。重要的是，MDC分类器在外部队列中，特别是MDC-T2，表现出一致的生存分层能力。CONCLUSION: 本研究定义了一个基于液体活检的多组学框架，用于NSCLC的分子分型以指导ICI治疗。我们的MDC特征揭示了具有临床意义、能为治疗决策提供信息的生物学信息，并为免疫肿瘤学中微创的患者分层提供了一条途径。

> **中文摘要：**
> 背景：非小细胞肺癌（NSCLC）患者对免疫治疗（IT）的反应具有异质性，且耐药率高，这凸显了对精确治疗结局生物标志物的需求。方法：在一项前瞻性队列研究中，我们在四个不同时间点（T1治疗前、T2第二周期后、T3 6个月、T4 1年）纵向评估了接受免疫治疗的NSCLC患者的液体活检样本。我们对79例接受免疫检查点抑制剂（ICIs）治疗的转移性NSCLC患者的血浆来源的游离DNA甲基化和细胞外囊泡相关microRNA进行了分析。使用多组学因子分析（MOFA2）整合高维组学数据，以揭示潜在的分子亚型，我们称之为MOFA衍生簇（MDCs），这些亚型分别在基线（MDC-T1）和第二周期后（MDC-T2）独立建立。采用差异表达和甲基化分析、通路富集以及通过流式细胞术进行的免疫表型分析来表征每个MDC的分子和免疫学特征。使用独立的NSCLC队列对miRNA（Genova， 2024， n=54）和甲基化（SMC Cohort， GSE119144， n=57）进行了外部验证。结果：MDCs捕获了不同的生存结局，并反映了生物学上一致的过程，包括血管生成、细胞骨架重塑和免疫信号传导。将MDCs投射到后续时间点（T3， T4）支持了早期分子特征的时间相关性。MDCs还通过循环免疫细胞亚群显示出免疫学相关性。重要的是，MDC分类器在外部队列中，特别是MDC-T2，表现出一致的生存分层能力。结论：本研究定义了一个基于液体活检的多组学框架，用于NSCLC的分子分型以指导ICI治疗。我们的MDC特征揭示了具有临床意义、能为治疗决策提供信息的生物学信息，并为免疫肿瘤学中微创的患者分层提供了一条途径。

### 第二部分 AI 大师评价

本研究旨在解决NSCLC免疫治疗反应异质性的难题，其核心创新在于整合了cfDNA甲基化与EV-miRNA两种液体活检标志物，并利用MOFA2模型进行纵向多时间点分析，从而构建了动态的分子分型框架（MDCs）。研究发现，早期（特别是第二周期后）建立的MDC-T2亚型能有效预测生存结局，并在外部队列中得到验证，揭示了与血管生成、免疫信号等相关的关键生物学过程。该方法为无创、动态监测免疫治疗反应和患者分层提供了有前景的工具，但研究结论仍需在前瞻性大样本临床试验中进一步验证其临床转化价值。

---

## 37. 通过重靶向溶瘤疱疹病毒诱导的胶质母细胞瘤治疗性疫苗接种。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545301)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41545301
**DOI：** 10.1136/jitc-2025-012840

### 第一部分 原文与翻译

**英文原标题：** Therapeutic vaccination for glioblastoma elicited by retargeted oncolytic herpes virus.

> **英文摘要：**
> BACKGROUND: Glioblastoma is an aggressive tumor with poor prognosis and limited treatment options due to its resistance to chemotherapy and radiotherapy, high heterogeneity, and ability to evade the immune system. Nevertheless, immunotherapy and oncolytic virotherapy are emerging as promising strategies. This study aimed to evaluate the therapeutic efficacy of an engineered oncolytic Herpes Simplex Virus for glioblastoma treatment. METHODS: We investigated the efficacy of R-115, a retargeted oncolytic Herpes Simplex Virus directed against the human epidermal growth factor receptor 2 (HER2) and engineered to express murine interleukin-12, in an immunocompetent glioblastoma model that recapitulates HER2 tumor heterogeneity. We tested the translatability and reliability of R-115 by assessing overall survival in HER2 or HER2/HER2 mixed tumors treated with different schedules. We assessed the potential of the treatment to elicit an antitumor vaccination effect by rechallenging previously treated mice with HER2-negative cells in the absence of any further therapy. Additionally, we characterized both the immune and tumor components by analyzing immune cells' proliferation, activation and the resulting tumor cells reduction. RESULTS: R-115 exhibited potent cytotoxic and immune-stimulatory effects, significantly prolonging survival and eradicating tumors in approximately 25% of treated mice independently from tumor composition and treatment schedule. Furthermore, it induced long-term immune memory, enabling the eradication of secondary transplanted tumors, effectively acting as a tumor-agnostic vaccination. Notably, in addition to the direct oncolysis mediated by the virus, R-115 treatment induced an immune response even against HER2-negative glioblastoma cells, potentially via cross-presentation or epitope spreading. CONCLUSIONS: Our findings candidate R-115 as a promising alternative to standard glioblastoma treatments and support further investigation to advance its clinical application.

> **中文摘要：**
> 背景：胶质母细胞瘤是一种侵袭性肿瘤，预后不良，治疗选择有限，原因在于其对化疗和放疗的抵抗性、高度异质性以及逃避免疫系统的能力。尽管如此，免疫疗法和溶瘤病毒疗法正在成为有前景的策略。本研究旨在评估一种工程化溶瘤单纯疱疹病毒用于胶质母细胞瘤治疗的治疗效果。方法：我们在一个重现HER2肿瘤异质性的免疫活性胶质母细胞瘤模型中，研究了R-115的疗效。R-115是一种针对人表皮生长因子受体2（HER2）的重靶向溶瘤单纯疱疹病毒，并被工程化以表达鼠白细胞介素-12。我们通过评估接受不同方案治疗的HER2或HER2/HER2混合肿瘤小鼠的总生存期，测试了R-115的可转化性和可靠性。我们通过在没有进一步治疗的情况下，用HER2阴性细胞再次攻击先前治疗过的小鼠，评估了该疗法引发抗肿瘤疫苗接种效应的潜力。此外，我们通过分析免疫细胞的增殖、活化以及由此导致的肿瘤细胞减少，对免疫和肿瘤成分进行了表征。结果：R-115表现出强大的细胞毒性和免疫刺激效应，显著延长了生存期，并在约25%的治疗小鼠中根除了肿瘤，且不受肿瘤组成和治疗方案的影响。此外，它诱导了长期的免疫记忆，能够根除二次移植的肿瘤，有效地起到了不依赖肿瘤类型的疫苗接种作用。值得注意的是，除了病毒介导的直接溶瘤作用外，R-115治疗甚至能诱导针对HER2阴性胶质母细胞瘤细胞的免疫反应，可能通过交叉呈递或表位扩散实现。结论：我们的研究结果表明R-115是标准胶质母细胞瘤治疗的一种有前景的替代方案，并支持进一步研究以推进其临床应用。

### 第二部分 AI 大师评价

本研究旨在评估一种靶向HER2并表达IL-12的工程化溶瘤疱疹病毒（R-115）治疗胶质母细胞瘤的疗效。其核心创新在于，在模拟HER2异质性的免疫活性模型中，不仅验证了R-115的直接溶瘤和延长生存效果，更关键地证明了其能诱导不依赖初始靶点的、广泛的抗肿瘤免疫记忆，即“治疗性疫苗接种”效应。这一发现通过二次攻击实验和针对HER2阴性细胞的免疫反应得到证实，暗示了表位扩散等机制，为克服肿瘤异质性提供了新思路。然而，研究主要在临床前模型中进行，其安全性和在人体的转化效果仍需进一步探索。

---

## 38. 对大型巴雷特癌常规采用内镜黏膜下剥离术的肿瘤学影响。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545198)
**期刊：** Gut
**PMID：** 41545198
**DOI：** 10.1136/gutjnl-2025-337434

### 第一部分 原文与翻译

**英文原标题：** Oncological impact of universal endoscopic submucosal dissection for large Barrett's cancers.

> **英文摘要：**
> BACKGROUND: Oncological principles favour en bloc R0 excision for curative endoscopic resection. In Barrett's neoplasia, endoscopically curable cancers include T1a and selected early T1b disease. Although endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) are established treatments, optimal lesion selection remains debated. OBJECTIVE: To evaluate the oncological impact of two selective resection strategies: (1) prioritising ESD for suspected Barrett's cancers >15 mm and (2) a historical approach reserving ESD mainly for advanced cancers. DESIGN: Multicentre retrospective observational study comparing an ESD-first strategy (period 2, 2017-2024) with a historical selective ESD approach (period 1, 2004-2016). Lesion allocation was based on endoscopic assessment of invasion in both periods. Outcomes included basal R0 resection, curative resection, recurrence and adverse events. RESULTS: A total of 581 resections were performed in 542 patients (median lesion size 20 mm). Cancer was present in 271 cases (178 T1a and 93 T1b). Period 2 had a higher cancer burden (52.3% vs 34.9%) and greater ESD use (77.1% vs 21.2%). Basal R0 resection improved from 69.7% to 91.2% (p<0.001), with the greatest benefit in T1b lesions (33.3% to 81.9%, p<0.001). In T1b cancers, curative resection increased (9.5% to 30.5%, p=0.043) and recurrence decreased (55.6% to 23.6%, p=0.043). ESD achieved higher 2-year cancer-free survival than EMR (87.4% vs 50%, p=0.021). Adverse events were infrequent (2.2%) and similar between techniques. CONCLUSION: Prioritising ESD for Barrett's cancers >15 mm improves basal R0 resection, reduces recurrence and improves short-term survival for T1b disease, supporting routine ESD for all larger Barrett's cancers.

> **中文摘要：**
> 背景：肿瘤学原则支持整块R0切除以实现治愈性内镜切除。在巴雷特瘤变中，内镜可治愈的癌症包括T1a期和部分早期T1b期病变。尽管内镜黏膜切除术（EMR）和内镜黏膜下剥离术（ESD）是成熟的治疗方法，但最佳病变选择策略仍存争议。目的：评估两种选择性切除策略的肿瘤学影响：（1）对疑似大于15毫米的巴雷特癌优先采用ESD；（2）历史上主要将ESD保留用于晚期癌症的方法。设计：一项多中心回顾性观察研究，比较ESD优先策略（时期2，2017-2024年）与历史选择性ESD方法（时期1，2004-2016年）。两个时期的病变分配均基于内镜对浸润程度的评估。结局指标包括基底切缘R0切除率、治愈性切除率、复发率和不良事件。结果：在542名患者中共进行了581次切除（中位病变大小20毫米）。271例存在癌症（178例T1a期，93例T1b期）。时期2的癌症负荷更高（52.3% vs 34.9%），ESD使用率也更高（77.1% vs 21.2%）。基底R0切除率从69.7%提高到91.2%（p<0.001），其中T1b期病变获益最大（从33.3%提高到81.9%，p<0.001）。在T1b期癌症中，治愈性切除率增加（9.5%到30.5%，p=0.043），复发率降低（55.6%到23.6%，p=0.043）。ESD的2年无癌生存率高于EMR（87.4% vs 50%，p=0.021）。不良事件发生率低（2.2%），两种技术间相似。结论：对大于15毫米的巴雷特癌优先采用ESD，可提高基底R0切除率，降低复发率，并改善T1b期疾病的短期生存率，这支持对所有较大的巴雷特癌常规采用ESD。

### 第二部分 AI 大师评价

本研究旨在评估对较大巴雷特癌优先采用ESD的肿瘤学获益。通过一项多中心回顾性观察研究，比较了ESD优先策略与历史选择性ESD方法的效果。核心发现是，优先策略显著提高了基底R0切除率，尤其是在T1b期病变中，并降低了复发率，改善了短期生存。该研究为临床实践提供了有力证据，支持对较大巴雷特癌常规使用ESD，但其回顾性观察性质可能引入选择偏倚，且长期生存数据有待进一步验证。

---

## 39. LY6D识别驱动胰腺肿瘤发生的持续性干细胞样细胞。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545197)
**期刊：** Gut
**PMID：** 41545197
**DOI：** 10.1136/gutjnl-2025-336460

### 第一部分 原文与翻译

**英文原标题：** LY6D identifies persistent stem-like cells driving pancreatic tumourigenesis.

> **英文摘要：**
> BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy characterised by remarkable cellular heterogeneity, which emerges early from the interplay of oncogenic KRAS signalling and inflammatory injury. However, the transcriptional, metabolic and functional properties of these pre-malignant cell states that initiate and drive PDAC progression remain elusive. OBJECTIVE: This study aimed to identify and functionally characterise the critical premalignant cell states that arise from this heterogeneity, to define novel biomarkers and targets for early intervention. DESIGN: Public and in-house scRNA-seq data of pancreatic tumour models were analysed to identify key subpopulations in early cellular heterogeneity. Genetic perturbation in KrasG12D-driven models was performed to assess functional impact. Mechanistic studies used TurboID proximity proteomics, epigenetic profiling and metabolic assays. Clinical relevance was validated in human PDAC cohorts. RESULTS: We identified LY6D as a marker of a distinct, gastric-like cell state that emerges early and persists throughout tumourigenesis. The LY6D population exhibits conserved stemness and a unique, pan-stage dependency on oxidative phosphorylation (OXPHOS). Genetic ablation of  specifically impaired the gastric lineage and delayed tumourigenesis, while its overexpression enhanced tumourigenic and metastatic potential. Mechanistically, the glycosylphosphatidylinositol (GPI)-anchored LY6D protein scaffolds a lipid raft-associated kinase network that drives FOSL1-dependent epigenetic-transcriptional reprogramming. In human PDAC, LY6D cells harbour stemness and Epithelial-Mesenchymal Transition (EMT) signatures, and high LY6D expression is an independent prognostic marker of poor survival. CONCLUSION: Our work defines the LY6D gastric-like cell state as a key driver linking early pre-malignant heterogeneity to PDAC initiation and progression. LY6D represents a pan-stage therapeutic target and a candidate biomarker for early detection and therapeutic targeting.

> **中文摘要：**
> 背景：胰腺导管腺癌（PDAC）是一种高度侵袭性的恶性肿瘤，其特征是显著的细胞异质性，这种异质性在肿瘤发生早期由致癌KRAS信号与炎症损伤的相互作用所引发。然而，这些启动并驱动PDAC进展的癌前细胞状态的转录、代谢和功能特性仍不清楚。目的：本研究旨在鉴定并功能表征这种异质性中产生的关键癌前细胞状态，以确定用于早期干预的新型生物标志物和治疗靶点。设计：分析胰腺肿瘤模型的公共和内部单细胞RNA测序数据，以识别早期细胞异质性中的关键亚群。在KrasG12D驱动的模型中进行遗传扰动以评估其功能影响。机制研究使用了TurboID邻近蛋白质组学、表观遗传谱分析和代谢测定。在人类PDAC队列中验证了临床相关性。结果：我们鉴定出LY6D作为一种独特的、胃样细胞状态的标志物，该状态在肿瘤发生早期出现并持续存在。LY6D阳性细胞群表现出保守的干性，以及对氧化磷酸化（OXPHOS）独特的、全阶段的依赖性。遗传学敲除LY6D特异性地损害了胃谱系并延迟了肿瘤发生，而其过表达则增强了致瘤和转移潜能。从机制上讲，糖基磷脂酰肌醇（GPI）锚定的LY6D蛋白支架了一个脂筏相关的激酶网络，该网络驱动了FOSL1依赖的表观遗传-转录重编程。在人类PDAC中，LY6D阳性细胞具有干性和上皮-间质转化（EMT）特征，并且高LY6D表达是生存不良的独立预后标志物。结论：我们的研究将LY6D胃样细胞状态定义为连接早期癌前异质性与PDAC起始和进展的关键驱动因素。LY6D代表了一个全阶段的治疗靶点，以及用于早期检测和治疗靶向的候选生物标志物。

### 第二部分 AI 大师评价

本研究旨在揭示胰腺导管腺癌（PDAC）早期异质性中的关键驱动细胞状态。通过整合单细胞测序、遗传学扰动、邻近标记蛋白质组学及代谢分析等多组学方法，研究团队鉴定出LY6D标记的胃样细胞群是贯穿肿瘤发生全过程的持续性干细胞样细胞，其依赖于氧化磷酸化并驱动表观遗传重编程。该发现创新性地将早期癌前状态与肿瘤进展直接联系起来，明确了LY6D作为全阶段治疗靶点和预后生物标志物的潜力。然而，研究主要基于模型和队列分析，LY6D靶向治疗的体内有效性和特异性仍需进一步的临床前和临床研究验证。

---

## 40. 一种用于预防化疗诱导心脏毒性的系统性选择性修饰mRNA递送平台

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41545029)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41545029
**DOI：** 10.1002/advs.202510543

### 第一部分 原文与翻译

**英文原标题：** A Systemic Selective Modified mRNA Delivery Platform for Preventing Chemotherapy-Induced Cardiotoxicity.

> **英文摘要：**
> Doxorubicin (Dox) is a widely employed chemotherapeutic agent, but its use is clinically limited by dose-accumulative cardiotoxicity. More specifically, Dox induces oxidative stress and causes pro-apoptotic ceramide accumulation in cardiomyocytes (CMs). Acid ceramidase (AC) modified mRNA (modRNA) has been shown to reduce ceramide levels and protect the heart following ischemic injury; however, therapeutic modRNA applications have been hindered by the need for invasive delivery. Here, we present a platform for minimally intrusive transmission of modRNA to the heart. This CM-selective modRNA translational system (cmSMRTs) is encapsulated in lipid nanoparticles for intravenous (IV) delivery to enable systemic administration with high cardiac selectivity via microRNA-guided translational control (miR143 and miR122) to suppress off-target expression in other tissues, including tumors. In vitro, AC treatment preserved sarcomere structure, calcium handling, and mitochondrial function in Dox-treated human induced pluripotent stem cell (iPSC)-derived CMs. Moreover, weekly IV delivery of this modRNA prevented cardiac dysfunction, fibrosis, and atrophy in chronic Dox-induced cardiotoxicity models. Notably, this cardioprotection is achieved without either compromising Dox's anti-tumor efficacy or producing overall toxicity. These findings establish cmSMRTs 143-122 as a minimally invasive, cardiac-selective mRNA therapy platform with strong potential to prevent chemotherapy-induced cardiotoxicity.

> **中文摘要：**
> 多柔比星（Dox）是一种广泛应用的化疗药物，但其临床应用因剂量累积性心脏毒性而受到限制。更具体地说，Dox会诱导氧化应激并导致心肌细胞中促凋亡神经酰胺的积累。酸性神经酰胺酶（AC）修饰的mRNA已被证明可以降低神经酰胺水平并在缺血性损伤后保护心脏；然而，治疗性修饰mRNA的应用因需要侵入性递送而受到阻碍。在此，我们提出了一种将修饰mRNA微创递送至心脏的平台。该心肌细胞选择性修饰mRNA翻译系统被封装在脂质纳米颗粒中，用于静脉内递送，以实现全身给药，并通过microRNA引导的翻译控制（miR143和miR122）实现高心脏选择性，从而抑制包括肿瘤在内的其他组织中的脱靶表达。在体外，AC处理保留了Dox处理的人诱导多能干细胞来源心肌细胞的肌节结构、钙处理和线粒体功能。此外，在慢性Dox诱导的心脏毒性模型中，每周静脉递送这种修饰mRNA可预防心功能障碍、纤维化和萎缩。值得注意的是，这种心脏保护作用是在既不损害Dox的抗肿瘤疗效，也不产生整体毒性的情况下实现的。这些发现确立了cmSMRTs 143-122作为一种微创、心脏选择性的mRNA治疗平台，在预防化疗诱导的心脏毒性方面具有巨大潜力。

### 第二部分 AI 大师评价

本研究旨在解决多柔比星化疗所致心脏毒性的临床难题。其核心创新在于开发了一种名为cmSMRTs的心肌细胞选择性修饰mRNA递送平台，通过静脉注射脂质纳米颗粒结合miR143/122的翻译调控，实现了对心脏的高选择性靶向。研究发现，递送酸性神经酰胺酶mRNA能有效保护心肌细胞结构和功能，并在动物模型中预防心脏损伤，且不影响化疗的抗肿瘤效果。该平台为心脏保护性mRNA疗法提供了微创且精准的递送策略，但研究目前处于临床前阶段，其人体内的安全性、长期效果及规模化生产可行性仍需进一步验证。

---

## 41. 全基因组筛选鉴定出BAP1是CDK4/6抑制剂的合成致死靶点。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41544174)
**期刊：** Science advances
**PMID：** 41544174
**DOI：** 10.1126/sciadv.aeb4348

### 第一部分 原文与翻译

**英文原标题：** Genome-wide screenings identify BAP1 as a synthetic-lethality target with CDK4/6 inhibitors.

> **英文摘要：**
> The nongenetic mechanisms by which cancer cells escape cell cycle inhibition remain inadequately understood. Here, we uncover an epigenetic pathway driving adaptive resistance to cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in hepatobiliary cancers using integrative approach combining genome-wide CRISPR screenings with transcriptional, epigenetic, and proteomic profiling. Sustained CDK4/6 inhibition triggers BAP1-dependent chromatin remodeling that induces a stem cell-like epigenetic state. Specifically, BAP1 removes ubiquitin modification (H2AK119ub) at the  promoter, activating WNT and EMT signaling to enhance cellular plasticity and survival under therapy. Notably, genetic and pharmacologic inhibition of BAP1 markedly improves abemaciclib efficacy in multiple mouse models and patient-derived organoids (PDOs). These findings establish BAP1 as a key regulator of tumor plasticity and adaptive resistance through epigenetic reprogramming and suggest a promising strategy for overcoming adaptive therapeutic CDK4/6i resistance by targeting quiescent, drug-resistant cancer cells.

> **中文摘要：**
> 癌细胞逃逸细胞周期抑制的非遗传机制仍未得到充分理解。本研究通过整合全基因组CRISPR筛选与转录组、表观基因组和蛋白质组分析，揭示了一种驱动肝胆管癌对细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制剂产生适应性耐药的表观遗传通路。持续的CDK4/6抑制会触发BAP1依赖的染色质重塑，从而诱导一种干细胞样表观遗传状态。具体而言，BAP1去除启动子区域的泛素化修饰（H2AK119ub），激活WNT和EMT信号通路，从而增强治疗条件下的细胞可塑性和生存能力。值得注意的是，在多种小鼠模型和患者来源类器官（PDOs）中，遗传和药理学抑制BAP1均能显著提高阿贝西利（abemaciclib）的疗效。这些发现确立了BAP1通过表观遗传重编程成为肿瘤可塑性和适应性耐药的关键调节因子，并提出了一种通过靶向静息、耐药癌细胞来克服CDK4/6抑制剂适应性耐药的有前景的策略。

### 第二部分 AI 大师评价

本研究旨在探索癌细胞对CDK4/6抑制剂产生适应性耐药的非遗传机制。核心方法是通过整合全基因组CRISPR筛选与多组学分析，系统性地寻找关键调控因子。主要发现是BAP1通过介导染色质重塑和激活WNT/EMT通路，驱动了表观遗传层面的适应性耐药，且靶向BAP1能显著增强CDK4/6抑制剂的疗效。其创新性在于从表观遗传视角揭示了耐药新机制，并提出了“合成致死”的治疗新策略，但结论主要基于肝胆管癌模型，在其他癌种中的普适性有待验证。

---

## 42. 源自癌症相关成纤维细胞的乳酸促进前列腺癌的选择性剪接和去势抵抗。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41544173)
**期刊：** Science advances
**PMID：** 41544173
**DOI：** 10.1126/sciadv.ady5324

### 第一部分 原文与翻译

**英文原标题：** Lactate derived from cancer-associated fibroblasts promotes alternative splicing and castration resistance in prostate cancer.

> **英文摘要：**
> Lactate in the tumor microenvironment (TME) is typically generated by cells exhibiting high glycolytic flux, exemplified by tumor cells. However, in glycolysis-low malignancies such as prostate cancer, stroma-derived lactate may drive noncanonical signaling and functions that remain unclear. Here, we identified APCDD1 cancer-associated fibroblasts (CAFs) as a distinct stromal population that secretes lactate into the TME in response to androgen deprivation therapy (ADT). Lactate uptake by prostate cancer cells induces androgen receptor variant 7 expression, thereby conferring resistance to ADT. Mechanistically, lactate-induced lactylation of the spliceosome component SNRPA at Lys (K123) enhances its recognition of cis-acting elements, increases chromatin binding, and promotes androgen receptor splicing. Targeting lactate transport with monocarboxylate transporter inhibitors effectively restores ADT sensitivity. These findings reveal a metabolic-epigenetic axis linking lactate in the microenvironment to alternative splicing regulation and suggest a promising therapeutic strategy to overcome ADT resistance.

> **中文摘要：**
> 肿瘤微环境（TME）中的乳酸通常由具有高糖酵解通量的细胞（例如肿瘤细胞）产生。然而，在前列腺癌等糖酵解水平较低的恶性肿瘤中，基质来源的乳酸可能驱动非经典的信号传导和功能，这些尚不清楚。在此，我们鉴定出APCDD1癌症相关成纤维细胞（CAFs）作为一种独特的基质细胞群，能够响应雄激素剥夺疗法（ADT）向TME分泌乳酸。前列腺癌细胞摄取乳酸会诱导雄激素受体变体7的表达，从而赋予对ADT的抵抗性。从机制上讲，乳酸诱导的剪接体组分SNRPA在赖氨酸（K123）处的乳酸化修饰，增强了其对顺式作用元件的识别，增加了染色质结合，并促进了雄激素受体的剪接。使用单羧酸转运蛋白抑制剂靶向乳酸转运，能有效恢复对ADT的敏感性。这些发现揭示了一条连接微环境中乳酸与选择性剪接调控的代谢-表观遗传轴，并提出了一种有前景的克服ADT抵抗的治疗策略。

### 第二部分 AI 大师评价

本研究旨在揭示前列腺癌去势抵抗（ADT抵抗）的新机制，聚焦于肿瘤微环境中基质细胞来源的乳酸。研究者通过鉴定APCDD1 CAFs这一特定细胞群，结合分子机制探索（乳酸化修饰、剪接调控）和功能验证（抑制剂干预），系统阐明了乳酸如何通过表观遗传修饰驱动雄激素受体选择性剪接，从而导致耐药。其创新性在于将肿瘤代谢（乳酸）、表观遗传（乳酸化）与RNA剪接调控联系起来，构建了“代谢-表观遗传轴”，并提出了靶向乳酸转运的治疗策略，具有重要的转化潜力。局限性在于，研究主要基于机制探索，该策略的临床前及临床疗效有待进一步验证，且微环境中其他细胞类型对乳酸通路的贡献可能未被完全揭示。

---

## 43. 巴豆酸酯通过诱导ACSS2介导的EZH2-K348巴豆酰化抑制乳腺癌转移并促进免疫治疗应答。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41544165)
**期刊：** Science advances
**PMID：** 41544165
**DOI：** 10.1126/sciadv.aea9892

### 第一部分 原文与翻译

**英文原标题：** Crotonate suppresses breast cancer metastasis and promotes immunotherapy response by inducing ACSS2-mediated EZH2-K348 crotonylation.

> **英文摘要：**
> Crotonate, a short-chain fatty acid, generates protein crotonylation. However, the role of crotonate in cancer progression is unknown. Here, we present a crotonate-crotonyl-coenzyme A (CoA)-enhancer of zeste homolog 2 (EZH2) crotonylation cascade blocking breast cancer growth and metastasis. We demonstrated that crotonate promotes EZH2 degradation via crotonyl-CoA-mediated crotonylation at Lys in EZH2 (EZH2-K348cr). EZH2-K348cr leads to reduced genome-wide H3K27me3 (trimethylation of lysine-27 on histone-3) occupancy. Crotonate metabolizes to crotonyl-CoA by ACSS2 (acyl-CoA synthetase 2), and then, acyltransferase p300 catalyzes crotonyl-CoA and generates EZH2-K348cr. Crotonylated EZH2 triggers EZH2 ubiquitination and degradation. Administration of crotonate markedly inhibits breast cancer cell growth and metastasis via a crotonate-crotonyl-CoA-EZH2-K348cr cascade. In comparison, crotonate showed better blocking effect than EZH2 inhibitor tazemetostat in suppressing breast cancer metastasis. The combination of crotonate and anti-PD-L1 (programmed cell death ligand 1) antibody enhances responses of breast cancer cells to immunotherapy. Together, our findings indicate that crotonate is a promising anticancer drug candidate that suppresses breast cancer growth and metastasis by specifically inducing EZH2 degradation.

> **中文摘要：**
> 巴豆酸酯是一种短链脂肪酸，可诱导蛋白质巴豆酰化。然而，巴豆酸酯在癌症进展中的作用尚不清楚。本研究揭示了一条巴豆酸酯-巴豆酰辅酶A（CoA）-果蝇zeste基因增强子同源物2（EZH2）巴豆酰化级联通路，可阻断乳腺癌的生长和转移。我们证明，巴豆酸酯通过巴豆酰辅酶A介导的EZH2赖氨酸位点（EZH2-K348cr）的巴豆酰化，促进EZH2降解。EZH2-K348cr导致全基因组范围内H3K27me3（组蛋白H3第27位赖氨酸的三甲基化）占据减少。巴豆酸酯通过ACSS2（酰基辅酶A合成酶2）代谢为巴豆酰辅酶A，随后，酰基转移酶p300催化巴豆酰辅酶A并生成EZH2-K348cr。巴豆酰化的EZH2触发EZH2的泛素化和降解。给予巴豆酸酯可通过巴豆酸酯-巴豆酰辅酶A-EZH2-K348cr级联通路显著抑制乳腺癌细胞的生长和转移。相比之下，在抑制乳腺癌转移方面，巴豆酸酯显示出比EZH2抑制剂他泽司他更好的阻断效果。巴豆酸酯与抗PD-L1（程序性细胞死亡配体1）抗体的联合应用增强了乳腺癌细胞对免疫治疗的反应。总之，我们的研究结果表明，巴豆酸酯是一种有前景的抗癌候选药物，它通过特异性诱导EZH2降解来抑制乳腺癌的生长和转移。

### 第二部分 AI 大师评价

本研究旨在探索短链脂肪酸巴豆酸酯在乳腺癌进展中的作用。其核心方法是利用分子生物学技术，揭示了一条从巴豆酸酯代谢到EZH2蛋白巴豆酰化修饰（K348cr）并最终导致其降解的级联通路。研究发现，该通路能有效抑制乳腺癌生长和转移，且效果优于现有EZH2抑制剂，并能与免疫检查点抑制剂（抗PD-L1）产生协同作用。其创新性在于首次系统阐明了巴豆酸酯通过翻译后修饰（巴豆酰化）靶向降解EZH2的抗癌新机制，并提出了其作为新型抗癌药物及免疫治疗增敏剂的潜力。局限性在于研究主要基于临床前模型，其在人体内的有效性和安全性尚待临床试验验证。

---

## 44. 用于原位口腔内TNF-α检测的组织粘附性水凝胶-MXene生物传感器。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41544161)
**期刊：** Science advances
**PMID：** 41544161
**DOI：** 10.1126/sciadv.ady9180

### 第一部分 原文与翻译

**英文原标题：** Tissue-adhesive hydrogel-MXene biosensor for in situ intraoral TNF-α detection.

> **英文摘要：**
> Current dental care relies on subjective assessments or sophisticated diagnostics, both struggling to balance efficiency and accuracy. In situ biosensors offer a promising solution for real-time biomarker detection, yet their practical deployment in oral tissue is hindered by challenges in sensitivity, specificity, and stability due to low biomarker concentrations, molecular-level heterogeneity, and dynamic intraoral interactions. Here, we develop a tissue-adhesive hydrogel-MXene (TAHM) biosensor, integrating a graphene/MXene sensing probe, a tissue-adhesive patch, and a selective-permeable hydrogel membrane, for in situ detection of tumor necrosis factor-α, a proinflammatory cytokine. Our TAHM biosensor achieves high sensitivity with a limit of detection of 18.2 femtograms per milliliter, excellent selectivity with an interference coefficient below 7%, and mechanical stability with resistance variation under 0.5% under varying stretch ratio and loading rates. The sensor's performance is further validated through in vitro, in vivo, and ex vivo experiments. The work highlights the potential of in situ biosensor as a transformative tool for real-time oral diagnostics.

> **中文摘要：**
> 当前的牙科诊疗依赖于主观评估或复杂的诊断技术，两者都难以在效率和准确性之间取得平衡。原位生物传感器为实时生物标志物检测提供了一种有前景的解决方案，然而，由于生物标志物浓度低、分子水平异质性以及动态的口腔内相互作用，其在口腔组织中的实际应用受到灵敏度、特异性和稳定性方面挑战的阻碍。在此，我们开发了一种组织粘附性水凝胶-MXene（TAHM）生物传感器，它集成了石墨烯/MXene传感探针、组织粘附贴片和选择性渗透水凝胶膜，用于原位检测促炎细胞因子肿瘤坏死因子-α。我们的TAHM生物传感器实现了高灵敏度，检测限为18.2飞克/毫升；优异的选择性，干扰系数低于7%；以及良好的机械稳定性，在不同拉伸比和加载速率下电阻变化小于0.5%。该传感器的性能通过体外、体内和离体实验得到进一步验证。这项工作凸显了原位生物传感器作为实时口腔诊断变革性工具的潜力。

### 第二部分 AI 大师评价

本研究旨在解决口腔实时诊断中效率与准确性难以兼顾的痛点。其核心创新在于开发了一种集成了石墨烯/MXene传感探针、组织粘附贴片和选择性渗透膜的多功能复合生物传感器（TAHM），专门用于原位检测口腔内低浓度的炎症标志物TNF-α。该传感器在灵敏度（检测限达飞克级）、选择性（干扰系数<7%）和机械稳定性（电阻变化<0.5%）方面表现卓越，并通过多层面实验验证了其性能。这项工作为实时、精准的口腔炎症监测提供了强有力的技术原型，其局限性可能在于长期体内稳定性的验证、对其他生物标志物的普适性以及未来临床转化路径的复杂性。

---

## 45. 用于诊断性生物标志物检测与肿瘤微环境评估的双模式微流控免疫染色装置

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41544154)
**期刊：** Science advances
**PMID：** 41544154
**DOI：** 10.1126/sciadv.aea2586

### 第一部分 原文与翻译

**英文原标题：** Dual-mode microfluidic immunostaining device for diagnostic biomarkers detection and tumor microenvironment evaluation.

> **英文摘要：**
> The limited availability of tissue samples from rare tumors poses a major barrier to advances in precise diagnosis, prognostic evaluation, and therapeutic research-challenges exemplified by primary central nervous system diffuse large B cell lymphoma (PCNS-DLBCL). Here, we developed a dual-mode microfluidic immunostaining (Dumi) device, which integrates diagnostic and research workflows into a single, automated platform, reducing tissue section consumption by more than 90%. Using just one to two slides, it enables both regional detection of biomarkers for diagnostic subtyping (≤16) and construction of multiplex tumor microenvironment (TME) maps. Joint analysis of multiregion diagnostic biomarkers in the TME map indicates that tumor cell subpopulations defined by specific diagnostic biomarkers can actively shape their in situ microenvironmental niche. Dumi offers an efficient, cost-effective, and multifunctional immunostaining method, overcoming the limitations of scarce tissue resources and providing a clinically accessible solution to the diagnostic and therapeutic challenges with rare tumors.

> **中文摘要：**
> 罕见肿瘤组织样本的有限可及性，是精准诊断、预后评估和治疗研究进展的主要障碍——这一挑战以原发性中枢神经系统弥漫大B细胞淋巴瘤（PCNS-DLBCL）为例。在此，我们开发了一种双模式微流控免疫染色（Dumi）装置，它将诊断和研究工作流程集成到一个单一的自动化平台中，将组织切片消耗量减少了90%以上。仅使用一到两张玻片，该装置即可同时实现用于诊断分型（≤16种）的生物标志物区域检测以及多重肿瘤微环境（TME）图谱的构建。对TME图谱中多区域诊断性生物标志物的联合分析表明，由特定诊断性生物标志物定义的肿瘤细胞亚群能够主动塑造其原位微环境生态位。Dumi提供了一种高效、经济且多功能的免疫染色方法，克服了组织资源稀缺的限制，为罕见肿瘤的诊断和治疗挑战提供了一种临床可及的解决方案。

### 第二部分 AI 大师评价

本研究旨在解决罕见肿瘤研究中组织样本稀缺的核心瓶颈。其核心方法是开发一种名为Dumi的双模式微流控免疫染色装置，该装置通过高度集成化和自动化，将诊断分型与肿瘤微环境（TME）多重分析整合于同一平台，显著节省了样本用量。主要发现是，通过联合分析TME图谱中的诊断标志物，揭示了由特定标志物定义的肿瘤细胞亚群具有主动塑造其局部微环境的能力。该研究的创新性在于提供了一种集高效、经济、多功能于一体的技术解决方案，有望直接应用于临床实践；其局限性在于摘要中未明确提及该技术在其他肿瘤类型中的普适性验证数据，也未讨论其与现有临床病理流程整合的具体挑战。

---

## 46. 胶质细胞中的βPix对于斑马鱼大脑中的血管发育至关重要。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41543887)
**期刊：** eLife
**PMID：** 41543887
**DOI：** 10.7554/eLife.106665

### 第一部分 原文与翻译

**英文原标题：** Glial  is essential for blood vessel development in the zebrafish brain.

> **英文摘要：**
> The formation of blood-brain barrier and vascular integrity depends on the coordinated development of different cell types in the brain. Previous studies have shown that zebrafish  () mutant, which has mutation in the  locus, develops spontaneous intracerebral hemorrhage during early development. However, it remains unclear in which brain cells  may function. Here, we established a highly efficient conditional knockout method in zebrafish by using homology-directed repair-mediated knockin and knockout technology and generated  conditional trap () allele in zebrafish. We found that  in glia, but neither neurons, endothelial cells, nor pericytes was critical for glial and vascular development and integrity, thus contributing to the formation of blood-brain barrier. Single-cell transcriptome profiling revealed that microtubule aggregation signaling stathmins and pro-angiogenic transcription factors  were downregulated in glial and neuronal progenitors, and further genetic analysis suggested that betaPix may act upstream on the PAK1-Stathmin and Zfhx3/4-Vegfaa signaling to regulate glia migration and angiogenesis. Therefore, this work reveals that glial  plays an important role in brain vascular development in zebrafish embryos and possibly human cells.

> **中文摘要：**
> 血脑屏障的形成和血管完整性依赖于大脑中不同细胞类型的协调发育。先前研究表明，在βPix基因座发生突变的斑马鱼βPix突变体，在早期发育阶段会出现自发性脑出血。然而，βPix究竟在哪些脑细胞中发挥作用尚不清楚。在此，我们利用同源定向修复介导的敲入和敲除技术，在斑马鱼中建立了一种高效的条件性敲除方法，并构建了βPix条件性陷阱等位基因。我们发现，胶质细胞中的βPix，而非神经元、内皮细胞或周细胞中的βPix，对于胶质细胞和血管的发育及完整性至关重要，从而有助于血脑屏障的形成。单细胞转录组分析显示，微管聚合信号蛋白Stathmins和促血管生成转录因子Zfhx3/4在胶质细胞和神经元前体细胞中表达下调；进一步的遗传学分析表明，βPix可能作用于PAK1-Stathmin和Zfhx3/4-Vegfaa信号通路的上游，以调控胶质细胞迁移和血管生成。因此，这项工作揭示了胶质细胞βPix在斑马鱼胚胎乃至可能的人类细胞的大脑血管发育中扮演着重要角色。

### 第二部分 AI 大师评价

本研究旨在阐明βPix基因在斑马鱼大脑血管发育中的细胞特异性功能。其核心创新在于开发了一种高效的条件性基因敲除方法，并成功应用于构建βPix条件性陷阱等位基因，从而实现了细胞类型特异性的功能解析。研究发现，胶质细胞特异性（而非神经元或血管细胞）的βPix缺失是导致血管发育缺陷和血脑屏障形成障碍的关键，并通过单细胞测序和遗传分析，初步揭示了其可能通过调控PAK1-Stathmin和Zfhx3/4-Vegfaa信号通路来影响胶质细胞迁移和血管生成。该工作将βPix的功能精确定位于胶质细胞，并提出了新的信号调控机制，为理解神经血管单元的发育提供了重要见解；局限性在于所提出的信号通路模型仍需更深入的分子机制实验验证，且其在人类细胞中的相关性仅为推测，有待后续研究证实。

---

## 47. COVID-19患者唾液病毒排出模式的层化分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41543519)
**期刊：** eLife
**PMID：** 41543519
**DOI：** 10.7554/eLife.96032

### 第一部分 原文与翻译

**英文原标题：** Stratification of viral shedding patterns in saliva of COVID-19 patients.

> **英文摘要：**
> Living with COVID-19 requires continued vigilance against the spread and emergence of variants of concern (VOCs). Rapid and accurate saliva diagnostic testing, alongside basic public health responses, is a viable option contributing to effective transmission control. Nevertheless, our knowledge regarding the dynamics of SARS-CoV-2 infection in saliva is not as advanced as our understanding of the respiratory tract. Here, we analyzed longitudinal viral load data of SARS-CoV-2 in saliva samples from 144 patients with mild COVID-19 (a combination of our collected data and published data). Using a mathematical model, we quantified individual-level viral dynamics and stratified them into three groups using a clustering approach. Notably, the three groups exhibited distinct differences in viral RNA detection durations: 11.5 days (95% CI: 10.6-12.4), 17.4 days (16.6-18.2), and 30.0 days (28.1-31.8), respectively. Surprisingly, this stratified grouping remained unexplained despite our analysis of 47 types of clinical data, including basic demographic information, clinical symptoms, results of blood tests, and vital signs. Additionally, we quantified the expression levels of 92 micro-RNAs in a subset of saliva samples, but these also failed to explain the observed stratification, although the mir-1846 level may have been weakly correlated with peak viral load. Our study provides insights into SARS-CoV-2 infection dynamics in saliva, highlighting the challenges in predicting the duration of viral RNA detection without indicators that directly reflect an individual's immune response, such as antibody induction. Given the significant individual heterogeneity in the kinetics of saliva viral shedding, identifying biomarker(s) for viral shedding patterns will be crucial for improving public health interventions in the era of living with COVID-19.

> **中文摘要：**
> 与COVID-19共存需要持续警惕关切变异株（VOCs）的传播和出现。快速、准确的唾液诊断检测，连同基本的公共卫生应对措施，是助力有效传播控制的可行选择。然而，我们对唾液中SARS-CoV-2感染动态的了解，远不如对呼吸道的理解深入。在此，我们分析了144名轻度COVID-19患者（结合了我们收集的数据和已发表数据）唾液样本中SARS-CoV-2的纵向病毒载量数据。利用数学模型，我们量化了个体水平的病毒动力学，并通过聚类方法将其分为三组。值得注意的是，这三组在病毒RNA检测持续时间上表现出明显差异：分别为11.5天（95% CI：10.6-12.4）、17.4天（16.6-18.2）和30.0天（28.1-31.8）。令人惊讶的是，尽管我们分析了47种临床数据（包括基本人口统计学信息、临床症状、血液检测结果和生命体征），这种分层分组仍然无法得到解释。此外，我们在部分唾液样本中量化了92种微小RNA的表达水平，但这些也未能解释观察到的分层现象，尽管mir-1846水平可能与病毒载量峰值存在弱相关性。我们的研究为唾液中SARS-CoV-2感染动态提供了见解，强调了在没有直接反映个体免疫反应（如抗体诱导）的指标时，预测病毒RNA检测持续时间所面临的挑战。鉴于唾液病毒排出动力学存在显著的个体异质性，识别病毒排出模式的生物标志物对于改善与COVID-19共存时代的公共卫生干预措施至关重要。

### 第二部分 AI 大师评价

本研究旨在深入解析轻度COVID-19患者唾液中SARS-CoV-2的病毒排出动力学模式。其核心方法是整合纵向病毒载量数据，运用数学模型和聚类分析对个体病毒动力学进行量化与分层。主要发现是患者可被划分为三个具有显著不同病毒RNA检出持续时间（约11.5天、17.4天和30.0天）的亚组，且这种差异无法被广泛的临床数据或唾液miRNA表达谱所解释。该研究的创新性在于首次系统揭示了唾液中病毒排出模式的显著异质性，并明确指出了当前临床指标在预测病毒脱落持续时间方面的局限性，为未来寻找相关生物标志物以优化公共卫生策略提供了关键方向。

---

## 48. 急性白血病患者的主要不良心血管事件与心功能不全：一项前瞻性研究。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41543472)
**期刊：** JACC. CardioOncology
**PMID：** 41543472
**DOI：** 10.1016/jaccao.2025.11.004

### 第一部分 原文与翻译

**英文原标题：** Major Adverse Cardiovascular Events and Cardiac Dysfunction in Patients With Acute Leukemia: A Prospective Study.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本研究是一项针对急性白血病患者心血管结局的前瞻性队列研究，旨在填补该人群中心血管并发症发生率和风险特征的知识空白。其核心目的是前瞻性地评估急性白血病患者中主要不良心血管事件（MACE）和心功能不全的发生情况。研究设计（前瞻性）是其关键优势，能够提供比回顾性分析更可靠的风险评估数据。然而，摘要的缺失使得我们无法了解其具体的研究方法（如患者队列规模、随访时间、心功能评估手段）、确切的发现结果以及研究的创新性或局限性。

---

## 49. 商业化CAR-T细胞的全球可及性：一项针对G20国家卫生技术评估的横断面研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41543441)
**期刊：** Blood
**PMID：** 41543441
**DOI：** 10.1182/blood.2025030872

### 第一部分 原文与翻译

**英文原标题：** Global access to commercial CAR T cells: A cross-sectional study of health technology assessment in the G20.

> **英文摘要：**
> Chimeric antigen receptor T-cells (CAR T) are a major treatment advance for many patients with haematological malignancies, especially those with disease that has relapsed or is refractory to chemotherapy. However, currently approved commercial CAR T-cells require highly specialised manufacturing processes that contribute to high costs and limit their widespread use. In many countries, positive reimbursement recommendations by health technology assessment (HTA) bodies enable patient access to CAR T therapies. We performed a cross-sectional analysis of HTA evaluations of commercial CAR T therapies among G20 member countries plus three G20 invitees (Spain, Singapore, Switzerland) through 1 August 2025. Across the 18 CAR T-cell product-indication pairs with current FDA approval, we analysed HTA review documentation to ascertain the timing and rationale for a positive or negative recommendation. Fourteen countries with public HTA data were included in our analysis. Forty-eight percent of CAR T-indication pairs (122/252) are currently recommended for reimbursement by public health systems. The median time from FDA approval to HTA decision was 1·54 years (interquartile range 1·15-2·59 years). Common barriers to CAR T cost-effectiveness cited in HTA reports included single-arm trial designs, small study populations, and immature data regarding survival, safety, and quality of life. Our findings demonstrate substantial global disparities in access to CAR T treatments even among high- and upper middle-income countries, highlighting the urgent need for both scientific and policy approaches to reduce costs and improve access to these impactful therapies.

> **中文摘要：**
> 嵌合抗原受体T细胞（CAR-T）是许多血液恶性肿瘤患者，尤其是那些疾病复发或对化疗难治的患者的一项重大治疗进展。然而，目前获批的商业化CAR-T细胞需要高度专业化的制造工艺，这导致了高昂的成本并限制了其广泛应用。在许多国家，卫生技术评估（HTA）机构的积极报销建议是患者获得CAR-T治疗的前提。我们对截至2025年8月1日，G20成员国加上三个受邀国（西班牙、新加坡、瑞士）对商业化CAR-T疗法的HTA评估进行了横断面分析。针对当前获得FDA批准的18个CAR-T细胞产品-适应症对，我们分析了HTA评审文件，以确定其获得积极或消极推荐的时间点和理由。我们的分析涵盖了14个拥有公开HTA数据的国家。目前，48%的CAR-T适应症对（122/252）获得了公共卫生系统的报销推荐。从FDA批准到HTA决定的中位时间为1.54年（四分位距1.15-2.59年）。HTA报告中提及的常见CAR-T成本效益障碍包括单臂试验设计、研究人群规模小以及关于生存、安全性和生活质量的数据不成熟。我们的研究结果表明，即使在高收入和中高收入国家之间，CAR-T治疗的可及性也存在显著的全球差异，这凸显了迫切需要从科学和政策两方面采取措施以降低成本并改善这些重要疗法的可及性。

### 第二部分 AI 大师评价

本研究通过横断面分析，系统评估了G20国家及受邀国对商业化CAR-T疗法的卫生技术评估现状，旨在揭示其全球可及性差异。研究创新性地量化了从FDA批准到HTA决策的时间延迟，并识别了单臂试验设计、小样本量及数据不成熟等关键成本效益评估障碍。核心发现是，即使在富裕国家，CAR-T疗法的报销推荐率也仅为48%，且决策耗时显著，揭示了政策与科学证据之间的鸿沟。其局限性在于仅纳入了拥有公开HTA数据的国家，且分析截止于未来时间点（2025年8月），可能无法反映最新动态。

---

## 50. BRAF V600E突变型甲状腺乳头状癌的分子谱分析与真实世界结局

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41543354)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41543354
**DOI：** 10.1158/1078-0432.CCR-25-3932

### 第一部分 原文与翻译

**英文原标题：** Molecular Profiling and Real-World Outcomes of BRAF V600E-Mutated Papillary Thyroid Cancer.

> **英文摘要：**
> INTRODUCTION: Radioactive iodine refractory papillary thyroid cancers (PTC) containing BRAF-V600E mutations can be treated with BRAF/MEK inhibitors (BRAF/MEKi), but their effectiveness compared to tyrosine kinase inhibitors (TKI) and immunotherapy (IO) remains unclear. Therefore, we compared real-world survival and molecular/transcriptional signatures in patients with BRAF-mut and BRAF-wildtype (wt) PTC.
> 
> METHODS: Thyroid tumor samples underwent DNA/RNA next-gen sequencing and immunohistochemistry at Caris Life Sciences. Tumor microenvironment (TME) cell fractions were estimated by RNA deconvolution using QuanTIseq. Insurance claims data was used to infer real-world overall survival (OS) and time on treatment.
> 
> RESULTS: A total of 1348 patients with differentiated thyroid cancer were identified; 81.8% were classified as PTC, of which 68.4% harbored a BRAF-V600E mutation. TERT promoter mutations were the most common mutation in PTC (72%), and more prevalent in BRAF-mut versus (vs) BRAF-wt. Mutations in NRAS, HRAS, and KRAS, as well as RET, BRAF, and ETV6 gene fusions, were predominantly found in BRAF-wt PTC. BRAF-mut PTC were more often PD-L1+ (33% vs. 18%, p<0.001) and had significantly higher IFNγ scores. OS was not significantly different between patients with BRAF-mut vs wt PTC. Systemic treatment (BRAF/MEKi, TKI or IO) was not associated with significant differences in OS in BRAF-mut PTC, although there was a trend for longer OS in those treated with TKI compared to BRAF/MEKi or IO.
> 
> CONCLUSIONS: BRAF-mut PTC is associated with a pro-inflammatory TME milieu compared to BRAF-wt PTC. However, in this limited data set, treatment choice was not associated with differences in OS in BRAF-mut PTC.

> **中文摘要：**
> 引言：含有BRAF-V600E突变的放射性碘难治性甲状腺乳头状癌（PTC）可采用BRAF/MEK抑制剂（BRAF/MEKi）治疗，但其与酪氨酸激酶抑制剂（TKI）和免疫疗法（IO）相比的有效性尚不明确。因此，我们比较了BRAF突变型与BRAF野生型（wt）PTC患者的真实世界生存情况及分子/转录特征。
> 
> 方法：甲状腺肿瘤样本在Caris Life Sciences进行了DNA/RNA新一代测序和免疫组织化学分析。使用QuanTIseq通过RNA反卷积估算肿瘤微环境（TME）细胞组分。利用保险理赔数据推断真实世界总生存期（OS）和治疗持续时间。
> 
> 结果：共识别出1348例分化型甲状腺癌患者；其中81.8%被归类为PTC，而PTC患者中68.4%携带BRAF-V600E突变。TERT启动子突变是PTC中最常见的突变（72%），且在BRAF突变型中比在BRAF野生型中更普遍。NRAS、HRAS和KRAS突变，以及RET、BRAF和ETV6基因融合，主要见于BRAF野生型PTC。BRAF突变型PTC更常呈PD-L1阳性（33% vs. 18%，p<0.001）且IFNγ评分显著更高。BRAF突变型与野生型PTC患者的OS无显著差异。在BRAF突变型PTC中，全身性治疗（BRAF/MEKi、TKI或IO）与OS的显著差异无关，尽管与接受BRAF/MEKi或IO治疗的患者相比，接受TKI治疗的患者有OS更长的趋势。
> 
> 结论：与BRAF野生型PTC相比，BRAF突变型PTC与促炎性TME环境相关。然而，在此有限的数据集中，治疗选择与BRAF突变型PTC的OS差异无关。

### 第二部分 AI 大师评价

本研究旨在通过真实世界数据，比较BRAF V600E突变型与野生型甲状腺乳头状癌（PTC）的分子特征、肿瘤微环境及不同系统治疗（BRAF/MEKi、TKI、IO）的生存结局。研究整合了大规模NGS分子谱分析、RNA反卷积量化TME以及保险理赔数据推断生存，方法学上具有综合性。核心发现是BRAF突变型PTC具有更高的PD-L1表达和IFNγ评分，提示其促炎性微环境，但不同治疗方式间的总生存期未见统计学显著差异。其创新性在于将分子特征与真实世界疗效关联，但局限性在于数据集的有限性，且生存分析基于保险理赔数据推断，可能影响结论的确定性。

---

## 51. 抗CD137（4-1BB）激动剂单克隆抗体urelumab瘤内注射联合纳武利尤单抗的安全性、可行性与药效动力学活性研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41543348)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41543348
**DOI：** 10.1158/1078-0432.CCR-25-2502

### 第一部分 原文与翻译

**英文原标题：** Safety, feasibility and pharmacodynamic activity of intratumoral injections of the agonist anti-CD137 (4-1BB) mAb urelumab in combination with nivolumab.

> **英文摘要：**
> PURPOSE: Intravenous dosing of the anti-CD137 (4-1BB) agonist monoclonal antibody urelumab is limited to 8 mg flat doses due to liver toxicity, thus reducing bioavailability. Here we explored intratumoral delivery of urelumab to increase bioavailability at the tumor, while reducing systemic exposure, in combination with systemic nivolumab (clinical trial INTRUST, NCT03792724). PATIENTS AND METHODS: We delivered three 8 mg intratumoral injections of urelumab, alternating with intravenous nivolumab 240 mg every two weeks, followed by maintenance nivolumab at 480 mg every 4 weeks. Patients presenting solid tumors with known sensitivity to PD-1/PD-L1 blockade were treated in two cohorts (Cohort A: PD-1/PD-L1 blockade naive; Cohort B: progression following PD-1/PD-L1 blockade). The first six patients were treated in a safety dose-escalation cohort. We collected fresh tumor biopsies before the first three cycles and performed multiplex tissue immunofluorescence and bulk RNA-seq of these specimens. Additionally, we analyzed a comprehensive series of cytokines in sequential plasma samples. RESULTS: Among 31 treated patients, we observed two objective responses and a 67.7% disease控制率。 Treatment was well tolerated. Serial biopsies revealed urelumab-induced increases in T lymphocyte density and CD137 expression. The increase in tumor-infiltrating CD8 T cells was associated with durable clinical benefit. RNA-seq results were consistent with such pharmacodynamic changes. We observed significant plasmatic elevations of T-cell activation cytokines. CONCLUSIONS: Intratumoral delivery of urelumab is feasible, safe, and induces favorable immunopharmacodynamic effects in serial biopsies and in peripheral blood. Our results support the development of tumor-targeted next-generation CD137 (4-1BB) agonists.

> **中文摘要：**
> 目的：抗CD137（4-1BB）激动剂单克隆抗体urelumab的静脉给药因肝脏毒性被限制在8 mg的固定剂量，从而降低了生物利用度。本研究旨在探索urelumab的瘤内给药方式，以增加其在肿瘤部位的生物利用度，同时减少全身暴露，并与全身性纳武利尤单抗联合使用（临床试验INTRUST，NCT03792724）。患者与方法：我们给予患者三次8 mg的urelumab瘤内注射，每两周与240 mg静脉注射纳武利尤单抗交替进行，随后每4周给予480 mg的纳武利尤单抗维持治疗。入组患者为已知对PD-1/PD-L1阻断敏感的实体瘤患者，分为两个队列（队列A：未接受过PD-1/PD-L1阻断治疗；队列B：PD-1/PD-L1阻断治疗后进展）。前六名患者纳入安全性剂量递增队列。我们在前三个周期治疗前收集新鲜肿瘤活检样本，并对这些样本进行多重组织免疫荧光染色和批量RNA测序。此外，我们还分析了连续血浆样本中的一系列细胞因子。结果：在31名接受治疗的患者中，我们观察到两例客观缓解和67.7%的疾病控制率。治疗耐受性良好。系列活检显示，urelumab诱导了T淋巴细胞密度和CD137表达的增加。肿瘤浸润CD8 T细胞的增加与持久的临床获益相关。RNA测序结果与这些药效动力学变化一致。我们观察到T细胞活化细胞因子的血浆水平显著升高。结论：urelumab的瘤内给药是可行且安全的，并在系列活检和外周血中诱导了有利的免疫药效动力学效应。我们的研究结果支持开发靶向肿瘤的下一代CD137（4-1BB）激动剂。

### 第二部分 AI 大师评价

本研究针对抗CD137激动剂urelumab因肝毒性限制系统给药剂量的问题，创新性地探索了其瘤内注射联合PD-1抑制剂纳武利尤单抗的治疗策略。通过严谨的临床试验设计（INTRUST），结合系列肿瘤活检的多组学分析（免疫荧光、RNA-seq）和血浆细胞因子监测，研究证实了该方案的安全性、可行性，并揭示了其诱导肿瘤局部T细胞浸润与活化的明确药效动力学证据。其核心创新在于通过局部给药策略克服了系统毒性限制，为CD137激动剂的临床应用开辟了新路径。然而，研究样本量有限，客观缓解率相对较低，提示未来需在更大规模人群中验证疗效并优化联合方案。

---

## 52. TUMORFISHER循环肿瘤细胞技术对甲状腺乳头状癌进行风险分层的临床意义

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41543346)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41543346
**DOI：** 10.1158/1078-0432.CCR-25-2694

### 第一部分 原文与翻译

**英文原标题：** Clinical Significance for risk stratification of papillary thyroid cancer by TUMORFISHER circulating tumor cells technique.

> **英文摘要：**
> PURPOSE: Preoperative risk stratification for papillary thyroid cancer (PTC) is a significant clinical challenge, as current systems primarily rely on postoperative pathology, limiting their utility for initial treatment planning. This study aimed to evaluate the effectiveness of using circulating tumor cells (CTCs) as a non-invasive liquid活检 tool to stratify patient risk preoperatively.
> 
> EXPERIMENTAL DESIGN: We conducted a prospective study evaluating preoperative CTC levels in 210 patients diagnosed with PTC. A dual-threshold model was developed to analyze the diagnostic performance of CTC counts. The study particularly focused on the Papillary Thyroid Microcarcinoma (PTMC) subgroup (n=100) to address clinical uncertainty regarding active surveillance versus definitive therapy. Patients were monitored over a median follow-up period of 44 months to assess progression-free survival (PFS) and long-term prognostic outcomes.
> 
> RESULTS: The dual-threshold model demonstrated excellent diagnostic performance. A cutoff of ≥ 2 CTCs effectively identified high-risk patients with 93.2% specificity and 88.2% positive predictive value (PPV). In the PTMC cohort, a CTC count < 2 reliably identified low-risk patients suitable for active surveillance (NPV=94.0%), while a count ≥ 2 pinpointed those with high-risk features warranting surgery (Specificity=96.4%, PPV=80.0%). Prognostic analysis revealed that CTC-negative patients had improved PFS. This was most significant in the PTMC subgroup, where the CTC-negative cohort remained recurrence-free and showed significantly longer PFS compared to CTC-positive cases (HR=0.035, 95% CI: 0.002-0.726; P=0.030).
> 
> CONCLUSIONS: Preoperative CTC detection enables precise risk stratification for PTC patients. This liquid biopsy approach allows clinicians to personalize therapy-confidently selecting conservative management for low-risk individuals and recommending aggressive treatment for high-risk patients-thereby optimizing clinical decision-making and long-term outcomes.

> **中文摘要：**
> 目的：甲状腺乳头状癌（PTC）的术前风险分层是一个重大的临床挑战，因为现有系统主要依赖于术后病理，限制了其在初始治疗规划中的应用。本研究旨在评估使用循环肿瘤细胞（CTCs）作为一种非侵入性液体活检工具在术前对患者进行风险分层的有效性。
> 
> 实验设计：我们进行了一项前瞻性研究，评估了210名诊断为PTC的患者术前CTC水平。开发了一个双阈值模型来分析CTC计数的诊断性能。该研究特别关注甲状腺微小乳头状癌（PTMC）亚组（n=100），以解决关于积极监测与确定性治疗的临床不确定性。患者接受了中位随访期为44个月的监测，以评估无进展生存期（PFS）和长期预后结果。
> 
> 结果：双阈值模型显示出优异的诊断性能。截断值≥ 2个CTC能有效识别高风险患者，特异性为93.2%，阳性预测值（PPV）为88.2%。在PTMC队列中，CTC计数< 2能可靠识别适合积极监测的低风险患者（阴性预测值NPV=94.0%），而计数≥ 2则能精确定位具有高风险特征、需要手术的患者（特异性=96.4%，PPV=80.0%）。预后分析显示，CTC阴性患者的PFS得到改善。这在PTMC亚组中最为显著，CTC阴性队列保持无复发，并且与CTC阳性病例相比，显示出显著更长的PFS（风险比HR=0.035，95%置信区间CI：0.002-0.726；P=0.030）。
> 
> 结论：术前CTC检测能够实现对PTC患者的精确风险分层。这种液体活检方法使临床医生能够个性化治疗方案——自信地为低风险个体选择保守管理，并为高风险患者推荐积极治疗——从而优化临床决策和长期预后。

### 第二部分 AI 大师评价

本研究旨在解决甲状腺乳头状癌（PTC）术前风险分层的临床难题。其核心创新在于前瞻性地应用TUMORFISHER技术检测循环肿瘤细胞（CTCs），并构建了具有临床可操作性的双阈值模型。研究发现，该模型在总体PTC及PTMC亚组中均表现出优异的诊断与预后预测性能，特别是为PTMC患者选择积极监测或手术提供了客观依据。然而，研究结论基于单中心前瞻性队列，其普适性有待多中心验证，且CTC检测技术的标准化及成本效益比是未来临床应用需考虑的因素。

---

## 53. RRAS和RRAS2突变是肺癌中复现的致癌驱动因子，并对泛RAS抑制剂RMC-6236敏感。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41543339)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41543339
**DOI：** 10.1158/1078-0432.CCR-25-2734

### 第一部分 原文与翻译

**英文原标题：** RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236.

> **英文摘要：**
> INTRODUCTION: RRAS and RRAS2 encode a subfamily of RAS-like small GTPases that share considerable structural and functional similarities with KRAS, HRAS, and NRAS. Whether homologous RRAS/RRAS2 mutations are oncogenic and actionable drivers in lung cancer remains underexplored. METHODS: An institutional cohort of 8,488 non-small cell lung carcinomas (NSCLC) sequenced by comprehensive targeted DNA sequencing (MSK-IMPACT) between 2016-2024 was evaluated for RRAS/RRAS2 mutations. RRASQ87L or RRAS2Q72L were modeled in murine IL3-dependent Ba/F3 cells and immortalized human bronchiolar epithelial cells (HBECs). The oncogenic potential, signaling characteristics, and sensitivity to PI3K and MAPK pathway inhibitors, including the novel pan-RAS inhibitor RMC-6236, were evaluated in vitro and in vivo. RESULTS: RRASQ87L or RRAS2Q72L, homologous to KRAS-codon Q61 substitutions, were found in ~0.45% of NSCLCs (38/8,488), with all but two lacking other MAPK pathway oncogenic drivers. RRASQ87L and RRAS2Q72L mutations transformed Ba/F3 and HBEC cells and robustly activated MAPK and PI3K-mTOR pathway signaling. RMC-6236 suppressed proliferation of RRASQ87L and RRAS2Q72L mutant cell lines, reduced ERK phosphorylation, induced apoptosis, and impeded cell-cycle progression. In vivo, RMC-6236 significantly inhibited growth of RRASQ87L/RRAS2Q72L-mutant HBEC-derived xenografts. CONCLUSIONS: RRASQ87L and RRAS2Q72L are recurrent, oncogenic, and potentially actionable drivers in NSCLC. Our study supports the inclusion of RRAS/RRAS2 into routine molecular diagnostic panels for precision oncology and provides preclinical rationale for investigating the potential therapeutic utility of pan-RAS inhibitors for patients with RRASQ87L/RRAS2Q72L-mutant lung cancers.

> **中文摘要：**
> 引言：RRAS和RRAS2编码一个RAS样小GTP酶亚家族，与KRAS、HRAS和NRAS具有显著的结构和功能相似性。同源的RRAS/RRAS2突变是否是肺癌中的致癌性和可靶向驱动因子，目前仍未得到充分探索。方法：我们对2016年至2024年间通过综合性靶向DNA测序（MSK-IMPACT）测序的8,488例非小细胞肺癌（NSCLC）的机构队列进行了RRAS/RRAS2突变评估。在小鼠IL3依赖性Ba/F3细胞和永生化人支气管上皮细胞（HBECs）中构建了RRASQ87L或RRAS2Q72L模型。在体外和体内评估了其致癌潜力、信号传导特征以及对PI3K和MAPK通路抑制剂（包括新型泛RAS抑制剂RMC-6236）的敏感性。结果：在约0.45%的NSCLC（38/8,488）中发现了与KRAS密码子Q61替换同源的RRASQ87L或RRAS2Q72L突变，其中除两例外均缺乏其他MAPK通路致癌驱动因子。RRASQ87L和RRAS2Q72L突变转化了Ba/F3和HBEC细胞，并强烈激活了MAPK和PI3K-mTOR通路信号。RMC-6236抑制了RRASQ87L和RRAS2Q72L突变细胞系的增殖，降低了ERK磷酸化，诱导了细胞凋亡，并阻碍了细胞周期进程。在体内，RMC-6236显著抑制了RRASQ87L/RRAS2Q72L突变HBEC来源的异种移植瘤的生长。结论：RRASQ87L和RRAS2Q72L是NSCLC中复现的、致癌性的、且可能具有可靶向性的驱动因子。我们的研究支持将RRAS/RRAS2纳入精准肿瘤学的常规分子诊断组合，并为研究泛RAS抑制剂对RRASQ87L/RRAS2Q72L突变肺癌患者的潜在治疗效用提供了临床前依据。

### 第二部分 AI 大师评价

本研究旨在探索RRAS/RRAS2同源突变在肺癌中的致癌作用及靶向治疗潜力。研究通过大样本队列测序（MSK-IMPACT）和细胞/动物模型，系统评估了RRASQ87L/RRAS2Q72L突变的频率、致癌性及信号通路特征。核心发现是，这些突变在约0.45%的NSCLC中作为独立的致癌驱动因子存在，并能被新型泛RAS抑制剂RMC-6236有效抑制。其创新性在于首次系统证实了RRAS亚家族突变在肺癌中的临床意义，并提出了将其纳入常规分子检测及使用泛RAS抑制剂治疗的策略。局限性在于研究主要基于临床前模型，其临床转化效果仍需后续临床试验验证。

---

## 54. 靶向计算设计具有增强折叠效率和免疫治疗效力的白细胞介素-7超级因子。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41542752)
**期刊：** eLife
**PMID：** 41542752
**DOI：** 10.7554/eLife.107671

### 第一部分 原文与翻译

**英文原标题：** Targeted computational design of an interleukin-7 superkine with enhanced folding efficiency and immunotherapeutic efficacy.

> **英文摘要：**
> Interleukin-7 (IL-7) plays a central role in maintaining T cell development and immune homeostasis, and enhancing the cytokine's immune-stimulatory functionality has broad therapeutic implications against various oncological malignancies. Herein, we show a computationally designed IL7 superkine, Neo-7, which exhibits enhanced folding efficiency and superior binding affinity to its cognate receptors. To streamline the protein candidate prediction and validation process, the loop region of IL7 was strategically targeted for redesign while most of the receptor-interacting regions were preserved. Leveraging advanced computational tools such as AlphaFold2, we show loop remodeling to rectify structural irregularities that allow for iterative stabilization of protein backbone and lead to identification of beneficial mutations conducive to receptor engagement. Neo-7 superkine shows improved thermostability and production yield, and it exhibits heightened immune-stimulatory and anticancer effect in C57BL/6 J mice. Neo-7 addresses intrinsic developability limitations of IL-7, including inefficient folding, aggregation propensity, and suboptimal receptor engagement, while in vivo pharmacokinetic limitations of wild-type IL-7 were addressed separately through Fc fusion. These findings underscore the utility of a targeted computational approach for de novo cytokine development.

> **中文摘要：**
> 白细胞介素-7 (IL-7) 在维持T细胞发育和免疫稳态中起着核心作用，增强该细胞因子的免疫刺激功能对多种肿瘤具有广泛的治疗意义。本文展示了一种通过计算设计的IL-7超级因子Neo-7，其表现出增强的折叠效率和对同源受体的优异结合亲和力。为了简化蛋白质候选物的预测和验证过程，我们策略性地将IL-7的环区作为重新设计的靶点，同时保留了大部分受体相互作用区域。利用AlphaFold2等先进计算工具，我们展示了通过环区重塑来纠正结构不规则性，从而实现蛋白质骨架的迭代稳定，并鉴定出有利于受体结合的有益突变。Neo-7超级因子显示出改善的热稳定性和生产产量，并在C57BL/6 J小鼠中表现出增强的免疫刺激和抗癌效果。Neo-7解决了IL-7固有的可开发性限制，包括低效折叠、聚集倾向和次优的受体结合，而野生型IL-7的体内药代动力学限制则通过Fc融合单独解决。这些发现强调了靶向计算方法在从头开发细胞因子方面的实用性。

### 第二部分 AI 大师评价

本研究核心目的是通过靶向计算设计，克服天然IL-7的可开发性缺陷，创造具有更强免疫治疗潜力的工程化细胞因子。研究团队采用聚焦于环区重塑的计算策略，结合AlphaFold2等工具，在保持核心受体结合区的同时优化了蛋白折叠与稳定性，成功获得了Neo-7超级因子。其创新性在于将计算设计精准应用于特定结构域，并系统性验证了其在折叠效率、稳定性、产量及体内外功能上的全面改善。然而，摘要中提及的体内药代动力学问题仍需通过Fc融合等额外策略解决，提示Neo-7本身可能仍存在半衰期等局限性，其临床转化潜力有待进一步评估。

---

## 55. 更正：FOXP4是YAP1的直接靶点，可促进胃癌干细胞特性并驱动转移。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41540851)
**期刊：** Cancer research
**PMID：** 41540851
**DOI：** 10.1158/0008-5472.CAN-25-5025

### 第一部分 原文与翻译

**英文原标题：** Correction: FOXP4 Is a Direct YAP1 Target That Promotes Gastric Cancer Stemness and Drives Metastasis.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文是一篇更正文章，其核心目的是修正先前关于FOXP4在胃癌中作用的研究。该研究聚焦于FOXP4作为Hippo通路关键效应分子YAP1的直接转录靶点，揭示了其在维持胃癌干细胞特性和驱动转移过程中的关键作用。这一发现为理解胃癌的进展机制提供了新的分子视角，并可能为靶向癌症干细胞或YAP1/FOXP4轴的治疗策略提供理论基础。然而，作为一篇更正，其具体的研究方法、实验细节及更深入的创新性或局限性评估，需参考原始及更正后的完整文献。

---

## 56. 【撤稿】SSBP1通过调控线粒体逆行信号通路抑制TGFβ驱动的三阴性乳腺癌上皮-间质转化与转移

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41540850)
**期刊：** Cancer research
**PMID：** 41540850
**DOI：** 10.1158/0008-5472.CAN-25-5106

### 第一部分 原文与翻译

**英文原标题：** Retraction: SSBP1 Suppresses TGFβ-Driven Epithelial-to-Mesenchymal Transition and Metastasis in Triple-Negative Breast Cancer by Regulating Mitochondrial Retrograde Signaling.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文为一篇撤稿声明，撤回了原题为《SSBP1通过调控线粒体逆行信号通路抑制TGFβ驱动的三阴性乳腺癌上皮-间质转化与转移》的研究。撤稿原因未在提供信息中说明，但通常涉及数据可靠性、结果无法重复或学术不端等问题。这提示原研究结论的有效性已受到质疑，相关发现不应再被引用。撤稿行为本身是维护学术诚信的重要机制，但也凸显了原始研究在方法学严谨性或数据验证方面可能存在重大局限性。

---

## 57. 克服抑制的局限：突变选择性BRAF降解剂

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41540849)
**期刊：** Cancer research
**PMID：** 41540849
**DOI：** 10.1158/0008-5472.CAN-25-4381

### 第一部分 原文与翻译

**英文原标题：** Overcoming the Limits of Inhibition: Mutant-Selective BRAF Degraders.

> **英文摘要：**
> Targeted inhibition of mutant BRAF has transformed the management of BRAF-V600-mutant melanoma and other malignancies, with multiple ATP-competitive kinase inhibitors now approved for clinical use. Despite their clinical success, these agents are limited by intrinsic and acquired resistance, paradoxical activation of the MAPK pathway, and dose-limiting toxicities. The development of BRAF-V600X oncoprotein-selective degraders offers a mechanistically distinct therapeutic approach that may bypass several of these liabilities. Thus, the discovery of an orally bioavailable mutant BRAF-selective degrader is highly sought after. In this issue of Cancer Research, Kreger and colleagues developed CFT1946, a clinical阶段、高效力、RAF家族选择性降解剂，在多种细胞和异种移植模型中均有效。 Importantly, CFT1946 is active in the privileged central nervous system environment, accessing a common site of metastasis for BRAF-mutant melanomas. By eliminating the BRAF-V600X oncoprotein, CFT1946 can overcome RAF dimer- and EGFR-driven resistance to standard inhibitors. Although the mechanism of mutant selectivity is unclear, this compound exhibits a promising therapeutic index by sparing wild-type RAF proteins in cells. As CFT1946 progresses through clinical development, the field of oncoprotein-specific degradation will mature. See related article by Kreger et al., p. 438.

> **中文摘要：**
> 突变BRAF的靶向抑制已经改变了BRAF-V600突变黑色素瘤和其他恶性肿瘤的治疗格局，目前已有多种ATP竞争性激酶抑制剂获批用于临床。尽管取得了临床成功，但这些药物仍受到固有和获得性耐药、MAPK通路的反常激活以及剂量限制性毒性的限制。BRAF-V600X癌蛋白选择性降解剂的开发提供了一种机制上不同的治疗方法，可能规避上述多种缺陷。因此，发现一种具有口服生物利用度的突变BRAF选择性降解剂备受期待。在本期《癌症研究》中，Kreger及其同事开发了CFT1946，这是一种处于临床阶段、高效力、RAF家族选择性降解剂，在多种细胞和异种移植模型中均有效。重要的是，CFT1946在具有免疫豁免特性的中枢神经系统环境中也具有活性，能够作用于BRAF突变黑色素瘤常见的转移部位。通过消除BRAF-V600X癌蛋白，CFT1946能够克服RAF二聚体和EGFR驱动的对标准抑制剂的耐药性。尽管其突变选择性的机制尚不清楚，但该化合物通过在细胞中保留野生型RAF蛋白，展现出良好的治疗指数。随着CFT1946在临床开发中不断推进，癌蛋白特异性降解领域将走向成熟。参见Kreger等人的相关文章，第438页。

### 第二部分 AI 大师评价

本研究旨在解决传统BRAF抑制剂面临的耐药、毒性及对中枢神经系统转移灶疗效有限等瓶颈。其核心方法是开发一种名为CFT1946的新型突变选择性RAF降解剂，通过直接清除癌蛋白而非抑制其活性来发挥作用。研究发现，CFT1946在临床前模型中显示出对包括中枢神经系统转移在内的广泛疗效，并能克服RAF二聚体及EGFR介导的耐药，展现出优于传统抑制剂的潜力。其创新性在于将蛋白降解技术应用于BRAF突变肿瘤治疗，并实现了突变选择性，但局限性在于其选择性机制尚未完全阐明，其临床疗效与安全性仍需后续试验验证。

---

## 58. Zanidatamab联合Tislelizumab及化疗一线治疗HER2阳性胃/胃食管结合部腺癌的Ib/II期研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41324998)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41324998
**DOI：** 10.1158/1078-0432.CCR-24-4295

### 第一部分 原文与翻译

**英文原标题：** Phase Ib/II Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma.

> **英文摘要：**
> PURPOSE: This phase Ib/II trial (NCT04276493) assessed the antitumor activity, safety, and pharmacokinetics (PK) of zanidatamab in combination with tislelizumab and chemotherapy in patients with advanced HER2-positive (HER2+) gastric cancer/gastroesophageal junction cancer (GEJC). PATIENTS AND METHODS: Adult patients with previously untreated, unresectable, locally advanced/metastatic HER2+ gastric cancer/GEJC received zanidatamab 30 mg/kg i.v. (cohort A) or zanidatamab 1800 mg i.v. (weight <70 kg)/2,400 mg i.v. (weight ≥70 kg; cohort B) once every 3 weeks (Q3W). Both cohorts received tislelizumab 200 mg i.v. once every 3 weeks and standard chemotherapy [capecitabine and oxaliplatin (CAPOX)] once every 3 weeks. Primary endpoints were investigator-assessed confirmed objective response rate (cORR) per RECIST v1.1, in addition to the frequency and severity of adverse events (AE) and serious AEs. Secondary endpoints included investigator-assessed progression-free survival (PFS), duration of response (DoR), overall survival (OS), PK, and immunogenicity of zanidatamab. RESULTS: As of December 7, 2023, 33 patients (cohort A, n = 19; cohort B, n = 14) received treatment. The confirmed objective response rate was 75.8%; the median duration of response, progression-free survival, and overall survival were 23.3, 16.7, and 32.4 months, respectively. The most common treatment-related AEs (TRAEs) were diarrhea (100%), nausea (63.6%), and decreased appetite (48.5%). Treatment-related AEs of grade ≥3 were reported in 22 (66.7%) patients; diarrhea was the most common (27.3%). CONCLUSIONS: Zanidatamab, in combination with tislelizumab and CAPOX, demonstrated clinically meaningful antitumor activity with a manageable safety profile as first-line therapy for patients with HER2+ gastric cancer/GEJC. These results support a further development of zanidatamab and tislelizumab with chemotherapy in this patient population in the ongoing phase III HERIZON-GEA-01 trial (NCT05152147).

> **中文摘要：**
> 目的：这项Ib/II期试验（NCT04276493）评估了zanidatamab联合tislelizumab及化疗在晚期HER2阳性（HER2+）胃癌/胃食管结合部癌（GEJC）患者中的抗肿瘤活性、安全性和药代动力学（PK）。患者与方法：既往未经治疗的、不可切除的局部晚期/转移性HER2+胃癌/GEJC成年患者接受zanidatamab 30 mg/kg静脉注射（队列A）或zanidatamab 1800 mg静脉注射（体重<70 kg）/2400 mg静脉注射（体重≥70 kg；队列B），每3周一次（Q3W）。两个队列均接受tislelizumab 200 mg静脉注射，每3周一次，以及标准化疗[卡培他滨和奥沙利铂（CAPOX）]，每3周一次。主要终点是研究者根据RECIST v1.1评估的确认客观缓解率（cORR），以及不良事件（AE）和严重AE的发生频率和严重程度。次要终点包括研究者评估的无进展生存期（PFS）、缓解持续时间（DoR）、总生存期（OS）、PK以及zanidatamab的免疫原性。结果：截至2023年12月7日，共有33名患者（队列A，n=19；队列B，n=14）接受了治疗。确认的客观缓解率为75.8%；中位缓解持续时间、无进展生存期和总生存期分别为23.3、16.7和32.4个月。最常见的治疗相关不良事件（TRAE）是腹泻（100%）、恶心（63.6%）和食欲下降（48.5%）。22名（66.7%）患者报告了≥3级的治疗相关不良事件；腹泻是最常见的（27.3%）。结论：Zanidatamab联合tislelizumab和CAPOX作为HER2+胃癌/GEJC患者的一线治疗，显示出具有临床意义的抗肿瘤活性和可控的安全性。这些结果支持在正在进行的III期HERIZON-GEA-01试验（NCT05152147）中，在该患者人群中进一步开发zanidatamab和tislelizumab联合化疗。

### 第二部分 AI 大师评价

本研究评估了双特异性抗体Zanidatamab联合PD-1抑制剂Tislelizumab及CAPOX化疗一线治疗HER2阳性胃/胃食管结合部腺癌的疗效与安全性。其核心创新在于探索HER2靶向治疗与免疫检查点抑制剂的协同作用。结果显示，该三联方案取得了高达75.8%的客观缓解率和令人鼓舞的生存数据（中位OS达32.4个月），但≥3级治疗相关不良事件发生率较高（66.7%），尤其是腹泻。主要局限性在于这是一项样本量较小的Ib/II期研究，其结论需在更大规模的III期随机对照试验（HERIZON-GEA-01）中得到验证。

---

## 59. 靶向PLK1可降低MMP10以增强HPV-头颈癌的放射敏感性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41252565)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41252565
**DOI：** 10.1158/1078-0432.CCR-25-2179

### 第一部分 原文与翻译

**英文原标题：** Targeting PLK1 Reduces MMP10 to Enhance Radiosensitivity in HPV- Head and Neck Cancer.

> **英文摘要：**
> PURPOSE: Radiotherapy is a key treatment for head and neck squamous cell carcinoma (HNSCC), yet local复发 remains a challenge, especially in patients with human papilloma virus negative (HPV-) HNSCC. Our studies identify polo-like kinase 1 (PLK1) as a promising target for HNSCC. PLK1 is overexpressed in HNSCC and associated with worse survival.
> 
> EXPERIMENTAL DESIGN: Onvansertib was used to assess the effect of PLK1 inhibition on cell viability and spheroid growth in HPV- and HPV-positive (HPV+) HNSCC cells. Cell-cycle analysis was done to assess G2/M arrest when combining PLK1 inhibition with radiation. Colony formation and in vivo tumor growth assays were done to evaluate the efficacy of the combination of PLK1 inhibition with radiation. RNA sequencing was done to identify targets of PLK1 after onvansertib treatment. Plk1 siRNA knockdown was used to confirm similar responses seen when inhibiting PLK1 with onvansertib.
> 
> RESULTS: PLK1 inhibition with onvansertib reduced cell viability and spheroid growth of HPV- HNSCC cells. PLK1 inhibition combined with radiation increased G2/M arrest, decreased colony formation of HPV- HNSCC cells, and reduced tumor growth in vivo. RNA sequencing demonstrated that radiation increased MMP10 expression but PLK1 inhibition reversed this effect in HPV- HNSCC cells. PLK1 inhibition reduced MMP10 activity, and Plk1 siRNA knockdown reduced MMP10 expression in HPV- HNSCC cells.
> 
> CONCLUSIONS: These findings suggest that combining PLK1 inhibition with radiation may improve therapeutic response for HPV- HNSCC via MMP10, offering a novel approach to overcome radiation resistance.

> **中文摘要：**
> 目的：放射治疗是头颈部鳞状细胞癌（HNSCC）的关键治疗方法，但局部复发仍然是一个挑战，尤其是在人乳头瘤病毒阴性（HPV-）的HNSCC患者中。我们的研究确定Polo样激酶1（PLK1）是HNSCC的一个有前景的靶点。PLK1在HNSCC中过表达，并与较差的生存率相关。
> 
> 实验设计：使用Onvansertib评估PLK1抑制对HPV-和HPV阳性（HPV+）HNSCC细胞活力和球体生长的影响。进行细胞周期分析以评估PLK1抑制联合放射治疗时的G2/M期阻滞。通过克隆形成和体内肿瘤生长实验来评估PLK1抑制联合放射治疗的疗效。进行RNA测序以鉴定onvansertib处理后PLK1的靶点。使用Plk1 siRNA敲低来确认与onvansertib抑制PLK1时观察到的相似反应。
> 
> 结果：使用onvansertib抑制PLK1降低了HPV- HNSCC细胞的活力和球体生长。PLK1抑制联合放射治疗增加了G2/M期阻滞，减少了HPV- HNSCC细胞的克隆形成，并抑制了体内肿瘤生长。RNA测序表明，放射治疗增加了MMP10的表达，但PLK1抑制在HPV- HNSCC细胞中逆转了这种效应。PLK1抑制降低了MMP10活性，并且Plk1 siRNA敲低降低了HPV- HNSCC细胞中MMP10的表达。
> 
> 结论：这些发现表明，PLK1抑制联合放射治疗可能通过MMP10改善HPV- HNSCC的治疗反应，为克服放射抵抗提供了一种新方法。

### 第二部分 AI 大师评价

本研究旨在探索通过靶向PLK1克服HPV-头颈癌放射抵抗的新策略。研究综合运用了细胞活力、球体生长、克隆形成、体内肿瘤模型及RNA测序等多种方法，系统评估了PLK1抑制剂onvansertib联合放疗的疗效。核心发现是PLK1抑制能逆转放疗诱导的MMP10上调，从而增强放射敏感性，这为理解放射抵抗机制提供了新的分子视角。其创新性在于明确了PLK1-MMP10轴在HPV-头颈癌放射抵抗中的关键作用，但研究主要基于临床前模型，其临床转化效果及潜在毒性仍需进一步验证。

---

## 60. 化疗处理的乳腺癌细胞通过激活WNT信号通路进入类滞育早期持续存在状态。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41117706)
**期刊：** Cancer research
**PMID：** 41117706
**DOI：** 10.1158/0008-5472.CAN-24-4165

### 第一部分 原文与翻译

**英文原标题：** Chemotherapy-Treated Breast Cancer Cells Activate the WNT Signaling Pathway to Enter a Diapause-Like Early Persister State.

> **英文摘要：**
> UNLABELLED: Cancer cells can acquire a reversible, dormant drug-tolerant persister state mimicking embryonic diapause to evade therapy pressure. Deciphering the precise mechanisms driving cancer cells into or out of a diapause-like persister cell state could provide strategies to overcome resistance. In this study, we showed that following chemotherapy, diverse therapeutic agents converge on WNT pathway activation to induce a de novo diapause-like cell state across various triple-negative breast cancer cell line, xenograft, and patient-derived organoid models. Among early persister cells, only transcriptionally WNT-active persisters exhibited the transcriptional and functional characteristics typical of diapause-like cells, including a negative correlation with MYC transcriptional activity and reversible restricted proliferation. The WNT signaling pathway functioned as both an inducer and biomarker of the diapause-like early persister cell state in both parental (chemotherapy-naïve) and chemotherapy-treated cells. Entry into and exit from the diapause-like early persister cell state was triggered by the transcriptional upregulation of components essential for canonical WNT ligand secretion. A combinatorial treatment strategy inhibiting WNT ligand secretion alongside chemotherapy effectively targeted the early mechanisms underlying the acquisition and enrichment of a diapause-like cell phenotype. These findings reveal WNT pathway activation as an early event that leads to a reversible diapause-like persister state and highlight the potential of targeting this axis to prevent the development of drug-resistant populations before they are firmly established. SIGNIFICANCE: WNT signaling is a crucial driver and biomarker of a reversible, dormant, diapause-like persister state in breast cancer cells, offering insights that could transform therapeutic strategies to disrupt tumor persistence.

> **中文摘要：**
> 无标签：癌细胞能够获得一种可逆的、休眠的、耐药的持续存在状态，该状态模拟胚胎滞育以逃避治疗压力。破译驱动癌细胞进入或退出类滞育持续存在细胞状态的确切机制，可能为克服耐药性提供策略。在本研究中，我们发现，化疗后，不同的治疗药物汇聚于WNT通路激活，从而在三阴性乳腺癌细胞系、异种移植瘤和患者来源类器官等多种模型中诱导出全新的类滞育细胞状态。在早期持续存在细胞中，只有转录上WNT活跃的持续存在细胞表现出典型的类滞育细胞的转录和功能特征，包括与MYC转录活性呈负相关以及可逆的增殖受限。WNT信号通路在亲代（未接受化疗）细胞和化疗处理细胞中，既是类滞育早期持续存在细胞状态的诱导者，也是其生物标志物。进入和退出类滞育早期持续存在细胞状态是由经典WNT配体分泌所必需的组分的转录上调触发的。一种抑制WNT配体分泌与化疗联合的治疗策略，有效地靶向了获得和富集类滞育细胞表型的早期机制。这些发现揭示了WNT通路激活是导致可逆的类滞育持续存在状态的早期事件，并强调了靶向这一轴心以防止耐药群体在牢固形成之前发展的潜力。意义：WNT信号是乳腺癌细胞中一种可逆的、休眠的、类滞育持续存在状态的关键驱动因素和生物标志物，为改变治疗策略以破坏肿瘤持续存在提供了可能带来变革的见解。

### 第二部分 AI 大师评价

本研究旨在揭示乳腺癌细胞在化疗压力下进入休眠、耐药持续存在状态（类滞育状态）的早期机制。研究通过整合多种三阴性乳腺癌模型（细胞系、异种移植瘤、类器官），发现多种化疗药物均能汇聚于激活WNT信号通路，从而诱导该状态。其核心创新性在于将WNT通路定位为该状态的关键早期驱动者和生物标志物，并提出了通过抑制WNT配体分泌联合化疗的预防性治疗策略，旨在在耐药细胞群体稳固前进行干预。局限性在于研究主要基于临床前模型，其转化至临床的有效性和安全性仍需进一步验证。

---

速递结束，祝您工作愉快！